Anti-cancer combination therapy including a CTLA-4 blockade and a PD-1 blockade
Patent Information
- Application Number
- JP2021553837
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-03-13
- Filing Date
- 2020-03-10
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2040-03-10
Smart Images

Figure 0007581225000051 
Figure 0007581225000052 
Figure 0007581225000053
Abstract
Description
[Technical field]
[0001] (1) Field of the invention The present invention relates to an anti-cancer (hereinafter referred to as cancer) combination therapy comprising a CTLA-4 blocking agent and a PD-1 blocking agent. In particular, the present invention relates to a combination therapy in which the CTLA-4 blocking agent is an anti-CTLA-4 antibody with reduced or no measurable effector function, or an anti-CTLA-4 antibody fragment lacking an Fc domain, and the PD-1 blocking agent is an anti-PD-1 antibody, an anti-PD-1 antibody fragment, an anti-PD-L1 antibody, or an anti-PD-L1 antibody fragment. [Background technology]
[0002] (2) Description of related art Tumor immunotherapy is assuming a more important role in the treatment of various cancer indications. Clinical success utilizing antibody blockade of immune checkpoint inhibitor receptors expressed on T cells, such as cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed death receptor 1 (PD-1), has prompted significant advances in immunotherapy against cancer. Monotherapy blockade of CTLA-4 or PD-1 with monoclonal antibodies (mAbs) has led to enhanced antitumor responses and beneficial clinical outcomes in controlled randomized clinical trials.
[0003] A prominent feature of immune checkpoint blockade (immune checkpoint inhibition) for treating various cancers is the clinically validated advantage of combination therapy involving anti-PD-1 and anti-CTLA-4 antibodies. As more and more clinical data are published, it is becoming clear that anti-PD-1 / CTLA-4 combination therapy can provide superior clinical efficacy compared to targeting only one checkpoint pathway. However, immune-related toxicities (irAEs) associated with anti-CTLA-4 antibodies are significant both in monotherapy and in combination with anti-PD-1 antibodies. For example, the anti-CTLA-4 antibody ipilimumab, marketed by Bristol-Myers Squibb under the trade name YERVOY and the only anti-CTLA-4 antibody approved by the United States Food and Drug Administration (US FDA), is subject to a Black Box warning because it may induce severe and potentially fatal immune-mediated side effects such as inflammation of the gut, liver, skin, hormone-producing glands, and / or eyes. Ipilimumab is also approved as a combination therapy with the anti-PD-1 antibody nivolumab (marketed by Bristol-Myers Squibb under the trade name OPDIVO) for advanced renal cell carcinoma and certain colorectal cancers, but because of the risk of serious irAEs, ipilimumab is administered at low doses of 1 mg / kg or at subtherapeutic doses. The subtherapeutic doses for combination therapy are significantly lower than the monotherapy doses of 3 mg / kg for unresectable or metastatic melanoma or 10 mg / kg for adjuvant melanoma treatment (see YERVOY Package Insert and Labeling, July 2018).
[0004] The FDA-approved anti-PD1 mAbs, nivolumab and pembrolizumab, are both humanized anti-PD1 IgG4 kappa antibodies, and are disclosed in U.S. Patent Nos. 8,008,449 and 8,354,509, respectively. The IgG4 isotype Fc domain is generally recognized as having little detectable effector function.
[0005] Ipilimumab is a human anti-CTLA-4 IgG1 kappa antibody, disclosed in U.S. Patent No. 6,984,720. The heavy chain (HC) constant domain of the IgG1 isotype contains the Fc domain, which is generally recognized as having high affinity for Fc receptors (FcRs), providing the antibody with important effector functions [e.g., antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP) and / or complement-dependent cytotoxicity (CDC)]. Studies have shown that Fc effector functions are necessary for the efficacy of anti-CTLA-4 antibodies. For example, Ingram et al., Proc. Natl. Acad. Sci. USA 115:3912-3917 (2018) described an anti-CTLA-4 alpaca heavy chain-only antibody fragment (VHC) that lacks the heavy chain Fc domain and associated effector functions. HH ) had no antitumor effect in mouse models. However, it was possible to restore antitumor effects to the molecule by fusing it with a mouse IgG2 heavy chain Fc domain that exhibits effector function. Also, Selby et al., Cancer Immunol. Res. 1:32-42 (2013) showed in mouse models that an anti-CTLA-4 antibody fused or conjugated to an Fc domain mutated to eliminate effector function did not exhibit antitumor activity. See also Simpson et al., J. Exp. Med.; 210:1695-710 (2013) and International Patent Application No. WO2014089113.
[0006] Tremelizumab is a human anti-CTLA-4 human IgG2 antibody and is disclosed in U.S. Patent No. 8,491,895. The human IgG2 isotype was selected to potentially reduce irAEs by minimizing potential effector function activity. However, as shown by Vargas et al., Cancer Cell 33:649-663 (2018), tremelizumab retains effector function, and Bertrand et al., BMC Med. 13:211-214 (2015) showed that although tremelizumab can be administered at higher doses than ipilimumab, it can still induce irAEs, particularly gut and skin inflammatory immune-mediated toxicity. See also Ribas et al., The Oncologist 12:873-993 (2007), Schneider-Merck et al., J. Immunol. 184:512-520 (2010), and Konitzer et al., PLoS One. 10:e0145633 (2015), which showed that other human IgG2 antibodies induce comparable ADCC and ADCP in vitro similar to IgG1 isoforms.
[0007] Other attempts to reduce ipilimumab irAEs include BMS-986249, a probody composed of ipilimumab linked via a protease-cleavable linker to a unique masking peptide that contains the active antigen-binding site of the antibody. The masking peptide may reduce irAEs by minimizing ipilimumab's ability to bind to CTLA-4 in normal tissues [see International Patent Applications WO2009025846, WO2010081173, WO2018222949, WO2018085555, Pai et al., J. Clin. Invest. 129:349-363 (2019), and Korman et al., Abstract SY09-01, AACR Annual Meeting Vol 77, issue 13 (2017)].
[0008] The therapeutic effect of anti-CTLA4 antibodies such as ipilimumab is to inhibit regulatory T cells (T regIn light of studies suggesting that ADCC may be accompanied by a decrease in CTLA-4 expression, it has been proposed that anti-CTLA-4 antibodies such as ipilimumab with enhanced ADCC activity would provide more effective anti-tumor activity than current antibodies. U.S. Patent No. 10,196,445 discloses several ipilimumab variants with enhanced ADCC activity.
[0009] Some anti-cancer therapies include administering anti-PD-1 antibodies in combination with chemotherapy. The anti-tumor activity of anti-CTLA-4 antibodies may further enhance the efficacy of these therapies; however, gastrointestinal toxicity is one of the most commonly encountered side effects during chemotherapy, so adding anti-CTLA-4 antibodies to the therapy may exacerbate gastrointestinal toxicity.
[0010] Clearly, an anti-CTLA-4 antibody that allowed dosing at higher, more optimal levels without the associated irAEs, particularly the skin and gut inflammatory immune-mediated toxicities associated with current anti-CTLA-4 antibodies, would likely allow for more effective treatment in combination with an anti-PD-1 antagonist and, optionally, chemotherapy. Summary of the Invention
[0011] A brief summary of the invention The inventors have found that certain CTLA-4 blocking agents that bind to CTLA-4 have reduced or no measurable anti-tumor activity when administered as monotherapy, but can exhibit clinically relevant anti-tumor activity when used in combination with PD-1 blockade. The inventors have also found that these certain CTLA-4 blocking agents can provide anti-tumor activity in CTLA-4 / PD-1 blockade combination therapy without inducing immune-mediated adverse events (irAEs) (including irAEs in the skin and gut) associated with currently approved CTLA-4 / PD-1 blockade combination therapies. The CTLA-4 / PD-1 blockade combinations disclosed herein allow for a higher therapeutic index of therapy than current CTLA-4 / PD-1 blockade combination therapies, including combination therapies with chemotherapy, which can result in more effective cancer treatments with improved clinical outcomes for patients.
[0012] Certain CTLA-4 blocking agents used as part of the CTLA-4 / PD-1 blockade combination therapy of the present invention may be selected from the group consisting of (i) effector-silent anti-CTLA-4 antibodies, and (ii) effector-silent anti-CTLA-4 antibody fragments lacking a fragment crystallizable (Fc) domain or having an Fc domain that includes a deletion of that region in the Fc domain that binds to an Fc receptor (FcR). Effector-silent antibodies or antibody fragments (i) exhibit no measurable binding to one or more FcRs as measured by Biacore assay (wherein an association constant in the micromolar range indicates no measurable binding), or (ii) exhibit reduced measurable binding to one or more FcRs as measured by Biacore assay compared to the binding typical for antibodies of the same isotype. These particular CTLA-4 blocking agents are effector-silent CTLA-4 blocking agents.
[0013] In certain embodiments, these effector-silent anti-CTLA-4 antibodies and effector-silent anti-CTLA-4 antibody fragments may not exhibit measurable anti-tumor activity in anti-cancer monotherapy, but in combination anti-cancer therapy with PD-1 or PD-L1 blockade, will exhibit measurable anti-tumor activity without the irAEs, particularly skin or gut inflammatory immune-related toxicities, typically associated with CTLA-4 / PD-1 blockade combination therapy.
[0014] The effector-silent anti-CTLA-4 antibodies or effector-silent anti-CTLA-4 antibody fragments disclosed herein can be used in combination with PD-1 or PD-L1 blockade at higher doses and for longer periods without the irAEs typically associated with CTLA-4 / PD-1 blockade combination therapy, particularly skin or gut inflammatory immune-related toxicities. Currently, the dose of the anti-CTLA-4 antibody ipilimumab approved for use in anti-CTLA-4 / PD-1 blockade combination therapy is 1 mg / kg, while the doses approved for use in monotherapy are 3 mg / kg or 10 mg / kg [see Package Insert and Label for YERVOY (July 2018)], or a fixed dose of 100 mg or less is envisioned for CTLA-4 / PD-1 blockade combination therapy in international patent application WO2018183408. Thus, the CTLA-4 / PD-1 blockade combination therapy of the present invention may use effector-silent anti-CTLA-4 antibodies or effector-silent anti-CTLA-4 antibody fragments at doses similar to or higher than those currently approved for anti-CTLA-4 antibodies in monotherapy. The effector-silent anti-CTLA-4 antibodies or anti-CTLA-4 antibody fragments disclosed herein may also be used in combination with anti-PD-1 or anti-PD-L1 antibodies at doses similar to those currently used or contemplated in CTLA-4 / PD-1 blockade combination therapy, and for longer durations than currently achievable with anti-CTLA-4 antibodies, and without exhibiting the irAEs typically associated with CTLA-4 / PD-1 blockade combination therapy, particularly skin or gut inflammatory immune-related toxicities.
[0015] Thus, the present invention provides a combination therapy for treating cancer in an individual in need thereof, the method comprising administering to an individual having cancer (i) a therapeutic amount of a PD-1 or PD-L1 blocking agent, and (ii) a therapeutic amount of an effector-silent CTLA-4 blocking agent to treat the cancer, wherein the effector-silent CTLA-4 blocking agent exhibits anti-tumor activity in the combination therapy that it does not exhibit when administered to the individual in monotherapy without the PD-1 or PD-L1 blocking agent. In another embodiment, the combination therapy does not induce or reduces the risk of inducing immune-mediated adverse events (irAEs) in the gut or skin during the course of the combination therapy that are greater than Grade 2 as defined in the Common Terminology Criteria for Adverse events (CTCAE) version 5.0. In certain embodiments, the effector-silent CTLA-4 blocking agent used as part of the combination therapy does not induce irAEs in the skin or intestine greater than grade 2 for at least the first 10 weeks of the combination therapy. In certain embodiments, the combination therapy does not result in detectable irAEs for at least the first 4 weeks of the combination therapy, or does not result in irAEs greater than grade 1 for at least the first 4 weeks of the combination therapy.
[0016] In one embodiment, the effector-silent CTLA-4 blocking agent used as part of the combination therapy described herein is an effector-silent anti-CTLA-4 antibody or an effector-silent anti-CTLA-4 antibody fragment.
[0017] In another embodiment, the PD-1 blocking agent used as part of the combination therapy described herein is an anti-PD-1 or anti-PD-L1 antibody or an anti-PD-1 or anti-PD-L1 antibody fragment. In a specific embodiment, the anti-PD-1 or anti-PD-L1 antibody comprises an HC domain that includes one or more mutations in the Fc domain that render the antibody effector-silent. The PD-1 blocking agent may be an anti-PD-1 or anti-PD-L1 antibody fragment, each of which lacks the Fc domain or a region of the Fc domain that binds to one or more FcRs, which renders the antibody fragment effector-silent.
[0018] The present invention further provides an anti-cancer combination therapy comprising administering to an individual in need of cancer treatment (i) a first formulation comprising a PD-1 blocking agent selected from the group consisting of an anti-PD-1 antibody having an IgG4 or IgG2 Fc domain, an effector-silent anti-PD-1 antibody, and an effector-silent anti-PD-1 antibody fragment, and (ii) a second formulation comprising an effector-silent CTLA-4 blocking agent selected from the group consisting of an effector-silent anti-CTLA-4 antibody and an effector-silent anti-CTLA-4 antibody fragment.
[0019] The present invention further provides an anti-cancer combination therapy comprising administering to an individual in need of cancer treatment a formulation comprising: (i) a PD-1 blocking agent selected from the group consisting of an anti-PD-1 antibody having an IgG4 or IgG2 Fc domain, an effector-silent anti-PD-1 antibody, and an effector-silent anti-PD-1 antibody fragment; and (ii) an effector-silent CTLA-4 blocking agent selected from the group consisting of an effector-silent anti-CTLA-4 antibody and an effector-silent anti-CTLA-4 antibody fragment.
[0020] The invention further provides an anti-cancer combination therapy comprising administering to an individual in need of cancer treatment (i) a first formulation comprising a PD-L1 blocking agent selected from the group consisting of an anti-PD-L1 antibody having an IgG4 or IgG2 Fc domain, an effector-silent anti-PD-L1 antibody, and an effector-silent anti-PD-L1 antibody fragment, and (ii) a second formulation comprising an effector-silent CTLA-4 blocking agent selected from the group consisting of an effector-silent anti-CTLA-4 antibody and an effector-silent anti-CTLA-4 antibody fragment.
[0021] The invention further provides an anti-cancer combination therapy comprising administering to an individual in need of cancer treatment a formulation comprising: (i) a PD-L1 blocking agent selected from the group consisting of an anti-PD-L1 antibody having an IgG4 or IgG2 Fc domain, an effector-silent anti-PD-L1 antibody, and an effector-silent anti-PD-L1 antibody fragment; and (ii) an effector-silent CTLA-4 blocking agent selected from the group consisting of an effector-silent anti-CTLA-4 antibody and an effector-silent anti-CTLA-4 antibody fragment.
[0022] In more particular embodiments of the combination therapy, the effector-silent anti-CTLA-4 antibody comprises: (i) an IgG1 Fc domain having a mutation at the N-glycosylation site Asn-Xaa-Ser / Thr starting at amino acid position 297 that prevents N-glycosylation at said N-glycosylation site, or said mutated Fc domain further comprising 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional amino acid substitutions, insertions and / or deletions; (ii) N297A, L2 an IgG1 Fc domain having an amino acid substitution mutation selected from the group consisting of 34A / L235A / D265A, L234A / L235A / P329G, L235E, D265A, E233A / L235A, S267E / L328F, S2339D / A330L / I332E, L235G / G236R, N297A / D356E / L358M, L234F / L235E / P331S / D365E / L358M, and D265A / N297G; or (iii) a mutation at the N-glycosylation site Asn-Xaa-Ser / Thr starting at amino acid position 297, which prevents N-glycosylation at said N-glycosylation site, and and an IgG1 Fc domain having an amino acid substitution mutation selected from the group consisting of: 332E, L235G / G236R, D356E / L358M, L234F / L235E / P331S / D365E / L358M, and D265A, or said mutant Fc domain further comprising 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional amino acid substitutions, insertions and / or deletions, wherein the amino acid positions in (i), (ii) and (iii) are identified according to EU numbering.
[0023] In certain embodiments of the combination therapy, the effector-silent anti-CTLA-4 antibody comprises: (i) an IgG2 Fc domain having a mutation at the N-glycosylation site Asn-Xaa-Ser / Thr starting at amino acid position 297 that prevents N-glycosylation at said N-glycosylation site, or said mutated Fc domain further comprising 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional amino acid substitutions, insertions and / or deletions; (ii) an IgG2 Fc domain having an amino acid substitution mutation selected from the group consisting of N297A / D265S, D265A, P329G / D265A / N297G, or V234A / G237A / P238S / H268A / V309L / A330S / P331S, or an IgG2 Fc domain having an amino acid substitution mutation selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional amino acid substitutions, insertions and / or deletions; or (iii) an IgG2 Fc domain having a mutation in the N-glycosylation site Asn-Xaa-Ser / Thr starting at amino acid position 297, which mutation prevents N-glycosylation at the N-glycosylation site, and an amino acid substitution mutation selected from the group consisting of N297A / D265S, D265A, P329G / D265A / N297G, or V234A / G237A / P238S / H268A / V309L / A330S / P331S, or said mutant Fc domain further comprising 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional amino acid substitutions, insertions and / or deletions, wherein the amino acid positions in (i), (ii) and (iii) are identified according to EU numbering.
[0024] In certain embodiments of the combination therapy, the effector-silent anti-CTLA-4 antibody comprises: (i) an IgG4 Fc domain having an S228P amino acid substitution and further comprising a mutation at the N-glycosylation site Asn-Xaa-Ser / Thr starting at amino acid position 297 that prevents N-glycosylation at said N-glycosylation site, or said mutated Fc domain further comprising 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional amino acid substitutions, insertions and / or deletions; (ii) an IgG4 Fc domain having an S228P amino acid substitution and further comprising an amino acid substitution mutation selected from the group consisting of N267A, P329G, and D265A / N297A, or said mutated Fc domain further comprising 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional amino acid substitutions, insertions and / or deletions; or (iii) an IgG4 Fc domain having an S228P amino acid substitution and further comprising a mutation in the N-glycosylation site Asn-Xaa-Ser / Thr starting at amino acid position 297, which mutation prevents N-glycosylation at said N-glycosylation site, and an amino acid substitution mutation selected from the group consisting of N267A, P329G, and D265A / N297A; or said mutant Fc domain further comprising 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional amino acid substitutions, insertions and / or deletions, wherein the amino acid positions in (i), (ii) and (iii) are identified according to EU numbering.
[0025] In another embodiment of the combination therapy, the effector-silent anti-CTLA-4 antibody fragment lacking an Fc domain is, or comprises, a single chain variable fragment (scFv), an antigen-binding fragment (Fab) or an antigen-binding fragment dimeric F(ab')2.
[0026] In certain embodiments of the combination therapy, the effector-silent anti-CTLA-4 antibody or effector-silent anti-CTLA-4 antibody fragment comprises three heavy chain (HC) complementarity determining regions (CDRs) and three light chain (LC) CDRs of an anti-CTLA-4 antibody selected from the group consisting of ipilimumab, tremelimumab, REGN4659, AGEN1884w, 8D2 / 8D2(RE), 8D2 / 8D2(RE)-mutant1, 8D2H1L1, 8D2H1L1-mutant1, 8D2H2L2, 8D2H2L2-mutant1, 8D3H3L3, 8D2H2L15, 8D2H2L15-mutant1, 8D2H2L17 and 8D2H2L17-mutant1.
[0027] In certain embodiments of the combination therapy, the effector-silent anti-CTLA-4 antibody or effector-silent anti-CTLA-4 antibody fragment is H and V L , V of tremelimumab H and V L ,REGN4659's V H and V L , AGEN1884w's V H and V L , 8D2 / 8D2(RE) V H and V L , 8D2 / 8D2(RE)-mutant 1 V H and V L , 8D2H1L1 V H and V L , 8D2H1L1-mutant 1 V H and V L , 8D2H2L2 V H and V L , 8D2H2L2-mutant 1 V H and V L , 8D3H3L3 V H and V L , 8D2H2L15V H and V L , 8D2H2L15V H and V L - Mutant 1, 8D2H2L17 V H and V L, or V of 8D2H2L17-mutant 1 H and V L Includes.
[0028] In certain embodiments, the effector-silent anti-CTLA-4 antibody or effector-silent anti-CTLA-4 antibody fragment comprises (i) a V H and V comprising the amino acid sequence set forth in SEQ ID NO:8 L (ii) V comprising the amino acid sequence set forth in SEQ ID NO: 15 H and V comprising the amino acid sequence set forth in SEQ ID NO:16 L (iii) V comprising the amino acid sequence set forth in SEQ ID NO: 95 H and V comprising the amino acid sequence set forth in SEQ ID NO:96 L or (iv) V having the amino acid sequence set forth in SEQ ID NO: 97. H and V having the amino acid sequence set forth in SEQ ID NO:98 L Includes.
[0029] In certain embodiments, the effector-silent anti-CTLA4 antibody or effector-silent anti-CTLA-4 antibody fragment comprises (i) a V H V domain and the amino acid sequence set forth in SEQ ID NO: 74 L (ii) a V domain comprising the amino acid sequence set forth in SEQ ID NO: 75; H V domain and the amino acid sequence set forth in SEQ ID NO: 76 L (iii) a V domain comprising the amino acid sequence set forth in SEQ ID NO: 77; H V domain and the amino acid sequence set forth in SEQ ID NO: 78 L (iv) a V domain comprising the amino acid sequence set forth in SEQ ID NO:79 H V domain and the amino acid sequence set forth in SEQ ID NO: 80 L (v) a domain comprising the amino acid sequence set forth in SEQ ID NO: 81; HV domain and the amino acid sequence set forth in SEQ ID NO: 82 L (vi) a domain comprising the amino acid sequence set forth in SEQ ID NO: 83; H V domain and the amino acid sequence set forth in SEQ ID NO: 84 L (vii) a V domain comprising the amino acid sequence set forth in SEQ ID NO: 85; H V domain and the amino acid sequence set forth in SEQ ID NO: 86 L (viii) a V domain comprising the amino acid sequence set forth in SEQ ID NO: 87; H V domain and the amino acid sequence set forth in SEQ ID NO: 88 L (ix) a V domain comprising the amino acid sequence set forth in SEQ ID NO: 89 H V domain and the amino acid sequence set forth in SEQ ID NO: 90 L (x) a domain comprising the amino acid sequence set forth in SEQ ID NO: 91; H V domain and the amino acid sequence set forth in SEQ ID NO: 92 L or (xi) a V domain comprising the amino acid sequence set forth in SEQ ID NO: 93. H V domain and the amino acid sequence set forth in SEQ ID NO: 94 L Includes the domain.
[0030] In other embodiments of the combination therapy, the effector-silent CTLA-4 blocking agent is an effector-silent anti-CTLA-4 antibody selected from the effector-silent anti-CTLA-4 antibodies disclosed in Tables 4-18.
[0031] In another embodiment of the combination therapy, the effector-silent CTLA-4 binding agent comprises one or more immunoglobulin single variable domains (ISVDs), each ISVD comprising a variable domain (V) of a camelid heavy chain-only antibody. HH), wherein each ISVD is a V having a CDR1 comprising the amino acid sequence FYGMG (SEQ ID NO:69), a CDR2 comprising the amino acid sequence DIRTSAGRTTYADSVKG (SEQ ID NO:70), and a CDR3 comprising the amino acid sequence EMSGISGWDY (SEQ ID NO:71) or EPSGISGWDY (SEQ ID NO:72). HH (the ISVDs of which are disclosed in International Patent Applications WO2008071447, WO2017087587 and WO2017087588), and which contain one, two or three mutations in CDR3 as disclosed in WO2008071447. HH except that an ISVD comprising a CDR in an embodiment in which the one or more ISVDs are fused or linked to an effector-silent heterologous HC domain or Fc domain (e.g., including any of the effector-silent antibody HC domains or Fc domains disclosed herein) is not excluded by this proviso.
[0032] In certain embodiments of the combination therapy, the anti-PD-1 antibody or anti-PD-1 antibody fragment comprises the three heavy chain complementarity determining regions (CDRs) and the three light chain CDRs of pembrolizumab, nivolumab, or cemiplimab-rwlc. In certain embodiments of the combination therapy, the anti-PD-1 antibody comprises (i) the V H and V L , (ii) V of nivolumab H and V L or (iii) V of cemiplimab-rwlc H and V L Includes.
[0033] In other embodiments, the anti-PD-1 antibody or anti-PD-1 antibody fragment has (i) a V H and V having the amino acid sequence set forth in SEQ ID NO:30 L (ii) V having the amino acid sequence set forth in SEQ ID NO:23 Hand V having the amino acid sequence set forth in SEQ ID NO:24 L or (iii) V having the amino acid sequence set forth in SEQ ID NO: 99. H and V having the amino acid sequence set forth in SEQ ID NO: 100 L In another embodiment, the anti-PD1 antibody comprises (i) a HC having the amino acid sequence set forth in SEQ ID NO:27 and a LC having the amino acid sequence set forth in SEQ ID NO:28, (ii) a HC having the amino acid sequence set forth in SEQ ID NO:25 and a LC having the amino acid sequence set forth in SEQ ID NO:26, or (iii) a HC having the amino acid sequence set forth in SEQ ID NO:101 and a LC having the amino acid sequence set forth in SEQ ID NO:102.
[0034] In certain embodiments of the combination therapy, the anti-PD-L1 antibody or anti-PD-L1 antibody fragment is H and V L domain, (ii) V of avelumab H and V L domain, or (iii) V of durvalumab H and V L Includes the domain.
[0035] In other embodiments, the anti-PD-L1 antibody or anti-PD-L1 antibody fragment comprises: (i) a V H V domain and the amino acid sequence set forth in SEQ ID NO: 104 L (ii) a V domain comprising the amino acid sequence set forth in SEQ ID NO: 105; H V domain and the amino acid sequence set forth in SEQ ID NO: 106 L or (iii) a V domain comprising the amino acid sequence set forth in SEQ ID NO: 107. H V domain and the amino acid sequence set forth in SEQ ID NO: 108 L Includes the domain.
[0036] In certain embodiments of the combination therapy, the anti-PD-1 or anti-PD-L1 antibody may comprise an IgG1, IgG2, or IgG4 Fc domain disclosed herein, which may include a C-terminal lysine or may lack the C-terminal lysine or the C-terminal glycine-lysine dipeptide.
[0037] In certain embodiments of the combination therapy, the anti-PD-1 or anti-PD-L1 antibody comprises: (i) an IgG2 or IgG4 Fc domain; (ii) an IgG1, IgG2 or IgG4 Fc domain that comprises a mutation in the N-glycosylation site Asn-Xaa-Ser / Thr starting at amino acid position 297 that prevents N-glycosylation at said N-glycosylation site; or 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 (iii) an IgG1 Fc domain comprising N297A, L234A / L235A / D265A, L234A / L235A / P329G, L235E, D265A, E233A / L235A, L235G / G236R, S267E / L328F, S2339D / A330L / I332E, or D265A / N297G amino acid substitution mutations; or (iv) an IgG2 Fc domain comprising N297A / D265S, D265A, P329G / D265A / N297G, or V234A / G237A / P238S / H268A / V309L / A330S / P331S amino acid substitutions; or or (v) an IgG4 Fc domain comprising an S228P amino acid substitution and an N267A, P329G or D265A / N297A amino acid substitution, or said mutant Fc domain further comprising 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional amino acid substitutions, insertions and / or deletions, wherein the amino acid positions are identified according to EU numbering.
[0038] In certain embodiments of the combination therapy, the PD-1 blockade is an anti-PD-1 antibody selected from the anti-PD-1 antibodies disclosed in Tables 19-27, or an anti-PD-L1 antibody selected from the PD-L1 antibodies disclosed in Tables 28-36.
[0039] In another embodiment of the combination therapy, the anti-PD-1 antibody fragment or the anti-PD-L1 antibody fragment, each of which lacks an Fc domain, is a single chain variable fragment (scFv), an antigen-binding fragment (Fab), or an antigen-binding fragment dimer F(ab')2.
[0040] In another embodiment of the combination therapy, the anti-PD-1 or anti-PD-L1 antibody fragment comprises one or more ISVDs, each ISVD being a V of a camelid heavy chain-only antibody. HH Includes.
[0041] In certain embodiments of the combination therapy, the CTLA-4 blocking agent is administered at a dose comprising about 1 mg / kg to about 3 mg / kg of CTLA-4 blocking agent or at a fixed dose of greater than about 100 mg of CTLA-4 blocking agent regardless of the individual's body weight.
[0042] In certain embodiments of the combination therapy, the CTLA-4 blocking agent is administered at a dose containing between 1 mg / kg and 3 mg / kg of the CTLA-4 blocking agent.
[0043] In certain embodiments of the combination therapy, the CTLA-4 blocking agent is administered at a dose comprising between 3 mg / kg and 10 mg / kg of the CTLA-4 blocking agent.
[0044] In certain embodiments of the combination therapy, the CTLA-4 blocking agent is administered at a dose comprising greater than about 10 mg / kg of CTLA-4 blocking agent.
[0045] In certain embodiments of the combination therapy, the PD-1 blockade is administered at a dose comprising about 2 or 3 mg / kg or more, or at a flat dose of about 200 mg or more, regardless of the weight of the individual.
[0046] In certain embodiments of the combination therapy, the PD-1 blockade is administered at a dose of 200 mg to 400 mg, regardless of the weight of the individual.
[0047] In a particular embodiment of the combination therapy, the PD-1 blockade is administered at a dose of 400 mg, independent of the individual's body weight.
[0048] In certain embodiments of the combination therapy, a PD-1 blocking agent is administered to the individual first and a CTLA-4 blocking agent is administered to the individual second, or a CTLA-4 blocking agent is administered to the individual first and a PD-1 blocking agent is administered to the individual second, hi certain embodiments, the PD-1 blocking agent and the CTLA-4 blocking agent are administered simultaneously.
[0049] In certain embodiments of the combination therapy, the individual is administered a chemotherapeutic agent prior to, concurrently with, or after the combination therapy. In certain embodiments, the chemotherapeutic agent is actinomycin, all-trans-retinoic acid, alitretinoin, azacitidine, azathioprine, bexarotene, bleomycin, bortezomib, carmoful, carboplatin, capecitabine, cisplatin, chlorambucil, cyclophosphamide, cytarabine, dacarbazine, daunorubicin, docetaxel, doxifluridine, doxorubicin, epirubicin, epothilone, etoposide, fluorouracil, gemcitabine, hydroxyurea, Selected from the group consisting of idarubicin, imatinib, ixabepilone, irinotecan, mechlorethamine, melphalan, mercaptopurine, methotrexate, mitoxantrone, nitrosourea, oxaliplatin, paclitaxel, pemetrexed, romidepsin, tegafur, temozolomide (oral dacarbazine), teniposide, thioguanine, topotecan, utiderone, barbicine, vemurafenib, vinblastine, vincristine, vindesine, vinorelbine, and vorinostat.
[0050] In certain embodiments of the combination therapy, the cancer is melanoma, non-small cell lung cancer, head and neck cancer, urothelial carcinoma, breast cancer, gastrointestinal cancer, multiple myeloma, hepatocellular carcinoma, non-Hodgkin's lymphoma, renal carcinoma, Hodgkin's lymphoma, mesothelioma, ovarian cancer, small cell lung cancer, esophageal cancer, anal cancer, biliary tract cancer, colorectal cancer, cervical cancer, thyroid cancer, or salivary gland cancer.
[0051] In certain embodiments of the combination therapy, the cancer is pancreatic cancer, bronchial cancer, prostate cancer, pancreatic cancer, gastric cancer, ovarian cancer, bladder cancer, brain or central nervous system cancer, peripheral nervous system cancer, uterine or endometrial cancer, oral or pharyngeal cancer, liver cancer, kidney cancer, testicular cancer, biliary tract cancer, small intestine or appendix cancer, adrenal cancer, osteosarcoma, chondrosarcoma, or cancer of the blood tissue.
[0052] In certain embodiments of the combination therapy, the individual is a human, the CTLA-4 blocking agent binds to human CTLA-4, the PD-1 blocking agent binds to human PD-1, and the PD-L1 blocking agent binds to human PD-L1.
[0053] Antibodies and Compositions The present invention further provides an effector-silent anti-CTLA-4 antibody or effector-silent anti-CTLA-4 antibody fragment, each of which is V H and V L where V H contains three heavy chain CDRs, and V L comprises three light chain CDRs, which together bind to CTLA-4. In a specific embodiment, the CTLA-4 is human CTLA-4.
[0054] In more particular embodiments, the effector-silent anti-CTLA-4 antibody comprises (i) an IgG1 Fc domain having a mutation at the N-glycosylation site Asn-Xaa-Ser / Thr starting at amino acid position 297 that prevents N-glycosylation at said N-glycosylation site, or said mutated Fc domain further comprising 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional amino acid substitutions, insertions and / or deletions (with the proviso that the effector-silent anti-CTLA-4 antibody comprises an N2 (ii) an IgG1 Fc domain having amino acid substitution mutations selected from the group consisting of N297A, L234A / L235A / D265A, L234A / L235A / P329G, L235E, D265A, E233A / L235A, S267E / L328F, S2339D / A330L / I332E, L235G / G236R, N297A / D356E / L358M, L234F / L235E / P331S / D365E / L358M, and D265A / N297G; or 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional amino acid substitutions, insertions and / or deletions, or (iii) a mutation in the N-glycosylation site Asn-Xaa-Ser / Thr starting at amino acid position 297 that prevents N-glycosylation at the N-glycosylation site, and a mutation in the N-glycosylation site that prevents N-glycosylation at the N-glycosylation site, comprising: L234A / L235A / D265A, L234A / L235A / P329G, L235E, D265A, E233A / L235A, S267E / L328F ... and an IgG1 Fc domain having an amino acid substitution mutation selected from the group consisting of 2339D / A330L / I332E, L235G / G236R, D356E / L358M, L234F / L235E / P331S / D365E / L358M, and D265A, or said mutant Fc domain further comprising 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional amino acid substitutions, insertions and / or deletions, wherein the amino acid positions in (i), (ii) and (iii) are identified according to Eu numbering.
[0055] In certain embodiments, the effector-silent anti-CTLA-4 antibody comprises: (i) an IgG2 Fc domain having a mutation at the N-glycosylation site Asn-Xaa-Ser / Thr starting at amino acid position 297 that prevents N-glycosylation at said N-glycosylation site, or said mutated Fc domain further comprising 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional amino acid substitutions, insertions and / or deletions; (ii) an IgG2 Fc domain having an amino acid substitution mutation selected from the group consisting of N297A / D265S, D265A, P329G / D265A / N297G, or V234A / G237A / P238S / H268A / V309L / A330S / P331S, or an IgG2 Fc domain having an amino acid substitution mutation selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional amino acid substitutions, insertions and / or deletions; or (iii) an IgG2 Fc domain having a mutation in the N-glycosylation site Asn-Xaa-Ser / Thr starting at amino acid position 297, which mutation prevents N-glycosylation at the N-glycosylation site, and an amino acid substitution mutation selected from the group consisting of N297A / D265S, D265A, P329G / D265A / N297G, or V234A / G237A / P238S / H268A / V309L / A330S / P331S, or said mutant Fc domain further comprising 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional amino acid substitutions, insertions and / or deletions, wherein the amino acid positions in (i), (ii) and (iii) are identified according to EU numbering.
[0056] In certain embodiments, the effector-silent anti-CTLA-4 antibody comprises: (i) an IgG4 Fc domain having an S228P amino acid substitution and further comprising a mutation in the N-glycosylation site Asn-Xaa-Ser / Thr starting at amino acid position 297, which prevents N-glycosylation at said N-glycosylation site, or said mutated Fc domain further comprising 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional amino acid substitutions, insertions and / or deletions; (ii) an IgG4 Fc domain having an S228P amino acid substitution and further comprising an amino acid substitution mutation selected from the group consisting of N267A, P329G and D265A / N297A, or said mutated Fc domain further comprising 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional amino acid substitutions, insertions and / or deletions; or (iii) an IgG4 Fc domain having a S228P amino acid substitution and further comprising a mutation at the N-glycosylation site Asn-Xaa-Ser / Thr starting at amino acid position 297, which mutation prevents N-glycosylation at said N-glycosylation site, and an amino acid substitution mutation selected from the group consisting of N267A, P329G, and D265A / N297A; or said mutant Fc domain further comprising 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional amino acid substitutions, insertions and / or deletions, wherein the amino acid positions in (i), (ii) and (iii) are identified according to EU numbering.
[0057] In certain embodiments, the effector-silent anti-CTLA-4 antibody or effector-silent anti-CTLA-4 antibody fragment comprises three heavy chain (HC) complementarity determining regions (CDRs) and three light chain (LC) CDRs of an anti-CTLA-4 antibody selected from the group consisting of ipilimumab, tremelimumab, REGN4659, AGEN1884w, 8D2 / 8D2(RE), 8D2H1L1, 8D2H2L2, 8D3H3L3, 8D2H2L15 and 8D2H2L17.
[0058] In certain embodiments, the effector-silent anti-CTLA-4 antibody or effector-silent anti-CTLA-4 antibody fragment has the V H and V L , V of tremelimumab H and V L ,REGN4659's V H and V L , AGEN1884w's V H and V L , 8D2 / 8D2(RE) V H and V L , 8D2H1L1 V H and V L , 8D2H2L2 V H and V L , 8D3H3L3 V H and V L , 8D2H2L15V H and V L , or 8D2H2L17 V H and V L Includes.
[0059] In certain embodiments, the effector-silent anti-CTLA-4 antibody or effector-silent anti-CTLA-4 antibody fragment has the V H and V L , 8D2H1L1-mutant 1 V H and V L , 8D2H2L2-mutant 1 V H and V L , 8D2H2L15-mutant 1 V H and V L , or V of 8D2H2L17-mutant 1 H and V L These mutants include V H It involves a substitution of methionine at position 18 in the amino acid sequence with isoleucine.
[0060] In certain embodiments, the effector-silent anti-CTLA-4 antibody or anti-effector-silent CTLA-4 antibody fragment comprises: (i) a V H and V having the amino acid sequence set forth in SEQ ID NO:8 L (ii) V having the amino acid sequence set forth in SEQ ID NO:15 H and V having the amino acid sequence set forth in SEQ ID NO:16 L (iii) V having the amino acid sequence set forth in SEQ ID NO: 95 H and V having the amino acid sequence set forth in SEQ ID NO:96 L or (iv) V having the amino acid sequence set forth in SEQ ID NO: 97. H and V having the amino acid sequence set forth in SEQ ID NO:98 L Includes.
[0061] In certain embodiments, the effector-silent anti-CTLA4 antibody or effector-silent anti-CTLA-4 antibody fragment comprises (i) a V H (ii) a V domain comprising the amino acid sequence set forth in SEQ ID NO: 75; H V domain and the amino acid sequence set forth in SEQ ID NO: 76 L (iii) a V domain comprising the amino acid sequence set forth in SEQ ID NO: 77; H V domain and the amino acid sequence set forth in SEQ ID NO: 78 L (iv) a V domain comprising the amino acid sequence set forth in SEQ ID NO:79 H V domain and the amino acid sequence set forth in SEQ ID NO: 80 L (v) a domain comprising the amino acid sequence set forth in SEQ ID NO: 81; H V domain and the amino acid sequence set forth in SEQ ID NO: 82 L (vi) a domain comprising the amino acid sequence set forth in SEQ ID NO: 83; HV domain and the amino acid sequence set forth in SEQ ID NO: 84 L (vii) a V domain comprising the amino acid sequence set forth in SEQ ID NO: 85; H V domain and the amino acid sequence set forth in SEQ ID NO: 86 L (viii) a V domain comprising the amino acid sequence set forth in SEQ ID NO: 87; H V domain and the amino acid sequence set forth in SEQ ID NO: 88 L (ix) a V domain comprising the amino acid sequence set forth in SEQ ID NO: 89 H V domain and the amino acid sequence set forth in SEQ ID NO: 90 L (x) a domain comprising the amino acid sequence set forth in SEQ ID NO: 91; H V domain and the amino acid sequence set forth in SEQ ID NO: 92 L or (xi) a V domain comprising the amino acid sequence set forth in SEQ ID NO: 93. H V domain and the amino acid sequence set forth in SEQ ID NO: 94 L Includes the domain.
[0062] In certain embodiments, the effector-silent anti-CTLA-4 antibody fragment is selected from the group consisting of F(ab), F(ab')2, Fv and scFv.
[0063] In another embodiment, the effector-silent anti-CTLA-4 antibody fragment comprises one or more immunoglobulin single variable domains (ISVDs), each ISVD comprising a variable domain (V) of a camelid heavy chain-only antibody. HH ), with the proviso that the ISVD comprises a CDR1 comprising the amino acid sequence FYGMG (SEQ ID NO: 69), a CDR2 comprising the amino acid sequence DIRTSAGRTTYADSVKG (SEQ ID NO: 70), and a CDR3 comprising the amino acid sequence EMSGISGWDY (SEQ ID NO: 71) or EPSGISGWDY (SEQ ID NO: 72); HH(the ISVDs of which are disclosed in international patent applications WO2008071447, WO2017087587 and WO2017087588), or V containing one, two or three mutations in CDR3 as disclosed in WO2008071447. HH except that an ISVD comprising a CDR in an embodiment in which the one or more ISVDs are fused or linked to an effector-silent heterologous HC domain or Fc domain (e.g., including any of the effector-silent antibody HC domains or Fc domains disclosed herein) is not excluded by this proviso.
[0064] The present invention further provides each of the effector-silent anti-CTLA-4 antibodies disclosed in Tables 4-18; with the proviso that the effector-silent anti-CTLA-4 antibodies do not include ipilimumab consisting solely of an N297A substitution.
[0065] The present invention further provides compositions comprising an effector-silent anti-CTLA-4 antibody or effector-silent anti-CTLA-4 antibody fragment disclosed herein and a pharma- ceutically acceptable carrier.
[0066] The present invention further comprises: (a) Heavy chain (HC) variable domain (V H ) having heavy chain (HC) and light chain (LC) variable domains (V L ) a light chain (LC) having V H contains at least three H complementarity determining regions (CDRs) of pembrolizumab, and V L contains at least three LC-CDRs of pembrolizumab; and (ii) V H contains at least three HC-CDRs of nivolumab and V L contains at least three LC-CDRs of nivolumab; or (iii) V H contains at least three HC-CDRs of cemiplimab-rwlc, and V L contains at least three LC-CDRs of cemiplimab-rwlc], and (b)(i) an IgG1, IgG2 or IgG4 Fc domain comprising a mutation in the N-glycosylation site Asn-Xaa-Ser / Thr starting at amino acid position 297, which prevents N-glycosylation at said N-glycosylation site, or said mutation further comprising 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional amino acid substitutions, insertions and / or deletions. (ii) an IgG1 Fc domain comprising an N297A, L234A / L235A / D265A, L234A / L235A / P329G, L235E, D265A, E233A / L235A, N297A / D356E / L358M, L234F / L235E / P331S / D365E / L358M, or D265A / N297G amino acid substitution; or (iii) an IgG2 Fc domain comprising N297A / D265S, D265A, P329G / D265A / N297G, or V234A / G237A / P238S / H268A / V309L / A330S / P331S amino acid substitutions; or or (iv) an IgG4 Fc domain comprising an S228P amino acid substitution and an N267A, P329G, D265A / N297A amino acid substitutions, or said mutant Fc domain further comprising 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional amino acid substitutions, insertions and / or deletions; wherein the amino acid positions are identified according to Eu numbering.
[0067] In still other embodiments of the above-described anti-PD-1 antibodies, the anti-PD-1 antibody comprises: (i) a V H and V having the amino acid sequence set forth in SEQ ID NO:30 L (ii) V having the amino acid sequence set forth in SEQ ID NO:23 Hand V having the amino acid sequence set forth in SEQ ID NO:24 L or (iii) V having the amino acid sequence set forth in SEQ ID NO: 99 H and V having the amino acid sequence set forth in SEQ ID NO: 100 L Includes.
[0068] In certain embodiments of the anti-PD-1 antibodies, the IgG1, IgG2, or IgG4 Fc Domains disclosed herein can further comprise a C-terminal lysine, or can lack either the C-terminal lysine or the C-terminal glycine-lysine dipeptide.
[0069] The present invention further provides a heavy chain (HC) variable domain (V H ) with heavy chain (HC) and light chain (LC) variable domains (V L and a light chain (LC) having V H contains at least three HC complementarity determining regions (CDRs) of pembrolizumab, and L contains at least three LC-CDRs of pembrolizumab; and (ii) V H contains at least three HC-CDRs of nivolumab, and V L contains at least three LC-CDRs of nivolumab; or (iii) V H contains at least three HC-CDRs of cemiplimab-rwlc, and L contains at least three LC-CDRs of cemiplimab-rwlc.
[0070] In yet another embodiment of the anti-PD-1 antibody fragment, the anti-PD-1 antibody fragment comprises: (i) a V H and V having the amino acid sequence set forth in SEQ ID NO:30 L (ii) V having the amino acid sequence set forth in SEQ ID NO:23 H and V having the amino acid sequence set forth in SEQ ID NO:24 Lor (iii) V having the amino acid sequence set forth in SEQ ID NO: 99 H and V having the amino acid sequence set forth in SEQ ID NO: 100 L Includes.
[0071] In certain embodiments of the above-described anti-PD-1 antibody fragments, the anti-PD-1 antibody fragment is selected from the group consisting of F(ab), F(ab')2, Fv, and scFv.
[0072] The invention further provides each of the anti-PD-1 antibodies disclosed in Tables 19-27.
[0073] The present invention further provides compositions comprising an anti-PD-1 antibody or anti-PD-1 antibody fragment disclosed herein and a pharma- ceutically acceptable carrier.
[0074] The present invention further comprises: (a) Heavy chain (HC) variable domain (V H ) having heavy chain (HC) and light chain (LC) variable domains (V L ) a light chain (LC) having V H contains at least three HC complementarity determining regions (CDRs) of durvalumab, and L contains at least three LC-CDRs of durvalumab; and (ii) V H contains at least three HC-CDRs of avelumab, and V L contains at least three LC-CDRs of avelumab; or (iii) V H contains at least three HC-CDRs of atezolizumab, and L contains at least three LC-CDRs of atezolizumab], and (b)(i) an IgG1, IgG2 or IgG4 Fc domain comprising a mutation in the N-glycosylation site Asn-Xaa-Ser / Thr starting at amino acid position 297, which prevents N-glycosylation at said N-glycosylation site, or said mutation further comprising 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional amino acid substitutions, insertions and / or deletions. (ii) an IgG1 Fc domain comprising an N297A, L234A / L235A / D265A, L234A / L235A / P329G, L235E, D265A, E233A / L235A, N297A / D356E / L358M, L234F / L235E / P331S / D365E / L358M, or D265A / N297G amino acid substitution; or (iii) an IgG2 Fc domain comprising N297A / D265S, D265A, P329G / D265A / N297G, or V234A / G237A / P238S / H268A / V309L / A330S / P331S amino acid substitutions, or or (iv) an IgG4 Fc domain comprising an S228P amino acid substitution and an N267A, P329G, D265A / N297A amino acid substitution, or said mutant Fc domain further comprising 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional amino acid substitutions, insertions and / or deletions; wherein the amino acid positions are identified according to Eu numbering, except that V H and V L have the amino acid sequences of SEQ ID NO: 107 and SEQ ID NO: 108, respectively, the heavy chain (HC) constant domain is not an IgG1 isotype having the substitution combination N297A / D356E / L358M, or H and V Lhave the amino acid sequences of SEQ ID NO: 103 and SEQ ID NO: 104, respectively, the HC constant domain is not of the IgG1 isotype with the substitution combination L234F / L235E / P331S / D356E / L358M.
[0075] In still other embodiments of the above-described anti-PD-L1 antibodies, the anti-PD-L1 antibody comprises: (i) a V H and V having the amino acid sequence set forth in SEQ ID NO: 104 L (ii) V having the amino acid sequence set forth in SEQ ID NO: 105 H and V having the amino acid sequence set forth in SEQ ID NO: 106 L or (iii) V having the amino acid sequence set forth in SEQ ID NO: 107. H and V having the amino acid sequence set forth in SEQ ID NO: 108 L Includes.
[0076] In certain embodiments of the anti-PD-L1 antibodies, the IgG1, IgG2, or IgG4 Fc Domains disclosed herein may further comprise a C-terminal lysine, or may lack either the C-terminal lysine or the C-terminal glycine-lysine dipeptide.
[0077] The present invention further provides a heavy chain (HC) variable domain (V H ) with heavy chain (HC) and light chain (LC) variable domains (V L and a light chain (LC) having a V H contains at least three HC complementarity determining regions (CDRs) of durvalumab, and L contains at least three LC-CDRs of durvalumab; and (ii) V H contains at least three HC-CDRs of avelumab, and V L contains at least three LC-CDRs of avelumab; or (iii) V H contains at least three HC-CDRs of atezolizumab, and Lcontains at least three LC-CDRs of atezolizumab.
[0078] In yet another embodiment, the anti-PD-L1 antibody fragment comprises: (i) a V H and V having the amino acid sequence set forth in SEQ ID NO: 104 L (ii) V having the amino acid sequence set forth in SEQ ID NO: 105 H and V having the amino acid sequence set forth in SEQ ID NO: 106 L or (iii) V having the amino acid sequence set forth in SEQ ID NO: 107. H and V having the amino acid sequence set forth in SEQ ID NO: 108 L Includes.
[0079] In certain embodiments of the above-mentioned anti-PD-L1 antibody fragments, the anti-PD-1 antibody fragment is selected from the group consisting of F(ab), F(ab')2, Fv, and scFv.
[0080] The invention further provides each of the anti-PD-L1 antibodies disclosed in Tables 28-36, except that H and V L have the amino acid sequences of SEQ ID NO: 107 and SEQ ID NO: 108, respectively, the heavy chain (HC) constant domain is not an IgG1 isotype having the substitution combination N297A / D356E / L358M, or H and V L have the amino acid sequences of SEQ ID NO: 103 and SEQ ID NO: 104, respectively, the HC constant domain is not of the IgG1 isotype with the substitution combination L234F / L235E / P331S / D356E / L358M.
[0081] The invention further provides compositions comprising an anti-PD-L1 antibody or anti-PD-L1 antibody fragment disclosed herein and a pharma- ceutically acceptable carrier.
[0082] The invention further provides a composition comprising (i) an anti-CTLA-4 antibody disclosed herein and an anti-PD-1 antibody disclosed herein and a pharma- ceutically acceptable carrier, or (ii) an anti-CTLA-4 antibody disclosed herein and an anti-PD-L1 antibody disclosed herein and a pharma- ceutically acceptable carrier.
[0083] The present invention further provides a composition comprising (i) an anti-CTLA-4 antibody fragment disclosed herein and an anti-PD-1 antibody disclosed herein and a pharma- ceutically acceptable carrier, or (ii) an anti-CTLA-4 antibody fragment disclosed herein and an anti-PD-L1 antibody disclosed herein and a pharma- ceutically acceptable carrier.
[0084] The present invention further provides a composition comprising (i) an anti-CTLA-4 antibody fragment disclosed herein and an anti-PD-1 antibody fragment disclosed herein and a pharma- ceutically acceptable carrier, or (ii) an anti-CTLA-4 antibody fragment disclosed herein and an anti-PD-L1 antibody fragment disclosed herein and a pharma- ceutically acceptable carrier.
[0085] The present invention further provides a composition comprising (i) an anti-CTLA-4 antibody disclosed herein and an anti-PD-1 antibody fragment disclosed herein and a pharma- ceutically acceptable carrier, or (ii) an anti-CTLA-4 antibody disclosed herein and an anti-PD-L1 antibody fragment disclosed herein and a pharma- ceutically acceptable carrier.
[0086] The invention further provides any of the anti-CTLA-4, anti-PD-1 or anti-PD-L1 antibodies or compositions disclosed herein for the treatment of cancer in an individual, or for the manufacture of a medicament for the treatment of cancer in an individual.
[0087] The invention further provides any of the anti-CTLA-4, anti-PD-1 or anti-PD-L1 antibody fragments or compositions disclosed herein for the treatment of cancer in an individual, or for the manufacture of a medicament for the treatment of cancer in an individual.
[0088] In certain embodiments, the cancer is melanoma, non-small cell lung cancer, head and neck cancer, urothelial carcinoma, breast cancer, gastrointestinal cancer, multiple myeloma, hepatocellular carcinoma, non-Hodgkin's lymphoma, renal carcinoma, Hodgkin's lymphoma, mesothelioma, ovarian cancer, small cell lung cancer, esophageal cancer, anal cancer, biliary tract cancer, colorectal cancer, cervical cancer, thyroid cancer, or salivary gland cancer.
[0089] In certain embodiments, the cancer is pancreatic cancer, bronchial cancer, prostate cancer, pancreatic cancer, gastric cancer, ovarian cancer, bladder cancer, brain or central nervous system cancer, peripheral nervous system cancer, uterine or endometrial cancer, oral or pharyngeal cancer, liver cancer, kidney cancer, testicular cancer, biliary tract cancer, small intestine or appendix cancer, adrenal cancer, osteosarcoma, chondrosarcoma, or cancer of the blood tissue. [Brief description of the drawings]
[0090] [Figure 1]Figures 1A-1E: CTLA-4 blockade mediated colitis is Fc dependent. Balb / c mice were treated twice weekly for 55 days with antibodies as indicated. Figure 1A: Intestinal inflammatory gene expression profiling following administration of Fc competent anti-CTLA-4 antibody (α-CTLA4) or effector-silent anti-CTLA-4 antibody with D265A substitution (α-CTLA4(D265S)). After twice weekly treatment for 7 weeks, proximal small intestine was collected for assessment of intestinal inflammatory markers by reverse transcription quantitative polymerase chain reaction (PCR). Heat maps of fold change in expression of intestinal inflammatory genes for the two antibodies compared to isotype control treatment are shown. Expression was analyzed in multiple panels and cycle threshold data was normalized to ubiquitin within each panel. Fold change relative to isotype control was determined after averaging normalized data from genes analyzed as part of multiple panels. Figure 1B: Weight loss over the experimental period. Figure 1C: Intestinal permeability was assessed by measuring FITC-dextran fluorescence in serum on days 49 and 50. Figure 1D: Histological findings for relative intestinal inflammation and colitis severity were examined and scored by a certified pathologist. Figure 1E: Representative photomicrographs of hematoxylin and eosin (H&E) stained tissue sections of colons from day 55. [Diagram 2] Figures 2A-2E: Characterization of CTLA-4 ISVD (nAb). Figure 2A: Comparison of effector-silent CTLA4 ISVD (CTLA4 nAb) with effector-competent α-CTLA4. Figure 2B: Splenic activated T cells were cultured for 3 days in the presence of CTLA4 nAb or α-CTLA4 as indicated. Proliferation (Figure 2C), production of IFNγ (Figure 2D) and production of IL-2 (Figure 2E) were measured and plotted as fold change relative to isotype control (mouse IgG2a). Data are representative of 2-3 independent experiments. [Diagram 3]Figures 3A-3D: CTLA4 nAb combined with anti-PD-1 antibody (α-PD1) has potent anti-tumor effects. Figure 3A: When tumors reached an average size of 100 mm3 (range 78-125 mm3), CT26 tumor-bearing mice were administered 5 doses of the indicated antibodies (α-CTLA4, α-PD1α-CTLA4(D265A)) at 20 mpk and / or CTLA4 nAb at 30 mpk every 4 days. Data show the average tumor volume over 32 days. Results are representative of two independent experiments (n=10 mice / group). Figure 3B: CD8 T cell / Foxp3+ Treg ratios in tumors on day 1 after treatment as indicated. Results are representative of two independent experiments (n=7 mice / group). Figures 3C and 3D: Gene expression profiles from whole tumors on day 8 after treatment. Results are representative of one or two independent experiments (n=5 mice / group). *p<0.05, **p<0.01, ***p<0.001 (paired t-test). Error bars ± SEM. Figure 3E: Individual animal tumor volumes for each treatment group compared to isotype control are shown. Complete responses (CR) by day 39 are shown for responding treatment groups. Data are representative of two independent experiments with n=10 mice / group. [Figure 4] Figures 4A-4D: Anti-CTLA-4 antibody-mediated colitis is Fc-dependent. Balb / c mice were treated with antibodies (α-CTLA4, α-PD1, α-CTLA4(D265A)) alone or in combination with CTLA4 nAb as indicated, twice weekly for 55 days. Figure 4A: Weight loss over the course of the experiment. Figure 4B: Histological assessment of intestinal inflammation in the proximal jejunum at day 55. Figure 4C: Photomicrographs of H&E stained tissue sections of colon. Figure 4D: Heatmap of fold change in expression of intestinal inflammatory genes for the indicated samples compared to isotype control treatment. Expression was analyzed in multiple panels and cycle threshold data was normalized to ubiquitin within each panel. Fold change relative to isotype control was determined after averaging normalized data from genes analyzed as part of multiple panels. [Diagram 5]Figures 5A-5C: Fc effector functional anti-CTLA-4 induces skin inflammation but not systemic inflammation. Balb / c mice were treated twice weekly for 55 days with α-CTLA4 or α-CTLA4(D265A) as indicated. Figure 5A: Photomicrographs of H&E stained tissue sections of ear skin. Figure 5B: Absolute numbers of ear skin IL-17 producing T cells, Foxp3+ Treg cells and neutrophils were measured by flow cytometry. Figure 5C: Photomicrographs of H&E stained tissue sections of kidney (upper panel), liver (middle panel) and lung (lower panel). Results represent one of two independent experiments (n=4-8 mice / group). Scale bars represent 100 μm. Error bars ± SEM. [Figure 6] Figures 6A-6D: Fc-sufficient anti-CTLA-4 antibodies do not deplete colonic Foxp3+ Tregs. Figure 6A: Intracellular CTLA-4 staining in CT26 tumor-bearing mice in the organs indicated. Figure 6B: Mean fluorescence intensity (MFI) of CTLA-4 in Foxp3+ Treg cells. **p<0.01, ***p<0.001 (paired t-test). Figures 6C and 6D: Representative dot plots and statistics of colonic lamina propria and CT26 tumor-infiltrating Foxp3+ Tregs after 24 hours of treatment as indicated. Data are representative of 2-4 independent experiments (n=4-12 mice / group). **p<0.01, ***p<0.001 (paired t-test). Error bars ± SEM. [Figure 7] Figures 7A-7D: Fc function was involved in the intestine in suppressing anti-CTLA-4 inhibitory Treg-mediated colitis. Splenic CD45Rbhigh naive T cells were transferred into CB17-SCID recipient mice and treated with α-CTLA4 or CTLA4 nAb as indicated. Figure 7A: Weight loss over the course of the experiment. Figure 7B: Photomicrographs of H&E stained tissue sections of the colon. Figure 7C: Pathological scores at day 47 (n=14-18 mice / group). Figure 7D: Gene expression profile of the whole colon at day 47 after naive T cell transfer (n=6 mice / group). Data represent one of two independent experiments. Ns=non-significant. ****p<0.0001 (unpaired t-test). Error bars ± SEM. [Figure 8]Figures 8A-8E: FcγR binding and CTLA-4 blockade activate colonic macrophages. Figures 8A and 8B: CD16 / CD32 surface expression on macrophages isolated from spleens, colonic lamina propria and tumors of CT26-bearing mice was assessed by flow cytometry. Figure 8C: The percentage of macrophages (CD45+ CD11b+ F4 / 80+) in spleens, colonic lamina propria and tumors of CT26-bearing mice was assessed by flow cytometry. Figure 8D: Il1b, Tnfα, Ifnγ and Stat1 mRNA expression from colons of mice treated with α-CTLA4, α-CTLA4(D265A) or CTLA4 nAb was assessed at days 0, 10 and 18 after treatment. Data are representative of two independent experiments (n=8-10 mice / group). ns = not significant, **p < 0.01, ***p < 0.001 (paired t-test). Error bars ± SEM. Figure 8E: Percentage of colonic lamina propria IL-17-producing CD4+ T cells (CD45+ TCRb+ CD4+ CD8a- IL-17A+), absolute numbers of IFNγ-producing CD8a+ T cells (CD45+ TCRb+ CD4- CD8a+ IFNγ+) and neutrophils (CD45+ CD11b+ Ly6Ghigh) were measured by flow cytometry. Results represent one of two independent experiments (n = 4–8 mice / group). **p < 0.01 (paired t-test). Scale bar represents 100 μm. Error bars ± SEM. [Figure 9] Figures 9A-9B: Antitumor efficacy in a mouse syngeneic MB49 bladder tumor model study. Figure 9A: Once tumors reached an average size of 102 mm3 (range 87-117 mm3), the indicated doses of antibody (30 mg / kg CTLA-4 nAb, 10 mg / kg α-CTLA4, 5 mg / kg α-PD1, or a combination of CTLA4 nAb and α-PD-1) were administered every 4 days for 4 doses to MB49 tumor-bearing mice. Data show the average tumor volume over 21 days. Results are representative of two independent experiments (n=10 mice / group). Figure 9B: Tumor volumes of individual animals for each treatment group are shown. Complete responses (CR) by day 21 are shown for the responding treatment groups. Data show the results of an experiment with n=10 mice / group. [Figure 10]Figures 10A-10B: Antitumor efficacy in a mouse syngeneic MC38 colon tumor model study. Figure 10A: Once tumors reached an average size of 220 mm3 (range 179-261 mm3), the indicated doses of antibody (30 mg / kg CTLA-4 nAb, 10 mg / kg α-CTLA4, 5 mg / kg α-PD1, or a combination of CTLA4 nAb and α-PD-1) were administered every 4 days for 4 doses to MC38 tumor-bearing mice. Data show the average tumor volume over 23 days. Results are representative of two independent experiments (n=10 mice / group). Figure 10B: Tumor volumes of individual animals for each treatment group are shown. Complete responses (CR) by day 23 are shown for the responding treatment groups. Data show the results of an experiment with n=10 mice / group. [Figure 11] Figure 11: Induction of intestinal inflammation by effector cells. Cartoon illustrating that Fc-mediated induction of intestinal inflammation can be induced by effector T cells independent of Treg depletion.
[0091] Detailed Description of the Invention definition As used herein, an "adverse event" or "AE" is any unfavorable and unintended sign (including abnormal laboratory findings), symptom, or disease (which may or may not be considered related to a medical treatment or procedure) that is temporarily associated with the administration of a medical treatment or procedure in a human individual, as described in the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 published by the US Department of Health and Human Services on November 27, 2017. An AE is a term that uniquely describes a specific event used in medical documentation and scientific analysis. A medical treatment may have one or more associated AEs, and each AE may have the same or different severity. A grade is assigned to the severity of the AE. Based on this general guideline, the CTCAE provides grades 1 to 5 with a specific clinical description of severity for each AE. Grade 1: Mild, or asymptomatic or mild symptoms, clinical or diagnostic observations only, or intervention is not indicated. Grade 2: Moderate or minimal, focal or non-invasive intervention indicated, or limitation of age-appropriate instrumental activities of daily living (ADLs). Grade 3: Severe or medically significant but not immediately life-threatening, or hospitalization or extended hospitalization indicated, disabling, or limitation of self-care (ADLs). Grade 4: Life-threatening consequences or urgent intervention indicated. Grade 5: Death related to the AE.
[0092] As used herein, an "antibody" refers to a glycoprotein comprising (a) at least two heavy chains (HC) and two light chains (LC) inter-connected by disulfide bonds, or (b) in the case of camelid antibody species, at least two heavy chains (HC) inter-connected by disulfide bonds. Each HC contains a heavy chain variable region or domain (V H) and the heavy chain constant region or domain. In certain naturally occurring IgG, IgD and IgA antibodies, the heavy chain constant region is composed of three domains: C H 1. C H 2 and C H 3. Generally, the basic antibody structural unit of an antibody is a tetramer containing two HC / LC pairs, except for camelid antibody species, which contain only two HCs, in which case the structural unit is a homodimer. Each tetramer contains two identical pairs of polypeptide chains, each pair having one LC (about 25 kDa) and one HC chain (about 50-70 kDa).
[0093] In certain naturally occurring antibodies, each light chain comprises an LC variable region or domain (V L ) and the LC constant domain. The LC constant domain consists of one domain C L It is composed of Human V H There are six family members, namely, V H 1. V H 2. V H 3. V H 4. V H 5 and V H 6, including human V L There are 16 family members, namely, V κ 1. V κ 2. V κ 3. V κ 4. V κ 5. V κ 6. V λ 1. V λ 2. V λ 3. V λ 4. V λ 5. V λ 6. V λ 7. V λ 8. V λ 9 and V λ 10. Each of these family members can be further divided into specific subtypes. H and V LDomains can be further subdivided into regions of hypervariability called complementarity determining regions (CDRs), interspersed with more conserved regions called framework regions (FRs). H and V L is composed of three CDR regions and four FR regions, arranged from the amino terminus to the carboxy terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.
[0094] The variable regions of the heavy and light chains contain a binding domain that includes CDRs that interact with an antigen. The constant region of the antibody can mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (C1q) of the classical complement system. The assignment of amino acids to each domain generally follows the definitions in Sequences of Proteins of Immunological Interest, Kabat et al.; National Institutes of Health, Bethesda, Md.; 5th ed.; NIH Publ. No. 91-3242 (1991); Kabat (1978) Adv. Prot. Chem. 32:1-75; Kabat et al., (1977) J. Biol. Chem. 252:6609-6616; Chothia et al., (1987) J Mol. Biol. 196:901-917 or Chothia et al., (1989) Nature 342:878-883.
[0095] Typically, the numbering of amino acids in the heavy chain constant domain starts at number 118, which is according to the Eu numbering scheme. The Eu numbering scheme is based on the amino acid sequence of human IgG1 (Eu), which has a constant domain starting at position 118 of the amino acid sequence of IgG1 as described in Edelman et al., Proc. Natl. Acad. Sci. USA. 63:78-85 (1969), and is shown for IgG1, IgG2, IgG3 and IgG4 constant domains in Beranger et al., eds., Ginetoux, Correspondence between the IMGT unique numbering for C-DOMAIN, the IMGT exon numbering, the Eu and Kabat numberings: Human IGHG, created 17 / 05 / 2001, version: 08 / 06 / 2016, which can be accessed at www.imgt.org / IMGTScientificChart / Numbering / Hu_IGHGnber.html#r.
[0096] In general, the V H / V L The pair consists of six CDRs (V H The top three CDRs and V LAlthough the CDR3 region of the heavy chain comprises the three CDRs above, the state of the art recognizes that in most cases, the CDR3 region of the heavy chain is the primary determinant of antibody specificity, and examples of generating specific antibodies based solely on the CDR3 of the heavy chain are known in the art (e.g., Beiboer et al., J. Mol. Biol. 296:833-849 (2000); Klimka et al., British J. Cancer 83:252-260 (2000); Rader et al., Proc. Natl. Acad. Sci. USA 95:8910-8915 (1998); Xu et al., Immunity 13:37-45 (2000)). See Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991) (defining the CDR regions of antibodies by sequence). See also Chothia & Lesk J. Mol. Biol. 196:901-917 (1987) (structurally defining antibody CDR regions).
[0097] To identify CDRs in an antibody sequence that contain amino acids that interact specifically with amino acids that comprise the epitope in the antigen to which the antibody binds, the following general rules may be used, as disclosed at www.bioinf.org.uk (Prof. Andrew C. Martin's group) and reproduced in the table below: Cys residues are the most conserved features, although there are rare instances where these generally invariant features are not found. [Table 1]
[0098] TIFF0007581225000002.tif42158
[0099] Generally, the basic antibody structural unit comprises a tetramer. Each tetramer comprises two identical pairs of polypeptide chains, each pair having one LC (about 25 kDa) and HC (about 50-70 kDa). The amino-terminal portion of each chain comprises a variable region of about 100-110 or more amino acids that are primarily responsible for antigen recognition. The carboxy-terminal portion of the HC may define a constant region that is primarily responsible for the effector functions of the antibody. Typically, human LCs are classified as kappa and lambda LCs. Furthermore, human HCs are typically classified as mu, delta, gamma, alpha or epsilon, which define the antibody isotype as IgM, IgD, IgG, IgA and IgE, respectively. In the LC and HC, the variable and constant regions are linked by a "J" region of about 12 or more amino acids, and the HC also comprises a "D" region of about 10 or more amino acids. See generally, Fundamental Immunology Ch. 7 (Paul, W., ed., 2nd ed. Raven Press, NY (1989)).
[0100] The heavy chain of an antibody may or may not have a terminal lysine (K) residue, or a terminal glycine and lysine (GK) residue. Thus, in certain embodiments, an antibody of the invention comprises a heavy chain constant region amino acid sequence as set forth herein, and further lacks a terminal lysine, terminates with a glycine residue, or in other embodiments also lacks a terminal glycine residue. This is because the terminal lysine, and sometimes the glycine and lysine together, may be cleaved off during expression of the antibody, or cleaved off once introduced into the human body, without any apparent adverse effect on the efficacy, stability, or immunogenicity of the antibody. In some cases, the nucleic acid molecule encoding the heavy chain may purposely omit the codon encoding the terminal lysine or the codons for the terminal lysine and glycine.
[0101] As used herein, "antibody fragment" or "antigen-binding fragment" refers to a fragment of a full-length antibody, i.e., an antibody fragment that retains the ability to specifically bind to the antigen bound by the full-length antibody, but is less than full-length, which lacks the entire Fc domain or the portion of the Fc domain that causes the antibody to bind to FcγR. Examples of antibody-binding fragments include, but are not limited to, Fab, Fab', F(ab')2 and Fv fragments; diabodies; scFv molecules; nanobodies, and multispecific antibodies formed from antibody fragments.
[0102] As used herein, a "chimeric antibody" is an antibody having variable domains from a first antibody and constant domains from a second antibody, where (i) the first and second antibodies are derived from different species (U.S. Pat. No. 4,816,567 and Morrison et al., Proc. Natl. Acad. Sci. USA 81:6851-6855 (1984)), or (ii) the first and second antibodies are derived from different isotypes, e.g., the variable domain is derived from an IgG1 antibody and the constant domain is derived from an IgG4 antibody. In one embodiment, the variable domain is obtained from a non-human antibody, e.g., a mouse antibody (the "parent antibody"), and the constant domain sequences are obtained from a human antibody. In another embodiment, the variable domain is a humanized variable domain derived from a mouse antibody and the constant domain is that of a human antibody.
[0103] As used herein, "combination therapy" refers to the treatment of a human or animal individual that includes administering a first therapeutic agent and a second therapeutic agent to the individual, either sequentially or simultaneously. Generally, the first and second therapeutic agents are administered to the individual separately, rather than as a mixture; however, there may be embodiments in which the first and second therapeutic agents are mixed prior to administration.
[0104] As used herein, "conservative substitution" refers to the substitution of an amino acid with another amino acid having similar properties (e.g., charge, side chain size, hydrophobicity / hydrophilicity, backbone conformation and rigidity, etc.) such that changes can be made frequently without modifying the biological activity of a protein. In general, those skilled in the art recognize that single amino acid substitutions in non-essential regions of a polypeptide do not substantially change biological activity (see, for example, Watson et al. Molecular Biology of the Gene, The Benjamin / Cummings Pub.Co., p.224(4th Ed.)(1987)). Also, substitution of structurally or functionally similar amino acids is unlikely to destroy biological activity. Exemplary conservative substitutions are shown in Table 2. [Table 2]
[0105] "Cytotoxic T-lymphocyte-associated antigen 4", "CTLA4", "CTLA4", "CTLA4 antigen" and "CD152" (see, e.g., Murata, Am. J. Pathol. 155:453-460 (1999)) are used interchangeably and include variants, isoforms, species homologs of human CTLA-4, and analogs that share at least one epitope in common with CTLA-4 (see, e.g., Balzano, Int. J. Cancer Suppl. 7:28-32 (1992)). The complete CTLA-4 nucleic acid sequence can be found in GenBank accession number L15006.
[0106] As used herein, "effector function" refers to a biological activity attributable to the Fc region of an antibody that varies with antibody isotype. Examples of antibody effector functions include Clq binding and complement-dependent cytotoxicity (CDC), Fc receptor binding, antibody-dependent cell-mediated cytotoxicity (ADCC), phagocytosis, downregulation of cell surface receptors (e.g., B cell receptors), and B cell activation. Antibodies act by several mechanisms, most of which involve other arms of the immune system. Antibodies can simply block molecular interactions, or they can activate the classical complement pathway (known as complement-dependent cytotoxicity or CDC) by interaction of clustered antibodies with C1q on the C1 complex. Importantly, antibodies also act as a link between antibody-mediated and cellular immune responses through the engagement of Fc receptors.
[0107] As used herein, "effector-silent" refers to an antibody or antibody fragment that (i) exhibits no measurable binding to one or more Fc receptors (FcRs) as measured by Biacore assay (wherein association constants in the micromolar range show no measurable binding), or (ii) exhibits reduced measurable binding to one or more FcRs as measured by Biacore assay compared to binding typical for antibodies of the same isotype. In certain embodiments, the antibody can contain one or more mutations in the HC constant domain and the Fc domain, in particular such that the mutant antibody has reduced or no measurable binding to FcγRIIIa, FcγRIIa and FcγRI compared to a wild-type antibody of the same isotype as the mutant antibody. In certain embodiments, the affinity or binding constant of an effector-silent antibody for one or more of FcγRIIIa, FcγRIIa, and FcγRI is at least 1000-fold decreased compared to the affinity of the wild-type isotype, at least 100-fold to 1000-fold decreased compared to the affinity of the wild-type isotype, at least 50-fold to 100-fold decreased compared to the affinity of the wild-type isotype, or at least 10-fold to 50-fold decreased compared to the affinity of the wild-type isotype. In certain embodiments, an effector-silent antibody does not exhibit detectable or measurable binding to one or more of FcγRIIIa, FcγRIIa, and FcγRI compared to binding by the wild-type isotype. In general, effector-silent antibodies lack measurable antibody-dependent cell-mediated cytotoxicity (ADCC) activity. Effector-silent antibody fragments lack the Fc domain, or the portion of the Fc domain that confers binding to an FcR, and therefore do not exhibit detectable or measurable binding to one or more of FcγRIIIa, FcγRIIa, or FcγRI. In the case of effector-silent antibodies or antibody fragments, binding is measured against a human FcR.
[0108] As used herein, a "Fab fragment" refers to a fragment of one LC and one HC V.H and C H 1 and does not contain the remainder of the HC constant domain. H 1 cannot form disulfide bonds with another Fab fragment or with an HC-containing molecule. A "Fab fragment" may be the product of papain cleavage of an antibody.
[0109] As used herein, a "Fab' fragment" refers to a fragment that contains one LC and one H 1 Domain and C H The HC constant domain and V H The Fab' fragments each contain one HC fragment containing the HC constant domain and no remainder of the HC constant domain, such that interchain disulfide bonds can form between the two HCs of the two Fab' fragments to form an F(ab')2 molecule.
[0110] As used herein, a "F(ab')2 fragment" comprises two LC and two HC fragments, each of which is a C H 1 Domain and C H The HC constant domain and V H The F(ab')2 fragment contains the C Fab' domain and does not contain the remainder of the HC constant domain, resulting in the formation of an interchain disulfide bond between the two HCs. Thus, the F(ab')2 fragment is composed of two Fab' fragments bound together by disulfide bonds between the two heavy chains. The F(ab')2 fragment is composed of the C Fab' fragment and the C Fab' fragment. H 1 Domain and C H This can be obtained by digesting the antibody with pepsin, which cleaves the antibody at the site between the two domains.
[0111] As used herein, "Fc domain" or "Fc" refers to the C domain of an antibody. H 2 domain and C H A crystallizable fragment domain or region obtained from an antibody that contains three Fc domains. In an antibody, the two Fc domains are separated by two or more disulfides and by C HThe three domains bind to each other through hydrophobic interactions. The Fc domain can be obtained by digesting an antibody with the protease papain.
[0112] As used herein, "Fc receptor" or "FcR" is an important immunoregulatory receptor that links antibody-mediated (humoral) immune responses with cellular effector functions. Receptors for all classes of immunoglobulins have been identified, including FcγR (IgG), FcεRI (IgE), FcαRI (IgA), FcμR (IgM) and FcδR (IgD). There are three classes of receptors for human IgG found on leukocytes: CD64 (FcγRI), CD32 (FcγRIIa, FcγRIIb and FcγRIIc) and CD16 (FcγRIIIa and FcγRIIIb). FcγRI is classified as a high affinity receptor (KD in the nanomolar range), while FcγRII and FcγRIII are low to moderate affinity (KD in the micromolar range). In antibody-dependent cellular cytotoxicity (ADCC), FcRs on the surface of effector cells (natural killer cells, macrophages, monocytes, and eosinophils) bind to the Fc region of IgG bound to a target cell. Upon binding, signaling pathways are initiated that lead to the secretion of various substances such as lytic enzymes, perforin, granzymes, and tumor necrosis factor, which result in the destruction of the target cell. The level of ADCC effector function differs among human IgG subtypes. This depends on the allotype and the particular FcR, but briefly, ADCC effector function is high in human IgG1 and IgG3 and low in IgG2 and IgG4.
[0113] As used herein, an "Fv region" refers to a single V H and V L pairs, where V H Polypeptides and V L The polypeptides are linked to each other by disulfide bonds.
[0114] "Humanization" as used herein (also referred to as reshaping or CDR grafting) is a well-established technique for reducing the immunogenicity and improving effector functions (ADCC, complement activation, C1q binding) of monoclonal antibodies (mAbs) of heterologous (usually rodent) origin. Engineered mAbs are engineered using molecular biology techniques, but simple CDR grafting of rodent complementarity determining regions (CDRs) onto a human framework often results in loss of binding affinity and / or specificity of the original mAb. To humanize an antibody, the design of the humanized antibody includes mutations such as conservative amino acid substitutions at residues of the CDRs and back-substitution (backmutation) of residues from the rodent mAb into the human framework regions. Positions can be identified or specified by sequence comparison for structural analysis or by analysis of homology models of the three-dimensional structure of the variable regions. The process of affinity maturation has most recently used phage libraries to change amino acids at selected positions. Similarly, numerous approaches have been used to select the most appropriate human framework for grafting rodent CDRs. As the data set of known parameters for antibody structure increases, so does the sophistication and refinement of these techniques. Consensus or germline sequences from a single antibody, or fragments of framework sequences within each light or heavy chain variable region from several different human mAbs, can be used. Another approach to humanization is to modify only the surface residues of rodent sequences with the most common residues found in human mAbs, and is called "resurfacing" or "veneering". Often, human or humanized antibodies are substantially non-immunogenic in humans.
[0115] As used herein, "humanized antibody" refers to a form of antibody or antibody fragment that contains sequences from both human and non-human (e.g., mouse, rat) antibodies. Generally, a humanized antibody contains all of at least one, and typically two, variable domains, in which the hypervariable loops correspond to those of a non-human immunoglobulin, and all or substantially all of the framework (FR) regions are those of a human immunoglobulin sequence. The humanized antibody may optionally contain at least a portion of a human immunoglobulin constant region (e.g., Fc domain).
[0116] As used herein, "hyperproliferative disease" refers to a condition in which cell proliferation is increased above normal levels. For example, hyperproliferative diseases or disorders include malignant diseases (e.g., esophageal cancer, colon cancer, bile duct cancer) and non-malignant diseases (e.g., atherosclerosis, benign hyperplasia, benign prostatic hyperplasia).
[0117] As used herein, "immune-related adverse events" or "irAEs" refer to AEs that are autoimmune symptoms due to an imbalance in the immune system that can result from the use of one or more immune checkpoint inhibitors, such as anti-PD-1, anti-PD-L1 and anti-CTLA-4 antibodies.
[0118] As used herein, "immune response" refers to the action of, for example, lymphocytes, antigen-presenting cells, phagocytes, granulocytes, and soluble macromolecules produced by such cells or the liver, including antibodies, cytokines, and complement, that result in the selective damage, destruction, and elimination from the body of invading pathogens, pathogen-infected cells or tissues, cancerous cells, or, in the case of autoimmunity or pathological inflammation, normal human cells or tissues.
[0119] As used herein, an "immunoglobulin single variable domain" (also referred to as an "ISV" or ISVD) is a variable domain that generally occurs without interaction with another variable domain (e.g., the V of a conventional four-chain monoclonal antibody). H Domain and V L V that is required between the domain H / V LImmunoglobulin variable domains (V domains) capable of forming a functional antigen-binding site (without interacting with each other) H , V HH or V L Examples of ISVDs include NANOBODY (V domains) and ISVD (V light chain domains). HH , humanized V HH and / or camelization V H , e.g. camelized human V H ), IgNAR, domain, V H Domain or V H Domain-derived (single domain) antibodies (e.g., dAbs™), and V L Domain or V L Domain-derived (single domain) antibodies (e.g., dAbs™). H or V HH ISVDs based on and / or derived from the nucleotide sequence (domain) are generally preferred.
[0120] As used herein, "monoclonal antibody" refers to a population of substantially homogeneous antibodies, i.e., the antibody molecules comprising the population are identical in amino acid sequence, except for possible naturally occurring mutations that may be present in minor amounts. In contrast, conventional (polyclonal) antibody preparations typically contain a large number of different antibodies having different amino acid sequences in the variable domains, which are often specific for different epitopes. The modifier "monoclonal" indicates the character of the antibody as being obtained from a substantially homogeneous antibody population, and is not to be construed as requiring production of the antibody by any particular method. For example, monoclonal antibodies to be used in accordance with the present invention can be made by the hybridoma method first described in Kohler et al., Nature 256:495 (1975), or can be made by recombinant DNA methods (see, e.g., U.S. Pat. No. 4,816,567). "Monoclonal antibodies" can also be isolated from phage antibody libraries using the techniques described in, for example, Clackson et al., Nature 352:624-628 (1991) and Marks et al., J. Mol. Biol. 222:581-597 (1991). See also Presta J. Allergy Clin. Immunol. 116:731 (2005).
[0121] As used herein, "NANOBODY" and "nanobody" are registered trademarks of Ablynx NV.
[0122] "Non-human amino acid sequence" as used herein with respect to an antibody or immunoglobulin means an amino acid sequence that is characteristic of the amino acid sequence of a non-human mammal. This term does not include amino acid sequences of antibodies or immunoglobulins obtained from fully human antibody libraries where the diversity of the library is generated in silico (see, e.g., U.S. Patent Nos. 8,877,688 or 8,691,730).
[0123] "PD-1" refers to the programmed death 1 (PD-1) protein, an inhibitory member of the extended CD28 / CTLA-4 family of T cell regulators (Okazaki et al., Curr. Opin. Immunol. 14:391779-82 (2002); Bennett et al., J. Immunol. 170:711-8 (2003)). Other members of the CD28 family include CD28, CTLA-4, ICOS, and BTLA. The PD-1 gene encodes a 55 kDa type I transmembrane protein (Agata et al., Intl. Immunol. 8:765-72 (1996)). Two ligands for PD-1, namely PD-L1 (B7-H1) and PD-L2 (B7-DC), have been identified and shown to downregulate T cell activation upon binding to PD-1 (Freeman et al. (2000) J. Exp. Med. 192:1027-34; Carter et al. (2002) Eur. J. Immunol. 32:634-43). PD-1 is known as an immunosuppressive protein that negatively regulates TCR signals (Ishida, Y. et al., EMBO J. 11:3887-3895 (1992); Blank, C. et al., Immunol. Immunother. 56(5):739-745 (Epub 2006 Dec.29)). The interaction between PD-1 and PD-L1 functions as an immune checkpoint that can lead, for example, to a reduction in tumor-infiltrating lymphocytes, reduced T cell receptor-mediated proliferation and / or immune evasion by cancer cells (Dong et al., J. Mol. Med. 81:281-7 (2003); Blank et al., Cancer Immunol. Immunother. 54:307-314 (2005); Konishi et al., Clin. Cancer Res. 10:5094-100 (2004)). Immunosuppression can be reversed by inhibiting the local interaction of PD-1 with PD-L1 or PD-L2, and the effect is additive when the interaction of PD-1 with PD-L2 is blocked (Iwai et al., Proc. Nat'l. Acad. Sci. USA 99:12293-12297 (2002); Brown et al., J. Immunol. 170:1257-66 (2003)).
[0124] "Programmed Death 1", "Programmed Cell Death 1", "Protein PD-1", "PD-1", "PD1", "PDCD1", "hPD-1" and "hPD-1" are used interchangeably and include variants, isoforms, species homologs of human PD-1, and analogs that share at least one epitope in common with PD-1. The complete PD-1 sequence can be found in GenBank Accession No. U64863.
[0125] As used herein, "ScFv" or "single chain variable fragment" refers to VFvs that are fused or linked together by a short linker peptide of 10 to about 25 amino acids. H and V L The linker is usually rich in glycine for flexibility and rich in serine or threonine for solubility, and contains V H N-terminus of V L or vice versa. The protein retains the specificity of the original immunoglobulin despite the removal of the constant region and the introduction of the linker.
[0126] As used herein, "subtherapeutic dose" refers to a dose of a therapeutic compound (e.g., an antibody) that is lower than the usual or typical dose of the therapeutic compound when administered alone for the treatment of a hyperproliferative disease (e.g., cancer). The dose of the therapeutic compound may vary depending on the disease being targeted. For example, a subtherapeutic dose of a CTLA-4 antibody is a single dose of the antibody less than about 3 mg / kg, which is the known monotherapy dose of the anti-CTLA-4 antibody YERVOY for the treatment of unresectable or metastatic melanoma, or a single dose of YERVOY less than about 10 mg / kg, which is the known monotherapy dose for melanoma adjuvant therapy.
[0127] As used herein, "treatment" or "treating" refers to the administration, internally or externally, of a therapeutic agent, such as a composition containing any of the antibodies or antigen-binding fragments of the present invention, to a subject or patient having or suspected of having one or more disease symptoms for which the agent exhibits therapeutic or prophylactic activity. Typically, the therapeutic agent is administered in an amount effective to reduce one or more disease symptoms in a treated subject or population, by inducing regression of such symptoms or inhibiting the progression of such symptoms by any clinically measurable degree. The amount of a therapeutic agent effective to reduce any particular disease symptom may vary depending on factors such as the condition, age, and weight of the patient, and the ability of the drug to elicit a desired response in the subject. Whether a disease symptom has been reduced may be assessed by any clinical scale typically used by a physician or other skilled health care provider to assess the severity or progression of the symptom. The term further includes delaying the onset of symptoms associated with a disorder and / or reducing the severity of symptoms of such a disorder. The term further includes amelioration of existing uncontrolled or undesirable symptoms, prevention of additional symptoms, and amelioration or prevention of the underlying cause of such symptoms. Thus, the term indicates that a beneficial result is provided to a human or animal subject having a disorder, disease or condition, or having a potential for developing such a disorder, disease or condition.
[0128] As used herein, a "therapeutically effective amount" refers to an amount of a particular substance sufficient to achieve a desired effect in the subject being treated. For example, this can be the amount of a CTLA-4 blocking agent necessary to suppress CTLA-4 activation and induce an anti-tumor response, or the amount necessary to enhance anti-PD-1 or anti-PD-L1 responsiveness when co-administered with an anti-PD-1 or anti-PD-L1 blocking agent, respectively.
[0129] As used herein, "therapeutic index," also known as the "therapeutic range," "margin of safety," or "therapeutic ratio," is the comparison of the amount of a therapeutic agent that produces a therapeutic effect to the amount of a therapeutic agent that causes toxicity.
[0130] As used herein, "treatment", as applied to a human or veterinary individual, means a therapeutic procedure involving contacting an antibody or antigen-binding fragment with the human or animal individual in need of treatment with the antibody or antibody fragment.
[0131] As used herein, "V HH " is V H It indicates that the domain is obtained or derived from an HC antibody or is derived from an HC antibody. A heavy chain antibody is a functional antibody that has two HCs and no LC. Heavy chain antibodies are present in and available from camelids, members of the biological family Camelidae.
[0132] Introduction Commercially available PD-1 antagonists such as the anti-PD-1 antibodies KEYTRUDA and OPDIVO contain a human IgG4 backbone with reduced FcγR function, because preclinical studies using anti-PD-1 antibodies with FcγR binding function showed poor antitumor effects due to the depletion of CD8+ cytotoxic T cells (CTLs), which are essential for tumor immunotherapy (see, for example, International Patent Application WO2014 / 089113). In contrast, mouse IgG with high FcγR binding affinity 2a In preclinical studies comparing a mouse IgG1-anti-CTLA-4 antibody with a mutant murine IgG1-anti-CTLA-4 antibody lacking measurable FcγR binding affinity, monotherapy with an anti-CTLA-4 antibody was shown to require FcγR function to elicit a potent antitumor response (Selby et al., Cancer Immunol Res. 1:32-42 (2013)). CTLA-4 expression was not associated with T cell proliferation in the spleen or lymph nodes, but was associated with a decreased FcγR function in TILs. reg The requirement for FcγR function in anti-CTLA-4 antagonist monotherapy was demonstrated in a mouse tumor model, because the expression of FcγR in the T regulatory cell (T reg ) correlated with depletion.
[0133] We hypothesized that the requirement for FcγR function for the efficacy of anti-CTLA-4 antibodies could be circumvented by combining anti-CTLA-4 antibodies with anti-PD-1 antibodies. + This is supported by new data showing the important role for CD28-mediated costimulation in anti-PD-1-mediated activation of cytotoxic T cells. Anti-CTLA-4 and anti-PD-1 antibodies exert their antitumor activity through different mechanisms. Importantly, the combinatorial effect of anti-CTLA-4 and anti-PD-1 antibodies is not merely additive, since the combined blockade provided by the two antibodies results in the activation of many genes (including proliferation-related and chemokine genes) that are not activated by either antibody alone (see, for example, Figures 3C and 4D). These data suggest that the mechanism of action of CTLA-4 blockade in monotherapy is different from that when performed in combination with PD-1 blockade.
[0134] New data suggest that after PD-1 blockade, effector T (T eff These results indicate the importance of CD28-mediated costimulation in the activation of irAE-mediated T cells. PD-1 signaling dephosphorylates CD28, rather than TCR as previously assumed, and CD28 signaling is required for the enhanced antitumor responses observed after PD-1 blockade. Thus, while monotherapy CTLA-4 blockade may primarily target T cell priming events, the combination of CTLA-4 blockade with PD-1 blockade is expected to promote activation of exhausted T cells beyond that expected from PD-1 blockade alone. We hypothesize that this mechanism is enhanced by CTLA-4 antagonists, which may be an important driver of irAE-mediated toxicity in T cells. reg Allows for cell depletion and enhancement of CD28-mediated activation independent of Fc receptor function.
[0135] A potential caveat in this case for anti-CTLA-4 antibodies that bind to FcR (Fc functional antibodies) is that regOne potential explanation is that depletion or cellular cross-linking of myeloid cells with T cells may induce undesirable immune-related inflammation. We hypothesized that it is Fc function that may contribute to the observed irAEs associated with CTLA-4 blockade cancer immunotherapy. One critique that has been used to argue against the potential role of Fc function for the induction of irAEs is that ipilimumab (on a human IgG1 backbone) and tremelimumab (on a human IgG2 backbone) treatments have both been associated with intestinal inflammation. Although the human IgG2 Fc domain has significantly lower affinity for human FcγR compared to human IgG1, direct comparison of antibodies with human IgG2 and IgG1 backbones shows that both induce similar levels of Fc function when using in vitro ADCC and ADCP bioassays (Vargas et al., Cancer Cell. 33:649-663 (2018)). Furthermore, in vivo T cells of chimeric anti-mouse CTLA-4 antibodies with either a human IgG1 or a human IgG2 isotype backbone were reg Depletion and antitumor activity was comparable in human FcγR knock-in mice (Vargas et al., ibid.).
[0136] A key obstacle to assessing the potential role of Fc function to induce intestinal inflammation in syngeneic tumor models was the lack of measurable inflammation and colitis when using mouse anti-CTLA-4 surrogate antibodies. To circumvent this obstacle, we employed a PCR-based panel, previously developed in Cayatte et al., Clin. Transl. Gastroenterol. 3: e10 (2012), to measure the upregulation of intestinal inflammatory genes associated with inflammatory bowel disease (IBD) in a mouse IBD model. As shown in the Examples herein, this PCR-based panel allowed us to detect increased expression of biomarker genes indicative of intestinal inflammation in mice treated with Fc functional anti-mouse CTLA-4 antibody (α-CTLA4), even in the absence of overt colitis or histological evidence of tissue damage (see Figures 1A, 3C, and 4D). This observation of subclinical stimulation of intestinal inflammatory gene expression pathways encouraged us to extend the treatment schedule to determine whether the underlying inflammation progresses to the development of clinical colitis. This irAE colitis mouse model allowed us to perform validation experiments to evaluate the requirement of Fc function for the induction of intestinal inflammation in the context or absence of a concomitant anti-tumor response in syngeneic tumor models utilized in preclinical immuno-oncology development.
[0137] The results described in the Examples clearly show that neither effector-silent anti-CTLA-4 antibodies nor effector-silent anti-CTLA-4 antibody fragments induce measurable anti-tumor activity in the case of monotherapy. However, administration of effector-silent antibodies or effector-silent antibody fragments in combination with anti-PD1 antibodies results in anti-tumor activity comparable to that induced by effector-functional anti-CTLA-4 antibodies alone or in combination with anti-PD-1 antibodies (see Figure 3A), and in this case does not result in gut or skin irAEs (Figures 4B and 5A) or weight loss (Figure 4A) as observed with effector-functional anti-CTLA-4 antibodies alone or in combination with anti-PD-1 antibodies. These results, as well as potential T-cell interactions associated with Fc-mediated anti-tumor activity and gut inflammation, are presented. reg Given our discovery of an independent mechanism, the present invention enables CTLA-4 / PD-1 blockade combination anti-cancer immunotherapy with improved therapeutic index and broader utility.
[0138] Combination therapy The present invention provides an anti-cancer combination therapy comprising administering to an individual in need of cancer treatment (i) a PD-1 blocking agent selected from the group consisting of an anti-PD-1 antibody, an anti-PD-L1 antibody, an effector-silent anti-PD-1 antibody, an effector-silent anti-PD-L1 antibody, an effector-silent anti-PD-1 antibody fragment, and an effector-silent anti-PD-L1 antibody fragment, and (ii) an effector-silent CTLA-4 blocking agent selected from the group consisting of an effector-silent anti-CTLA-4 antibody and an effector-silent anti-CTLA-4 antibody fragment.
[0139] The effector-silent CTLA-4 blockers can be administered in combination with PD-1 blockers at a dose greater than the sub-therapeutic 1 mg / kg dose of ipilimumab approved by the US FDA for ipilimumab / nivolumab combination therapy targeting advanced renal cell carcinoma or microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer, where the risk of inducing skin or intestinal irAEs greater than Grade 1-2 during the combination therapy or for at least a portion of the time that an individual is receiving the combination therapy is lower than that observed with ipilimumab / nivolumab combination therapy. In certain embodiments, the dose does not induce irAEs greater than Grade 1 during the combination therapy or for at least a portion of the time that an individual is receiving the combination therapy.
[0140] Thus, in certain embodiments, the effector-silent CTLA-4 blocking agent may be administered to an individual at a dose of more than 1 mg / kg. In certain embodiments, the effector-silent CTLA-4 blocking agent may be administered to an individual at a dose of at least 3 mg / kg. In certain embodiments, the effector-silent CTLA-4 blocking agent may be administered to an individual at a dose of at least 10 mg / kg. In certain embodiments, the effector-silent CTLA-4 blocking agent may be administered to an individual at a dose of at least 15 mg / kg. In certain embodiments, the effector-silent CTLA-4 blocking agent may be administered to an individual at a dose of at least 20 mg / kg. In certain embodiments, the effector-silent CTLA-4 blocking agent may be administered to an individual at a dose of 3 mg / kg to 20 mg / kg. In certain embodiments, the effector-silent CTLA-4 blocking agent may be administered to an individual at a fixed dose that is not dependent on the individual's body weight, for example, a dose of more than 100 mg.
[0141] In a particular embodiment of the combination therapy, the effector-silent CTLA-4 blocking agent is an effector-silent anti-CTLA-4 antibody or (b) an effector-silent anti-CTLA-4 antibody fragment. Since the anti-CTLA-4 antibody does not need effector function activity, the anti-CTLA-4 antibody has an HC domain engineered to be "effector-silent", i.e., its Fc domain is modified, and the antibody has reduced or no measurable FcR binding, as measured by Biacore assay, compared with the Fc domain of a wild-type antibody of the same isotype as the effector-silent antibody (e.g., the Fc domain of an unmutated IgG1, IgG2, IgG3 or IgG4 Fc domain). The effector-silent anti-CTLA-4 antibody fragment lacks an Fc domain or lacks the region of the Fc domain that binds to one or more FcRs.
[0142] In certain embodiments, the combination therapies of the invention are administered to an individual before or after surgery to remove a tumor, and may be used before, during, or after radiation therapy.
[0143] In certain embodiments, the combination therapy of the invention is administered to an individual who has not been previously treated with a biotherapeutic or chemotherapeutic agent, i.e., the individual is treatment naive, hi other embodiments, the combination therapy is administered to an individual who has not achieved a durable response following previous therapy with a biotherapeutic or chemotherapeutic agent, i.e., the individual is treatment experienced.
[0144] In certain embodiments, the combination therapy of the present invention is used to treat tumors large enough to be detected by palpation or by imaging techniques well known in the art, such as MRI, ultrasound, or CAT scan. 3 , 300mm 3 , 400mm 3 , 500mm 3 , 750mm 3or up to 1000mm 3 It is used to treat advanced stage tumors having dimensions of
[0145] In certain embodiments, the combination therapy of the invention is administered to an individual whose cancer tests positive for PD-L1 expression. In some embodiments, PD-L1 expression is detected using a diagnostic anti-human PD-L1 antibody or antigen-binding fragment thereof in an immunohistochemical (IHC) assay on fixed formalin paraffin embedded (FFPE) or frozen tissue sections of a tumor sample removed from the individual. The individual's physician may prescribe a diagnostic test to determine PD-L1 expression in a tumor tissue sample removed from the individual prior to the initiation of treatment with the combination therapy of the invention, although it is contemplated that the physician may prescribe an initial or subsequent diagnostic test at any time after the initiation of treatment, for example, after completion of a treatment cycle.
[0146] The combination therapy may include any one of the exemplary effector-silent anti-CTLA-4 antibodies or effector-silent anti-CTLA-4 antibody fragments disclosed herein in combination with any one of the exemplary anti-PD-1 antibodies or anti-PD-1 antibody fragments disclosed herein, or any one of the exemplary anti-PD-L1 antibodies or anti-PD-L1 antibody fragments disclosed herein.
[0147] (a) Effector-silent antibodies The effector-silent antibodies of the invention comprise an HC constant domain or an Fc domain modified such that the antibody exhibits no measurable binding to one or more FcRs or exhibits reduced binding to one or more FcRs compared to that of an unmodified antibody of the same IgG isotype. In other embodiments, the effector-silent antibody may exhibit no measurable binding to each of FcγRIIIa, FcγRIIa, and FcγRI, or exhibit reduced binding to each of FcγRIIIa, FcγRIIa, and FcγRI, compared to that of an unmodified antibody of the same IgG isotype. In a specific embodiment, the HC constant domain or Fc domain is a human HC constant domain or Fc domain.
[0148] In certain embodiments, the effector-silent antibody comprises an Fc domain of an IgG1 or IgG2, IgG3 or IgG4 isotype that has been modified to lack N-glycosylation of the asparagine (Asn) residue at position 297 (Eu numbering system) of the HC constant domain. The consensus sequence for N-glycosylation is Asn-Xaa-Ser / Thr (wherein Xaa at position 298 is any amino acid other than Pro), and in all four isotypes, the consensus sequence for N-glycosylation is Asn-Ser-Thr. The modification can be achieved by replacing the codon encoding Asn at position 297 in the nucleic acid molecule encoding the HC constant domain with a codon encoding another amino acid, such as Ala, Asp, Gln, Gly or Glu, for example N297A, N297Q, N297G, N297E or N297D. Alternatively, the codon for Ser at position 298 can be replaced with a codon for Pro, and the codon for Thr at position 299 can be replaced with any codon other than the codon for Ser. In another embodiment, each of the amino acids comprising the N-glycosylation consensus sequence is replaced with another amino acid. Such modified IgG molecules have no measurable effector function. In certain embodiments, these mutant HC molecules can further comprise 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional amino acid substitutions, insertions and / or deletions, where the substitutions can be conservative or non-conservative mutations. In other embodiments, such IgGs modified to lack N-glycosylation at position 297 can further comprise one or more additional mutations disclosed herein to eliminate measurable effector function.
[0149] An exemplary IgG1 HC constant domain mutated at position 297 to prevent N-glycosylation of the HC constant domain is set forth in SEQ ID NO: 44, an exemplary IgG2 HC constant domain mutated at position 297 to prevent N-glycosylation of the HC constant domain is set forth in SEQ ID NO: 50, and an exemplary IgG4 HC constant domain mutated at position 297 to prevent N-glycosylation of the HC constant domain is set forth in SEQ ID NO: 56. In certain embodiments, these mutant HC molecules can further comprise 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional amino acid substitutions, insertions and / or deletions, where the substitutions can be conservative or non-conservative mutations.
[0150] In certain embodiments, the Fc domain of an IgG1, IgG2, IgG3 or IgG4 HC constant domain comprising an effector-silent antibody is modified to contain one or more amino acid substitutions selected from E233P, L234A, L235A, L235E, N297A, N297D, D265S and P331S (wherein the positions are identified according to Eu numbering), and wherein the HC constant domain is effector-silent. In certain embodiments, the modified IgG1 further comprises 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional amino acid substitutions, insertions and / or deletions, where the substitutions may be conservative or non-conservative mutations.
[0151] In certain embodiments, the HC constant domain comprises an L234A, L235A and D265S substitution, where the positions are identified according to Eu numbering. In certain embodiments, the HC constant domain comprises an amino acid substitution at position Pro329 and at least one additional amino acid substitution selected from E233P, L234A, L235A, L235E, N297A, N297D, D265S and P331S, where the positions are identified according to Eu numbering. These and other substitutions are disclosed in WO9428027; WO2004099249; WO20121300831; U.S. Patent Nos. 9,708,406, 8,969,526, 9,296,815; Sondermann et al., Nature 406,267-273 (20 Jul. 2000).
[0152] In certain of the foregoing embodiments, the HC constant domain comprises a L234A / L235A / D265A, a L234A / L235A / P329G, a L235E, a D265A, a D265A / N297G, or a V234A / G237A / P238S / H268A / V309L / A330S / P331S substitution, where the positions are identified according to Eu numbering. In certain embodiments, the HC molecule further comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 additional amino acid substitutions, insertions, and / or deletions, where the substitutions may be conservative or non-conservative mutations.
[0153] In certain embodiments, the effector-silent antibody comprises an IgG1 isotype, in which the Fc domain of the HC constant domain has been modified to be effector-silent by substituting amino acids 233-236 of IgG1 with the corresponding amino acids of human IgG2HC, and amino acids 327, 330, and 331 with the corresponding amino acids of human IgG4HC, where the positions are identified according to Eu numbering (Armour et al., Eur. J. Immunol. 29(8):2613-24 (1999); Shields et al., J. Biol. Chem. 276(9):6591-604 (2001)). In certain embodiments, the modified IgG1 further comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 additional amino acid substitutions, insertions, and / or deletions, in which the substitutions may be conservative or non-conservative mutations.
[0154] In certain embodiments, the effector-silent antibody comprises a V fused or linked, in an N-terminal to C-terminal direction, to a hybrid human immunoglobulin HC constant domain comprising a hinge region, a CH2 domain, and a CH3 domain. H domain, wherein the hinge region comprises at least a portion of the amino acid sequence of a human IgG1 hinge region or a human IgD hinge region, and the CH2 domain is that of a human IgG4 CH2 domain, a portion of which is substituted in its N-terminal region with 4 to 37 amino acid residues of the N-terminal region of a human IgG2 CH2 or human IgD CH2 domain. Such a hybrid human HC constant domain is disclosed in U.S. Patent No. 7,867,491, which is incorporated herein by reference in its entirety.
[0155] In certain embodiments, the effector-silent antibody comprises an IgG4HC constant domain, in which the serine at position 228 according to the Eu system is replaced with a proline. See, for example, SEQ ID NO: 52. This modification prevents the formation of a potential interchain disulfide bond between the cysteine at position Cys226 and the cysteine at position Cys229 in the Eu system, which may prevent proper intrachain disulfide bond formation. See Angal et al., Mol. Immunol. 30:105 (1993). See also Schuurman et al., Mol. Immunol. 38:1-8, (2001); SEQ ID NOs: 14 and 41. In other embodiments, the IgG4 constant domain comprises, in addition to the S228P substitution, a P239G, D265A or D265A / N297G amino acid substitution, where the positions are identified according to the Eu numbering. In said particular embodiment, the IgG4HC constant domain is a human HC constant domain. In certain embodiments, the HC molecule further comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 additional amino acid substitutions, insertions and / or deletions, where the substitutions can be conservative or non-conservative mutations.
[0156] Exemplary IgG1 HC constant domains include HC constant domains comprising an amino acid sequence selected from the group consisting of the amino acid sequences set forth in SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43 and SEQ ID NO: 44. Exemplary IgG2 HC constant domains have an amino acid sequence selected from the group consisting of the amino acid sequences set forth in SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48 and SEQ ID NO: 49. Exemplary IgG4 HC constant domains have an amino acid sequence selected from the group consisting of the amino acid sequences set forth in SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55 and SEQ ID NO: 56.
[0157] More specific examples of effector-silent antibodies are described below in combination with certain exemplary effector-silent anti-CTLA-4 antibodies, anti-PD-1 antibodies and anti-PD-1 antibodies.
[0158] (b) Exemplary effector-silent anti-CTLA-4 antibodies Exemplary effector-silent anti-CTLA-4 antibodies that may be used in the combination therapies and antibody-containing compositions of the invention include any effector-silent anti-CTLA-4 antibody that binds to CTLA-4 and inhibits binding of CTLA-4 to B7. Particular effector-silent anti-CTLA-4 antibodies include the following effector-silent anti-CTLA-4 antibodies, and compositions comprising any one of these antibodies and a pharma- ceutically acceptable carrier.
[0159] In certain embodiments, the effector-silent anti-CTLA-4 antibody comprises (i) a polypeptide comprising the three HC-CDRs of ipilimumab fused or linked to a HC constant domain that exhibits no measurable binding to FcγRIIIA, FcγRIIA, and FcγRI, or reduced binding compared to a polypeptide comprising a wild-type IgG constant domain region, as measured by a Biacore assay. H and (ii) a V comprising the three LC-CDRs of ipilimumab fused or linked to an LC kappa or lambda constant domain. L The three HC-CDRs comprise SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6, respectively, and the three LC-CDRs comprise SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3, respectively.
[0160] In other embodiments, the effector-silent anti-CTLA-4 antibody comprises (i) a polypeptide comprising the three HC-CDRs of tremelimumab fused or linked to a HC constant domain that exhibits no measurable binding to FcγRIIIA, FcγRIIA, and FcγRI, or reduced binding compared to a polypeptide comprising a wild-type IgG constant domain region, as measured by a Biacore assay. H and (ii) a V comprising the three LC-CDRs of tremelimumab fused or linked to an LC kappa or lambda constant domain. LThe three HC-CDRs comprise SEQ ID NO:12, SEQ ID NO:13 and SEQ ID NO:14, respectively, and the three LC-CDRs comprise SEQ ID NO:9, SEQ ID NO:10 and SEQ ID NO:11, respectively.
[0161] In other embodiments, the effector-silent anti-CTLA-4 antibody is (i) the V H and V L domain, (ii) V of tremelimumab H and V L domain, (iii) V of REGN4659 H and V L domain, (iv) V of AGEN1884w H and V L or (v) the V domain of the anti-CTLA-4 antibody clone 2C8 disclosed in International Patent Application WO2017194265. H and V L domain. V of ipilimumab H The domain comprises the amino acid sequence set forth in SEQ ID NO:7, L The domain comprises the amino acid sequence set forth in SEQ ID NO: 8. H The domain comprises the amino acid sequence set forth in SEQ ID NO: 15, L The domain comprises the amino acid sequence set forth in SEQ ID NO: 16. H The domain comprises the amino acid sequence set forth in SEQ ID NO:95, L The domain comprises the amino acid sequence set forth in SEQ ID NO: 96. H The domain comprises the amino acid sequence set forth in SEQ ID NO:97, L The domain comprises the amino acid sequence set forth in SEQ ID NO: 98. H and V L The domain may further comprise 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional amino acid substitutions, insertions and / or deletions, where the substitutions may be conservative or non-conservative mutations.
[0162] In other embodiments, the effector-silent anti-CTLA-4 antibody is selected from the group consisting of 8D2 / 8D2(RE) (see U.S. Published Patent Application No. 20170216433 and International Application WO2018183480), 8D2H1L1, 8D2H2L2, 8D3H3L3, 8D2H2L15, or 8D2H2L17. H and V L domain, where V H The domain is fused or linked to an HC constant domain that exhibits no measurable binding to FcγRIIIA, FcγRIIA, and FcγRI, or exhibits reduced binding compared to a polypeptide comprising a wild-type IgG constant domain region, as measured by a Biacore assay; L The domain is fused or linked to an LC kappa or lambda constant domain.
[0163] In certain embodiments, the effector-silent anti-CTLA-4 antibody comprises a variant of 8D2 / 8D2(RE), 8D2H1L1, 8D2H2L2, 8D2H2L15, or 8D2H2L17, wherein the V H The methionine at position 18 of the amino acid sequence is replaced with isoleucine. Thus, the effector-silent anti-CTLA-4 antibody is the V H and V L , 8D2H1L1-mutant 1 V H and V L , 8D2H2L2-mutant 1 V H and V L , 8D2H2L15-mutant 1 V H and V L , or V of 8D2H2L17-mutant 1 H and V L may include.
[0164] In other embodiments, the effector-silent anti-CTLA4 antibody comprises (i) a V H V domain and the amino acid sequence set forth in SEQ ID NO: 74 L(ii) a V domain comprising the amino acid sequence set forth in SEQ ID NO: 75; H V domain and the amino acid sequence set forth in SEQ ID NO: 76 L (iii) a V domain comprising the amino acid sequence set forth in SEQ ID NO: 77; H V domain and the amino acid sequence set forth in SEQ ID NO: 78 L (iv) a V domain comprising the amino acid sequence set forth in SEQ ID NO:79; H V domain and the amino acid sequence set forth in SEQ ID NO: 80 L (v) a domain comprising the amino acid sequence set forth in SEQ ID NO: 81; H V domain and the amino acid sequence set forth in SEQ ID NO: 82 L (vi) a domain comprising the amino acid sequence set forth in SEQ ID NO: 83; H V domain and the amino acid sequence set forth in SEQ ID NO: 84 L (vii) a V domain comprising the amino acid sequence set forth in SEQ ID NO: 85; H V domain and the amino acid sequence set forth in SEQ ID NO: 86 L (viii) a V domain comprising the amino acid sequence set forth in SEQ ID NO: 87; H V domain and the amino acid sequence set forth in SEQ ID NO: 88 L (ix) a V domain comprising the amino acid sequence set forth in SEQ ID NO: 89 H V domain and the amino acid sequence set forth in SEQ ID NO: 90 L (x) a domain comprising the amino acid sequence set forth in SEQ ID NO: 91; H V domain and the amino acid sequence set forth in SEQ ID NO: 92 L or (xi) a V domain comprising the amino acid sequence set forth in SEQ ID NO: 93. H V domain and the amino acid sequence set forth in SEQ ID NO: 94 L In certain embodiments, the V H and V LThe domain may further comprise 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional amino acid substitutions, insertions and / or deletions, where the substitutions may be conservative or non-conservative mutations.
[0165] In another embodiment of the effector-silent anti-CTLA-4 antibody, H The domain is fused or linked to an IgG4HC constant domain, or to an IgG1, IgG2 or IgG4HC constant domain that has been modified to contain one or more mutations that render the resulting anti-CTLA4 antibody effector-silent.
[0166] In one embodiment, the effector-silent anti-CTLA-4 antibody comprises (i) an IgG1 Fc domain having a mutation at the N-glycosylation site Asn-Xaa-Ser / Thr starting at amino acid position 297 that prevents N-glycosylation at said N-glycosylation site, or said mutated Fc domain further comprising 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional amino acid substitutions, insertions and / or deletions; (ii) an IgG1 Fc domain having a mutation at the N-glycosylation site Asn-Xaa-Ser / Thr starting at amino acid position 297 that prevents N-glycosylation at said N-glycosylation site, or said mutated Fc domain further comprising 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional amino acid substitutions, insertions and / or deletions; an IgG1 Fc domain having an amino acid substitution mutation selected from the group consisting of 235A / D265A, L234A / L235A / P329G, L235E, D265A, E233A / L235A, S267E / L328F, S2339D / A330L / I332E, L235G / G236R, N297A / D356E / L358M, L234F / L235E / P331S / D365E / L358M, and D265A / N297G; or (iii) a mutation at the N-glycosylation site Asn-Xaa-Ser / Thr starting at amino acid position 297, which prevents N-glycosylation at said N-glycosylation site, and and an IgG1 Fc domain having an amino acid substitution mutation selected from the group consisting of: L235G / G236R, D356E / L358M, L234F / L235E / P331S / D365E / L358M, and D265A, or said mutant Fc domain further comprising 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional amino acid substitutions, insertions and / or deletions, wherein the amino acid positions in (i), (ii) and (iii) are identified according to EU numbering.
[0167] In another embodiment, the effector-silent anti-CTLA-4 antibody comprises: (i) an IgG2 Fc domain having a mutation at the N-glycosylation site Asn-Xaa-Ser / Thr starting at amino acid position 297, which mutation prevents N-glycosylation at said N-glycosylation site, or said mutated Fc domain further comprising 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional amino acid substitutions, insertions and / or deletions; (ii) an IgG2 Fc domain having an amino acid substitution mutation selected from the group consisting of N297A / D265S, D265A, P329G / D265A / N297G, or V234A / G237A / P238S / H268A / V309L / A330S / P331S, or an IgG2 Fc domain having an amino acid substitution mutation selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional amino acid substitutions, insertions and / or deletions. or (iii) an IgG2 Fc domain having a mutation in the N-glycosylation site Asn-Xaa-Ser / Thr starting at amino acid position 297, which prevents N-glycosylation at the N-glycosylation site, and an amino acid substitution mutation selected from the group consisting of N297A / D265S, D265A, P329G / D265A / N297G, or V234A / G237A / P238S / H268A / V309L / A330S / P331S, or said mutant Fc domain further comprising 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional amino acid substitutions, insertions and / or deletions, wherein the amino acid positions in (i), (ii) and (iii) are identified according to EU numbering.
[0168] In another embodiment, the effector-silent anti-CTLA-4 antibody comprises: (i) an IgG4 Fc domain having an S228P amino acid substitution and further a mutation in the N-glycosylation site Asn-Xaa-Ser / Thr starting at amino acid position 297, which prevents N-glycosylation at said N-glycosylation site, or said mutated Fc domain further comprising 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional amino acid substitutions, insertions and / or deletions; (ii) an IgG4 Fc domain having an S228P amino acid substitution and further an amino acid substitution mutation selected from the group consisting of N267A, P329G, and D265A / N297A, or said mutated Fc domain further comprising 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional amino acid substitutions, insertions and / or deletions; or (iii) an IgG4 Fc domain having a S228P amino acid substitution and, further, a mutation in the N-glycosylation site Asn-Xaa-Ser / Thr starting at amino acid position 297, which mutation prevents N-glycosylation at said N-glycosylation site, and an amino acid substitution mutation selected from the group consisting of N267A, P329G, and D265A / N297A; or said mutant Fc domain further comprising 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional amino acid substitutions, insertions and / or deletions, wherein the amino acid positions in (i), (ii) and (iii) are identified according to EU numbering.
[0169] Tables 4-18 provide certain exemplary anti-CTLA-4 antibodies that may be used in combination with anti-PD-1 or anti-PD-L1 antibodies in a therapy to treat an individual with cancer. The invention also provides antibodies shown in the tables other than ipilimumab that consists only of an N297A substitution, and also provides compositions, each of which comprises an antibody shown in the tables and a pharma- ceutically acceptable carrier, other than a composition comprising ipilimumab that consists only of an N297A substitution. All HC amino acid substitution positions in Tables 4-18 follow the Eu numbering scheme. [Table 3]
[0170] TIFF0007581225000005.tif102160
[0171] TIFF0007581225000006.tif96160
[0172] TIFF0007581225000007.tif138160
[0173] TIFF0007581225000008.tif101159
[0174] TIFF0007581225000009.tif96160
[0175] TIFF0007581225000010.tif138160
[0176] TIFF0007581225000011.tif102161
[0177] TIFF0007581225000012.tif95160
[0178] TIFF0007581225000013.tif139159
[0179] TIFF0007581225000014.tif101160
[0180] TIFF0007581225000015.tif97160
[0181] TIFF0007581225000016.tif169160
[0182] TIFF0007581225000017.tif127164
[0183] TIFF0007581225000018.tif120160
[0184] (c) Exemplary effector-silent anti-CTLA-4 antibody fragments. Exemplary effector-silent anti-CTLA-4 antibody fragments that may be used in the combination therapies and antibody-containing compositions of the invention include any antibody fragment that binds to CTLA-4 and inhibits binding of CTLA-4 to B7. Specific examples of these anti-CTLA-4 antibody fragments include the following anti-CTLA-4 antibody fragments and compositions, each composition comprising an effector-silent anti-CTLA-4 antibody fragment and a pharma- ceutically acceptable carrier.
[0185] In certain embodiments, the effector-silent anti-CTLA-4 antibody fragment comprises (i) a V domain that contains the three HC-CDRs of ipilimumab H and (ii) V, which contains the three LC-CDRs of ipilimumab. L and an Fv, scFv, F(ab) or F(ab')2 comprising: the three HC-CDRs comprise SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3, respectively, and the three LC-CDRs comprise SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:7, respectively.
[0186] In certain embodiments, the effector-silent anti-CTLA-4 antibody fragment comprises (i) a V domain comprising the three HC-CDRs of tremelimumab. H and (ii) V, which contains the three LC-CDRs of tremelimumab. L The three HC-CDRs comprise SEQ ID NO:9, SEQ ID NO:10 and SEQ ID NO:11, respectively, and the three LC-CDRs comprise SEQ ID NO:12, SEQ ID NO:13 and SEQ ID NO:14, respectively.
[0187] In certain embodiments, the effector-silent anti-CTLA-4 antibody fragment comprises: (i) the V H and V L domain, (ii) V of tremelimumab H and V L domain, (iii) V of REGN4659H and V L domain, (iv) V of AGEN1884w H and V L or (v) the V domain of the anti-CTLA-4 antibody clone 2C8 disclosed in International Patent Application WO2017194265. H and V L domain. V of ipilimumab H The domain comprises the amino acid sequence set forth in SEQ ID NO:7, L The domain comprises the amino acid sequence set forth in SEQ ID NO: 8. H The domain comprises the amino acid sequence set forth in SEQ ID NO: 15, L The domain comprises the amino acid sequence set forth in SEQ ID NO: 16. H The domain comprises the amino acid sequence set forth in SEQ ID NO:95, L The domain comprises the amino acid sequence set forth in SEQ ID NO: 96. H The domain comprises the amino acid sequence set forth in SEQ ID NO:97, L The domain comprises the amino acid sequence set forth in SEQ ID NO:98.
[0188] In certain embodiments, the effector-silent anti-CTLA-4 antibody fragment is the V H and V L , V of tremelimumab H and V L ,REGN4659's V H and V L , AGEN1884w's V H and V L , 8D2 / 8D2(RE) V H and V L , 8D2H1L1 V H and V L , 8D2H2L2 V H and V L , 8D3H3L3 V H and V L , 8D2H2L15V H and V L, or 8D2H2L17 V H and V L Includes.
[0189] In certain embodiments, the anti-CTLA-4 antibody or anti-CTLA-4 antibody fragment comprises the V H and V L , 8D2H1L1-mutant 1 V H and V L , 8D2H2L2-mutant 1 V H and V L , 8D2H2L15-mutant 1 V H and V L , or V of 8D2H2L17-mutant 1 H and V L Includes.
[0190] In certain embodiments, the effector-silent anti-CTLA-4 antibody fragment comprises (i) a V H V domain and the amino acid sequence set forth in SEQ ID NO: 74 L (ii) a V domain comprising the amino acid sequence set forth in SEQ ID NO: 75; H V domain and the amino acid sequence set forth in SEQ ID NO: 76 L (iii) a V domain comprising the amino acid sequence set forth in SEQ ID NO: 77; H V domain and the amino acid sequence set forth in SEQ ID NO: 78 L (iv) a V domain comprising the amino acid sequence set forth in SEQ ID NO:79 H V domain and the amino acid sequence set forth in SEQ ID NO: 80 L (v) a domain comprising the amino acid sequence set forth in SEQ ID NO: 81; H V domain and the amino acid sequence set forth in SEQ ID NO: 82 L (vi) a domain comprising the amino acid sequence set forth in SEQ ID NO: 83; H V domain and the amino acid sequence set forth in SEQ ID NO: 84 L(vii) a V domain comprising the amino acid sequence set forth in SEQ ID NO: 85; H V domain and the amino acid sequence set forth in SEQ ID NO: 86 L (viii) a V domain comprising the amino acid sequence set forth in SEQ ID NO: 87; H V domain and the amino acid sequence set forth in SEQ ID NO: 88 L (ix) a V domain comprising the amino acid sequence set forth in SEQ ID NO: 89 H V domain and the amino acid sequence set forth in SEQ ID NO: 90 L (x) a domain comprising the amino acid sequence set forth in SEQ ID NO: 91; H V domain and the amino acid sequence set forth in SEQ ID NO: 92 L or (xi) a V domain comprising the amino acid sequence set forth in SEQ ID NO:93. H V domain and the amino acid sequence set forth in SEQ ID NO: 94 L Includes the domain.
[0191] In certain embodiments, the effector-silent anti-CTLA-4 antibody fragment comprises one or more immunoglobulin single variable domains (ISVDs), each ISVD comprising a variable domain (V) of a camelid heavy chain-only antibody. HH), with the proviso that the ISVD does not comprise a CDR1 comprising the amino acid sequence FYGMG (SEQ ID NO:69), a CDR2 comprising the amino acid sequence DIRTSAGRTTYADSVKG (SEQ ID NO:70), and a CDR3 comprising the amino acids EMSGISGWDY (SEQ ID NO:71) or EPSGISGWDY (SEQ ID NO:72) (such ISVDs are disclosed in International Patent Applications WO2008071447, WO2017087587 and WO2017087588), and does not include ISVD variants comprising one, two or three mutations in CDR3 as disclosed in WO2008071447, except that an ISVD comprising a CDR in an embodiment in which one or more of the ISVDs are fused or linked to an effector-silent antibody constant domain or Fc domain (e.g., any of the effector-silent antibody constant domains or Fc domains disclosed herein) is not excluded by this proviso.
[0192] (d) Exemplary Anti-PD-1 Antibodies Exemplary anti-PD-1 antibodies that may be used in the combination therapy of the invention include any antibody that binds to PD-1 and inhibits binding of PD-1 to PD-L1. In another embodiment, the exemplary anti-PD-1 antibody is selected from the group consisting of nivolumab, pembrolizumab, and cemiplimab-rwlc. Exemplary antibodies include the following anti-PD-1 antibodies, and compositions comprising an anti-PD1 antibody and a pharmaceutically acceptable salt:
[0193] Pembrolizumab, also known as KEYTRUDA, lambrolizumab, MK-3475 or SCH-900475, is a humanized anti-PD-1 antibody described in U.S. Patent No. 8,354,509 and WO2009 / 114335, and disclosed in Hamid et al., New England J. Med. 369(2):134-144 (2013). The heavy and light chains of pembrolizumab are represented by the amino acid sequences set forth in SEQ ID NOs: 27 and 28, respectively.
[0194] Nivolumab, also known as OPDIVO, MDX-1106-04, ONO-4538 or BMS-936558, is a fully human IgG4 anti-PD-1 antibody described in WO2006 / 121168 and U.S. Patent No. 8,008,449. The heavy and light chains of nivolumab are represented by the amino acid sequences set forth in SEQ ID NOs: 25 and 26, respectively.
[0195] Cemiplimab-rwlc, also known as cemiplimab, LIBTAYO or REGN2810, is a recombinant human IgG4 monoclonal antibody described in WO2015112800 and US Patent No. 9,987,500. The heavy and light chains of cemiplimab-rwlc are represented by the amino acid sequences set forth in SEQ ID NOs: 101 and 102, respectively.
[0196] In certain embodiments, the anti-PD-1 antibody comprises (i) a V domain that contains the three HC-CDRs of pembrolizumab fused or linked to an effector-silent HC constant domain. H and (ii) a V comprising the three LC-CDRs of pembrolizumab fused or linked to an LC kappa or lambda constant domain. L The three HC-CDRs comprise SEQ ID NO:31, SEQ ID NO:32 and SEQ ID NO:33, respectively, and the three LC-CDRs comprise SEQ ID NO:34, SEQ ID NO:35 and SEQ ID NO:36, respectively.
[0197] In certain embodiments, the anti-PD-1 antibody comprises (i) a VDG comprising the three HC-CDRs of nivolumab fused or linked to an effector-silent HC constant domain. H and (ii) a V comprising the three LC-CDRs of nivolumab fused or linked to an LC kappa or lambda constant domain. L The three HC-CDRs comprise SEQ ID NO:17, SEQ ID NO:18 and SEQ ID NO:19, respectively, and the three LC-CDRs comprise SEQ ID NO:20, SEQ ID NO:21 and SEQ ID NO:2, respectively.
[0198] In certain embodiments, the anti-PD-1 antibody comprises (i) a VDG comprising the three HC-CDRs of cemiplimab-rwlc fused or linked to an effector-silent HC constant domain. H and (ii) a V comprising the three LC-CDRs of nivolumab fused or linked to an LC kappa or lambda constant domain. L Including,
[0199] In certain embodiments, the anti-PD-1 antibody is (i) the V H and V L Domain (where V H The domain is fused or linked to an effector-silent HC constant domain, and V L domain is fused or linked to an LC kappa or lambda constant domain), (ii) the V H and V L Domain (where V H The domain is fused or linked to an effector-silent HC constant domain, and V L domain is fused or linked to an LC kappa or lambda constant domain), or (iii) the V H and V L Domain (where V H The domain is fused or linked to an effector-silent HC constant domain, and V L The V domain of pembrolizumab is fused or linked to an LC kappa or lambda constant domain. H The domain comprises the amino acid sequence set forth in SEQ ID NO:29, L The domain comprises the amino acid sequence set forth in SEQ ID NO: 30. H The domain comprises the amino acid sequence set forth in SEQ ID NO:23, L The domain comprises the amino acid sequence set forth in SEQ ID NO: 24. H The domain comprises the amino acid sequence set forth in SEQ ID NO:99, LThe domain comprises the amino acid sequence set forth in SEQ ID NO: 100. H and V L The domain can further comprise 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional amino acid substitutions, insertions and / or deletions, where the substitutions can be conservative or non-conservative mutations.
[0200] In certain embodiments, the anti-PD-1 antibody V H A domain is a specific V H The antibody can be fused or linked to an IgG1, IgG2, IgG3, or IgG4HC constant domain that is not currently linked to an IgG1, IgG2, IgG3, or IgG4HC constant domain that has been modified to contain one or more mutations in the Fc domain that render the resulting anti-PD-1 antibody effector silent.
[0201] In certain embodiments, the HC constant domain is of IgG1, IgG2, IgG3 or IgG4 isotype, which is modified to lack N-glycosylation of the asparagine (Asn) residue at position 297 of the HC constant domain by substituting the codon for Asn at position 297 with another amino acid, for example, Gln, in the nucleic acid molecule encoding the HC constant domain. In other embodiments, such IgG modified to lack N-glycosylation at position 297 further comprises one or more additional mutations disclosed herein to eliminate detectable effector function. In certain embodiments, the HC constant domain is a human HC constant domain. In certain embodiments, the molecule further comprises 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional amino acid substitutions, insertions and / or deletions, where the substitutions can be conservative or non-conservative mutations.
[0202] In certain embodiments, the invention provides an anti-PD-1 antibody comprising an IgG4HC constant domain that has been modified to have a S228P substitution, and further comprising, in addition to the S228P substitution, a P239G, D265A, or D265A / N297G amino acid substitution, where the positions are identified according to Eu numbering. In certain of said embodiments, the IgG4HC constant domain is a human HC constant domain. In certain embodiments, the molecule further comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 additional amino acid substitutions, insertions and / or deletions, where the substitutions may be conservative or non-conservative mutations.
[0203] In another embodiment, the anti-PD-1 antibody can comprise a human IgG1 isotype, where the Fc domain of the HC constant domain has been modified to be effector-silent by substituting amino acids 233-236 of IgG1 with the corresponding amino acids of human IgG2HC, and amino acids 327, 330, and 331 with the corresponding amino acids of human IgG4HC, where the positions are identified according to Eu numbering. In certain embodiments, the HC molecule further comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 additional amino acid substitutions, insertions, and / or deletions, where the substitutions can be conservative or non-conservative mutations.
[0204] In another embodiment, the Fc domain of an IgG1, IgG2, IgG3 or IgG4HC constant domain has been modified to include one or more amino acid substitutions selected from E233P, L234A, L235A, L235E, N297A, N297D, D265S and P331S, wherein the polypeptide exhibits no measurable binding to FcγRIIIA, FcγRIIA and FcγRI, or exhibits reduced binding compared to a polypeptide comprising a wild-type IgG constant domain region, as measured by a Biacore assay. These and other substitutions are disclosed in WO9428027, WO2004099249, WO20121300831; U.S. Patent Nos. 9,708,406, 8,969,526, 9,296,815; Sondermann et al., Nature 406, 267-273 (July 20, 2000). In certain embodiments, the HC molecule further comprises 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional amino acid substitutions, insertions and / or deletions, where the substitutions may be conservative or non-conservative mutations.
[0205] Tables 19-27 show certain exemplary anti-PD-1 antibodies that may be used in combination with the anti-CTLA-4 antibodies disclosed herein in a therapy to treat an individual with cancer. The invention also provides the antibodies and compositions shown in the tables, each composition comprising the antibody shown in the table and a pharma- ceutically acceptable carrier. All HC amino acid substitution positions in Tables 19-27 follow the Eu numbering scheme. [Table 4]
[0206] TIFF0007581225000020.tif101159
[0207] TIFF0007581225000021.tif96159
[0208] TIFF0007581225000022.tif138160
[0209] TIFF0007581225000023.tif101160
[0210] TIFF0007581225000024.tif95159
[0211] TIFF0007581225000025.tif138160
[0212] TIFF0007581225000026.tif101160
[0213] TIFF0007581225000027.tif96161
[0214] (e) Exemplary anti-PD-1 antibody fragments Exemplary anti-PD-1 antibody fragments that may be used in the combination therapies of the invention include any anti-PD-1 antibody fragment that binds to PD-1 and inhibits binding of PD-1 to PD-L1, and further include the following anti-PD-1 antibody fragments that bind to PD-1, and compositions comprising the following anti-PD-1 antibody fragments and a pharma- ceutically acceptable carrier:
[0215] In a specific embodiment, the antibody fragment is pembrolizumab V having the amino acid sequence set forth in SEQ ID NO:29. H and pembrolizumab V having the amino acid sequence set forth in SEQ ID NO: 30. L and
[0216] In a specific embodiment, the anti-PD-1 antibody fragment is pembrolizumab V having the amino acid sequence set forth in SEQ ID NO:29. H and pembrolizumab V having the amino acid sequence set forth in SEQ ID NO: 30. H and F(ab) comprising:
[0217] In a specific embodiment, the anti-PD-1 antibody fragment is pembrolizumab V having the amino acid sequence set forth in SEQ ID NO:29. H and pembrolizumab V having the amino acid sequence set forth in SEQ ID NO: 30. H and F(ab')2 comprising:
[0218] In certain embodiments, the anti-PD-1 antibody fragment is nivolumab V having the amino acid sequence set forth in SEQ ID NO:23. H and Nivolumab V having the amino acid sequence set forth in SEQ ID NO: 24. H and
[0219] In certain embodiments, the anti-PD-1 antibody fragment is nivolumab V having the amino acid sequence set forth in SEQ ID NO:23. H and Nivolumab V having the amino acid sequence set forth in SEQ ID NO: 24. H and F(ab) comprising:
[0220] In certain embodiments, the anti-PD-1 antibody fragment is nivolumab V having the amino acid sequence set forth in SEQ ID NO:23. H and Nivolumab V having the amino acid sequence set forth in SEQ ID NO: 24. H and F(ab')2 comprising:
[0221] In certain embodiments, the anti-PD-1 antibody fragment comprises one or more immunoglobulin single variable domains (ISVDs), each ISVD comprising a variable domain (V) of a camelid heavy chain-only antibody. HH), with the proviso that the ISVD does not include a CDR1 comprising the amino acid sequence THAMG (SEQ ID NO: 73), a CDR2 comprising the amino acid sequence VITWSGGITTYADSVKG (SEQ ID NO: 74) or VITVSGGITYYADSVKG (SEQ ID NO: 75), and a CDR3 comprising the amino acids DKHQSSWYDY (SEQ ID NO: 76) or DKHQSSFYDY (SEQ ID NO: 77) (these ISVDs are described in International Patent Applications WO2008071447, WO2017087587 and WO20170875 89), and the ISVD variants comprising one, two or three mutations in CDR3 as disclosed in WO2008071447, except in embodiments in which one or more of the ISVDs are fused or linked to an effector-silent antibody constant domain or Fc domain (e.g., any of the effector-silent antibody constant domains or Fc domains disclosed herein), are not excluded by this proviso.
[0222] (f) Exemplary anti-PD-L1 antibodies Exemplary anti-PD-L1 antibodies that may be used in the combination therapies of the invention include any anti-PD-L1 antibody that inhibits the binding of PD-1 to PD-L1, and further include the following anti-PD-L1 antibodies, and compositions comprising the following anti-PD-L1 antibodies and a pharma- ceutical acceptable carrier: In certain embodiments, the anti-PD-L1 antibody is selected from the group consisting of atezolizumab, avelumab, and durvalumab.
[0223] In certain embodiments, the anti-PD-L1 antibody is: (i) the V H and V L Domain (where V H The domain is fused or linked to an HC constant domain or an effector-silent HC constant domain, L domain is fused or linked to an LC kappa or lambda constant domain), (ii) the V H and V L Domain (where V HThe domain is fused or linked to an HC constant domain or an effector-silent HC constant domain, L domain is fused or linked to an LC kappa or lambda constant domain), or (iii) the V H and V L Domain (where V H The domain is fused or linked to an HC constant domain or an effector-silent HC constant domain, L The V domain of durvalumab is fused or linked to an LC kappa or lambda constant domain. H The domain comprises the amino acid sequence set forth in SEQ ID NO: 103, L The domain comprises the amino acid sequence set forth in SEQ ID NO: 104. H The domain comprises the amino acid sequence set forth in SEQ ID NO: 105, L The V domain comprises the amino acid sequence set forth in SEQ ID NO: 106. H The domain comprises the amino acid sequence set forth in SEQ ID NO: 107, L The domain comprises the amino acid sequence set forth in SEQ ID NO: 108. H and V L The domain may further comprise 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional amino acid substitutions, insertions and / or deletions, where the substitutions may be conservative or non-conservative mutations.
[0224] In certain embodiments, the anti-PD-1 antibody V H A domain is a specific V H The antibody can be fused or linked to an IgG1, IgG2, IgG3, or IgG4HC constant domain that is not currently linked to an IgG1, IgG2, IgG3, or IgG4HC constant domain that has been modified to contain one or more mutations in the Fc domain that render the resulting anti-PD-1 antibody effector silent.
[0225] In certain embodiments, the HC constant domain is of IgG1, IgG2, IgG3 or IgG4 isotype, which is modified to lack N-glycosylation of the asparagine (Asn) residue at position 297 of the HC constant domain by substituting the codon for Asn at position 297 in the nucleic acid molecule encoding the HC constant domain with another amino acid, for example, Gln. Alternatively, the codon for Ser can be substituted with a codon for Pro, or the codon for Thr can be substituted with any codon other than the codon for Ser (e.g., N297A, N297G or N297D). Alternatively, all three codons are modified. In other embodiments, such IgG modified to lack N-glycosylation at position 297 further comprises one or more additional mutations disclosed herein to eliminate detectable effector functions. In certain embodiments, the HC constant domain is a human HC constant domain. In certain embodiments, the molecule further comprises 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional amino acid substitutions, insertions and / or deletions, where the substitutions may be conservative or non-conservative mutations.
[0226] In certain embodiments, the invention provides an anti-PD-L1 antibody comprising an IgG4 HC constant domain that has been modified to have a S228P substitution, and further to include, in addition to the S228P substitution, a P239G, D265A, or D265A / N297G amino acid substitution, where the positions are identified according to Eu numbering. In certain such embodiments, the IgG4 HC constant domain is a human HC constant domain. In certain embodiments, the molecule further comprises 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional amino acid substitutions, insertions and / or deletions, where the substitutions may be conservative or non-conservative mutations.
[0227] In another embodiment, the anti-PD-L1 antibody may comprise a human IgG1 isotype, where the Fc domain of the HC constant domain has been modified to be effector-silent by substituting amino acids 233-236 of IgG1 with the corresponding amino acids of human IgG2HC, and amino acids 327, 330, and 331 with the corresponding amino acids of human IgG4HC, where the positions are identified according to Eu numbering. In certain embodiments, the HC molecule further comprises 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional amino acid substitutions, insertions and / or deletions, where the substitutions may be conservative or non-conservative mutations.
[0228] In another embodiment, the Fc domain of an IgG1, IgG2, IgG3 or IgG4HC constant domain has been modified to include one or more amino acid substitutions selected from E233P, L234A, L235A, L235E, N297A, N297D, D265S and P331S, wherein the polypeptide exhibits no measurable binding to FcγRIIIA, FcγRIIA and FcγRI, or exhibits reduced binding compared to a polypeptide comprising a wild-type IgG constant domain region, as measured by a Biacore assay. These and other substitutions are disclosed in WO9428027, WO2004099249, WO20121300831; U.S. Patent Nos. 9,708,406, 8,969,526, 9,296,815; Sondermann et al., Nature 406, 267-273 (July 20, 2000). In certain embodiments, the HC molecule further comprises 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional amino acid substitutions, insertions and / or deletions, where the substitutions may be conservative or non-conservative mutations.
[0229] Tables 28-36 provide exemplary anti-PD-L1 antibodies that may be used in combination with the anti-CTLA-4 antibodies disclosed herein in a therapy to treat an individual with cancer. The present invention also provides antibodies shown in the tables other than antibodies 25-9 and 31-8, and also provides compositions, each of which comprises an antibody shown in the tables other than antibodies 25-9 and 31-8, and a pharma- ceutically acceptable carrier. All HC amino acid substitution positions in Tables 28-36 follow the Eu numbering scheme. [Table 5]
[0230] TIFF0007581225000029.tif101159
[0231] TIFF0007581225000030.tif95159
[0232] TIFF0007581225000031.tif138159
[0233] TIFF0007581225000032.tif101159
[0234] TIFF0007581225000033.tif96159
[0235] TIFF0007581225000034.tif138159
[0236] TIFF0007581225000035.tif107159
[0237] TIFF0007581225000036.tif95159
[0238] (g) Exemplary anti-PD-L1 antibody fragments Exemplary anti-PD-L1 antibody fragments that may be used in the combination therapies of the invention include any anti-PD-L1 antibody fragment that binds to PD-L1 and inhibits binding of PD-L1 to PD-1, and further include the following anti-PD-L1 antibody fragments, and compositions comprising the following anti-PD-L1 antibody fragments and a pharma- ceutically acceptable carrier:
[0239] In a specific embodiment, the anti-PD-L1 antibody fragment is durvalumab V, having the amino acid sequence set forth in SEQ ID NO:103. H and durvalumab V having the amino acid sequence set forth in SEQ ID NO: 104. L and
[0240] In a specific embodiment, the anti-PD-L1 antibody fragment is durvalumab V, having the amino acid sequence set forth in SEQ ID NO:103. H and durvalumab V having the amino acid sequence set forth in SEQ ID NO: 104. H and F(ab) comprising:
[0241] In a specific embodiment, the anti-PD-L1 antibody fragment is durvalumab V, having the amino acid sequence set forth in SEQ ID NO:103. H and durvalumab V having the amino acid sequence set forth in SEQ ID NO: 104. H and F(ab')2 comprising:
[0242] In certain embodiments, the anti-PD-L1 antibody fragment is avelumab V, having the amino acid sequence set forth in SEQ ID NO:105. H and avelumab V having the amino acid sequence set forth in SEQ ID NO: 106. H and
[0243] In certain embodiments, the anti-PD-L1 antibody fragment is avelumab V, having the amino acid sequence set forth in SEQ ID NO:105. H and avelumab V having the amino acid sequence set forth in SEQ ID NO: 106.H and F(ab) comprising:
[0244] In certain embodiments, the anti-PD-L1 antibody fragment is avelumab V, having the amino acid sequence set forth in SEQ ID NO:105. H and avelumab V having the amino acid sequence set forth in SEQ ID NO: 106. H and F(ab')2 comprising:
[0245] In a specific embodiment, the anti-PD-L1 antibody fragment is atezolizumab V, having the amino acid sequence set forth in SEQ ID NO:107. H and atezolizumab V having the amino acid sequence set forth in SEQ ID NO: 108. H and
[0246] In a specific embodiment, the anti-PD-L1 antibody fragment is atezolizumab V, having the amino acid sequence set forth in SEQ ID NO:107. H and atezolizumab V having the amino acid sequence set forth in SEQ ID NO: 108. H and F(ab) comprising:
[0247] In a specific embodiment, the anti-PD-L1 antibody fragment is atezolizumab V, having the amino acid sequence set forth in SEQ ID NO:107. H and atezolizumab V having the amino acid sequence set forth in SEQ ID NO: 108. H and F(ab')2 comprising:
[0248] In certain embodiments, the anti-PD-L1 antibody fragment comprises one or more immunoglobulin single variable domains (ISVDs), each ISVD comprising a variable domain (V) of a camelid heavy chain-only antibody. HH), with the proviso that the ISVD does not include the anti-PD-L1 ISVD having SEQ ID NOs: 394-399 in the disclosure of International Patent Application WO2008071447, and does not include the anti-PD-L1 ISVD disclosed in WO2009030285, both of which are incorporated herein by reference, with the exception that this provisos does not exclude an ISVD in which one or more of the ISVDs are fused or linked to an effector-silent antibody constant domain or Fc domain (e.g. any of the effector-silent antibody constant domains or Fc domains disclosed herein).
[0249] (h) Exemplary Combination Therapy Dosing Regimens The present invention provides an anti-cancer therapy that combines the immune stimulatory effect of PD-1 blockers with the anti-tumor effect of CTLA-4 blockers, without the skin or gut irAEs typically observed with CTLA-4 blockers administered in combination with PD-1 blockers. A feature of the present invention is that the CTLA-4 blockers do not exhibit measurable binding to one or more FcRs as measured by Biacore assay, or exhibit reduced binding to one or more FcRs as compared to a wild-type antibody of the same isotype as measured by Biacore assay. Thus, the CTLA-4 blockers do not exhibit measurable effector function, or exhibit reduced effector function, allowing effector-silent CTLA-4 blockers to be used in combination therapy with PD-1 blockers at doses and durations not available for CTLA-4 blockers that exhibit effector function. This feature distinguishes the CTLA-4 blockers of the present invention from currently available CTLA-4 blockers.
[0250] In a typical dosing regimen of the present invention, the CTLA-4 blocking agent and the PD-1 blocking agent can be administered to an individual at the same time in separate doses and different ways. In general, the CTLA-4 blocking agent of the present invention can be administered in combination with the PD-1 blocking agent at at least the same dose, dosing frequency and duration of treatment as currently approved by the US FDA for ipilimumab / nivolumab combination therapy for a particular indication. However, the combination therapy is not limited to the particular indication approved by the US FDA, but can include any indication that can benefit from the combination therapy of the present invention. The currently approved dose is ipilimumab 1 mg / kg, followed by administration of nivolumab administered at a dose of 3 mg / kg. This dose combination can then be repeated every 3 weeks for 4 doses, and then the dose of nivolumab can be continued every 2 weeks as needed. However, in other embodiments, the CTLA-4 blocking agent of the present invention can be administered in combination therapy at a dose of more than 1 mg / kg, for example at least 3 mg / kg. In yet another embodiment, the dose can be at least 10 mg / kg, and in yet another embodiment, the dose can be about 1 mg / kg to 10 mg / kg. In certain embodiments, the CTLA-4 blocking agents of the present invention can be administered at the same dosing frequency and duration of treatment as in approved ipilimumab / nivolumab combination therapies. In certain embodiments, the CTLA-4 blocking agents of the present invention can be administered at the same dosing frequency and duration of treatment as that of nivolumab in approved ipilimumab / nivolumab combination therapies.
[0251] In certain embodiments of the combination therapy, the CTLA-4 blocking agent is administered at a dose that is not based on the individual's body weight. Thus, in certain embodiments, the CTLA-4 binding agent may be administered at a dose between about 10 mg and 300 mg. In another embodiment, the dose is selected from the group consisting of 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 250 mg, and 300 mg.
[0252] In the combination therapies of the invention, the PD-1 blocking agent may be administered at the same dose, frequency of administration, and duration of treatment approved for the PD-1 blocking agent in monotherapy for a particular indication. The dose of the CTLA-4 blocking agent may be as described above, and the CTLA-4 blocking agent may be administered at the same frequency of administration and duration of treatment described above or for the particular PD-1 blocking agent that is being combined with the CTLA-4 blocking agent.
[0253] The specific doses of currently marketed PD-1 blockers vary depending on the PD-1 blocker, and thus, in certain embodiments of the combination therapy of the invention, the dose, frequency of administration and / or duration of treatment may be at least the same as that approved by the US FDA for the particular PD-1 blocker for a particular indication. For example, pembrolizumab is approved as a 200 mg dose administered every 3 weeks as needed [2 mg / kg to 200 mg every 3 weeks in pediatric individuals (ages 2 to 18), as needed], nivolumab is approved as a 3 mg / kg dose every 2 weeks, cemiplimab-rwlc is approved as a 350 mg dose administered every 3 weeks as needed, atezolizumab is approved as a 1200 mg dose administered every 3 weeks as needed, avelumab is approved as a 10 mg / kg or 800 mg dose administered every 2 weeks as needed, and durvalumab is approved as a 10 mg / kg dose administered every 2 weeks as needed.
[0254] In certain embodiments of the combination therapy, the PD-1 blocker is an anti-PD-1 antibody or an anti-PD-1 antibody fragment, which may be administered at a dose of about 150 mg to about 250 mg, about 175 mg to about 250 mg, about 200 mg to about 250 mg, about 150 mg to about 240 mg, about 175 mg to about 240 mg, or about 200 mg to about 240 mg. In some embodiments, the dose of the anti-PD-1 antibody or antigen-binding fragment thereof is 150 mg, 175 mg, 200 mg, 225 mg, 240 mg, or 250 mg. In other embodiments, the anti-PD-1 antibody or anti-PD-1 antibody fragment may be administered as frequently as every 3 weeks, as needed. In another embodiment of the combination therapy of the present invention, the anti-PD-1 antibody or anti-PD-1 antibody fragment may be administered at a dose of more than 250 mg, for example, at a dose of about 400 mg, as frequently as every 6 weeks, as needed.
[0255] In certain embodiments of the combination therapy, the PD-1 blockade agent is an anti-PD-1 antibody or an anti-PD-1 antibody fragment, which may be administered at a dose of about 10 mg / kg to about 1200 mg. In other embodiments, the anti-PD-1 antibody or anti-PD-1 antibody fragment may be administered as frequently as every 2-3 weeks, as needed.
[0256] The PD-1 blockers may be administered at least at the same dose, frequency of administration, and duration of treatment approved for currently marketed PD-1 blockers in monotherapy, although the actual dose, frequency of administration, and duration of treatment for any particular combination of the invention may differ from that approved for PD-1 blocker monotherapy. Thus, in certain embodiments of the combination therapy of the invention, the dose, frequency of administration, and duration of treatment of any particular PD-1 blocker in the combination therapy will be determined from clinical trials conducted for the combination therapy.
[0257] In certain embodiments of the combination therapy, the PD-1 blocker is nivolumab or an effector-silent variant of nivolumab, which is administered intravenously to the individual at a dose of 3 mg / kg over 30-60 minutes every 2-3 weeks as needed, where each dose of CTLA-4 blocker is administered intravenously for the same treatment period as the PD-1 blocker or for a period shorter or longer than that of the PD-1 blocker following administration of the PD-1 blocker. In certain embodiments, nivolumab or an effector-silent variant of nivolumab is administered intravenously to the individual at an initial dose of 3 mg / kg over 30 minutes, then the CTLA-4 blocker is administered intravenously over 30 minutes for four doses every three weeks on the same day, then nivolumab is administered intravenously at a flat dose of 240 mg over 30 minutes every two weeks or 480 mg over 30 minutes every four weeks.
[0258] In certain embodiments, the PD-1 blocking agent is pembrolizumab or an effector-silent variant of pembrolizumab, which is administered intravenously to an adult individual at a dose of 200 mg over 30 minutes every three weeks, or to a pediatric individual at a dose of 2 mg / kg up to about 200 mg over 30 minutes every three weeks, as appropriate, where after each treatment, a dose of a CTLA-4 blocking agent is administered, where each dose of the CTLA-4 blocking agent is administered intravenously for the same treatment period as the PD-1 blocking agent or for a period that is shorter or longer than the period of the PD-1 blocking agent after administration of the PD-1 blocking agent.
[0259] In a specific embodiment, the PD-1 blocking agent is pembrolizumab or an effector-silent variant of pembrolizumab, which is administered intravenously to an adult individual at a dose of 400 mg over 30 minutes every six weeks as needed, where each treatment is followed by a dose of a CTLA-4 blocking agent, where each dose of the CTLA-4 blocking agent is administered intravenously for the same treatment period as the PD-1 blocking agent or for a period that is shorter or longer than the period of the PD-1 blocking agent following administration of the PD-1 blocking agent.
[0260] In certain embodiments, the PD-1 blocking agent is cemiplimab-rwlc or an effector-silent variant of cemiplimab-rwlc, which is administered intravenously to an individual at a dose of 350 mg over 30 minutes every three weeks as needed, where administration of the PD-1 blocking agent is followed by each dose of a CTLA-4 blocking agent administered intravenously for the same treatment duration as the PD-1 blocking agent or for a duration shorter or longer than that of the PD-1 blocking agent. In certain embodiments, cemiplimab-rwlc or an effector-silent variant of cemiplimab-rwlc is administered intravenously to an individual at an initial dose of 350 mg over 30 minutes, followed by administration of a CTLA-4 blocking agent over 30 minutes on the same day every three weeks as needed.
[0261] In certain embodiments, the PD-1 blocking agent is atezolizumab or an effector-silent variant of atezolizumab, which is administered intravenously to the individual at a dose of 1200 mg over 60 minutes every three weeks as needed, where administration of the PD-1 blocking agent is followed by each dose of a CTLA-4 blocking agent administered intravenously for the same treatment duration as the PD-1 blocking agent or for a duration that is shorter or longer than that of the PD-1 blocking agent. In certain embodiments, atezolizumab or an effector-silent variant of atezolizumab is administered intravenously to the individual at an initial dose of 1200 mg over 60 minutes, followed by administration of a CTLA-4 blocking agent over 30 minutes on the same day every three weeks as needed.
[0262] In certain embodiments, the PD-1 blocking agent is avelumab or an effector-silent variant of avelumab, which is administered intravenously to an individual at a dose of 10 mg / kg or 800 mg over 60 minutes every two weeks as needed, where administration of the PD-1 blocking agent is followed by each dose of a CTLA-4 blocking agent administered intravenously for the same treatment duration as the PD-1 blocking agent or for a duration that is shorter or longer than that of the PD-1 blocking agent. In certain embodiments, avelumab or an effector-silent variant of avelumab is administered intravenously to an individual at an initial dose of 10 mg / kg or 800 mg over 60 minutes, followed by administration of a CTLA-4 blocking agent over 30 minutes on the same day every two weeks as needed.
[0263] In certain embodiments, the PD-1 blocking agent is durvalumab or an effector-silent variant of durvalumab, which is administered intravenously to the individual at a dose of 10 mg / kg over 60 minutes every two weeks as needed, where administration of the PD-1 blocking agent is followed by each dose of a CTLA-4 blocking agent administered intravenously for the same treatment duration as the PD-1 blocking agent or for a duration that is shorter or longer than that of the PD-1 blocking agent. In certain embodiments, durvalumab or an effector-silent variant of durvalumab is administered intravenously to the individual at an initial dose of 10 mg / kg over 60 minutes, followed by administration of a CTLA-4 blocking agent over 30 minutes on the same day every two weeks as needed.
[0264] While currently approved CTLA-4 and PD-1 blocking agents are provided in formulations at concentrations that allow for intravenous administration to an individual over a 30-60 minute time frame, the combination therapy of the present invention contemplates embodiments in which the CTLA-4 and / or PD-1 blocking agents are each provided in formulations that allow for each to be administered separately to an individual in a single injection. The ability to administer at least one of the two blocking agents in a single injection would significantly reduce the time to administer both blocking agents to an individual.
[0265] In another embodiment, the present invention provides a combination therapy in which a CTL-4 blocking agent and a PD-1 blocking agent are co-administered simultaneously. Co-administration can be achieved by providing the CTLA-4 blocking agent and the PD-1 blocking agent in separate formulations and providing each formulation to the individual at the same time via separate IVs, or by mixing and then administering the mixture to the individual via IV, or by injecting each formulation separately to the individual. Co-administration can also be achieved by providing the CTL-4 blocking agent and the PD-1 blocking agent in a single formulation and then administering it to the individual in one IV or one injection.
[0266] (i) Combination Therapy Treatment The combination therapy of the present invention can be used to treat any proliferative disease, particularly cancer.In certain embodiments, the combination therapy of the present invention can be used to treat melanoma, non-small cell lung cancer, head and neck cancer, urothelial cancer, breast cancer, gastrointestinal cancer, multiple myeloma, hepatocellular carcinoma, non-Hodgkin's lymphoma, renal cancer, Hodgkin's lymphoma, mesothelioma, ovarian cancer, small cell lung cancer, esophageal cancer, anal cancer, biliary tract cancer, colorectal cancer, cervical cancer, thyroid cancer or salivary gland cancer.
[0267] In another embodiment, the combination therapy of the present invention may be used to treat pancreatic cancer, bronchial cancer, prostate cancer, pancreatic cancer, gastric cancer, ovarian cancer, bladder cancer, brain or central nervous system cancer, peripheral nervous system cancer, uterine or endometrial cancer, oral or pharyngeal cancer, liver cancer, kidney cancer, testicular cancer, biliary tract cancer, small intestine or appendix cancer, adrenal cancer, osteosarcoma, chondrosarcoma, or cancer of the blood tissue.
[0268] Currently available PD-1 blockers are approved by the US FDA to treat at least one or more cancers selected from melanoma (metastatic or unresectable), primary mediastinal large B-cell lymphoma (PMBCL), urothelial carcinoma, MSIHC, gastric cancer, cervical cancer, hepatocellular carcinoma (HCC), Merkel cell carcinoma (MCC), renal cell carcinoma (including advanced), and cutaneous squamous cell carcinoma. Thus, the combination therapy of the present invention can be used to treat at least one or more cancers selected from melanoma (metastatic or unresectable), primary mediastinal large B-cell lymphoma (PMBCL), urothelial carcinoma, MSIHC, gastric cancer, cervical cancer, hepatocellular carcinoma (HCC), Merkel cell carcinoma (MCC), renal cell carcinoma (including advanced), and cutaneous squamous cell carcinoma.
[0269] (j) Combination therapy with chemotherapy The combination therapy of the present invention may be administered to an individual with cancer in combination with chemotherapy. The individual may receive chemotherapy at the same time the individual is receiving the combination therapy of the present invention. The individual may receive the combination therapy of the present invention after completing chemotherapy. The individual may be administered chemotherapy after completing the combination therapy. The combination therapy of the present invention may also be administered to an individual with recurrent or metastatic cancer who is receiving or has completed chemotherapy and has disease progression or recurrent cancer.
[0270] The chemotherapy may include a chemotherapeutic agent selected from the group consisting of:
[0271] (i) Alkylating agents, including but not limited to bifunctional alkylating agents, cyclophosphamide, mechlorethamine, chlorambucil and melphalan; (ii) monofunctional alkylating agents, including but not limited to dacarbazine, nitrosoureas and temozolomide (oral dacarbazine); (iii) Anthracyclines, including but not limited to daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone and barbicin; (iv) cytoskeletal disruptors (taxanes), including but not limited to paclitaxel, docetaxel, abraxane, and taxotere; (v) Epothilones, including but not limited to ixabepilone and utiderone; (vi) histone deacetylase inhibitors, such as, but not limited to, vorinostat and romidepsin; (vii) inhibitors of topoisomerase I, including but not limited to irinotecan and topotecan; (viii) topoisomerase II inhibitors, such as (but not limited to) etoposide, teniposide, and tafluposide; (ix) kinase inhibitors, including but not limited to bortezomib, erlotinib, gefitinib, imatinib, vemurafenib and vismodegib; (x) Nucleotide analogs and precursor analogs, including, but not limited to, azacitidine, azathioprine, fluoropyrimidines (e.g., capecitabine, carmofur, doxifluridine, fluorouracil, and tegafur), cytarabine, gemcitabine, hydroxyurea, mercaptopurine, methotrexate, and tioguanine (formerly thioguanine); (xi) peptide antibiotics, such as, but not limited to, bleomycin and actinomycin; platinum-based agents, such as, but not limited to, carboplatin, cisplatin, and oxaliplatin; (xii) retinoids, such as, but not limited to, tretinoin, alitretinoin, and bexarotene; and (xiii) Vinca alkaloids and their derivatives, including, but not limited to, vinblastine, vincristine, vindesine, and vinorelbine.
[0272] The choice of the dose of the chemotherapy chemotherapeutic agent depends on several factors, including the serum or tissue turnover rate of the substance, the severity of symptoms, the immunogenicity of the substance, and the accessibility of the target cells, tissues or organs in the individual being treated. The dose of the additional therapeutic agent should be an amount that produces an acceptable level of side effects. Thus, the dose and frequency of administration of each additional therapeutic agent depends, in part, on the individual therapeutic agent, the severity of the cancer being treated, and the characteristics of the patient. Guidance is available for selecting the appropriate dose of antibodies, cytokines, and small molecules. See, e.g., Wawrzynczak (1996) Antibody Therapy, Bios Scientific Pub. Ltd, Oxfordshire, UK; Kresina (ed.) (1991) Monoclonal Antibodies, Cytokines and Arthritis, Marcel Dekker, New York, NY; Bach (ed.) (1993) Monoclonal Antibodies and Peptide Therapy in Autoimmune Diseases, Marcel Dekker, New York, NY; Baert et al. (2003) New Engl. J. Med. 348:601-608; Milgrom et al. (1999) New Engl. J. Med. 341:1966-1973; Slamon et al. (2001) New Engl. J. Med. 344:783-792; Beniaminovitz et al. (2000) New Engl. J. Med. 344:783-792. Engl. J. Med. 342:613-619; Ghosh et al. (2003) New Engl. J. Med. 348:24-32; Lipsky et al. (2000) New Engl. J. Med. 343:1594-1602; Physicians' Desk Reference 2003 (Physicians' Desk Reference, 57th Ed); Medical Economics Company; ISBN: 1563634457; 57th Edition (November 2002).The determination of an appropriate dosing regimen can be made by the clinician using, for example, parameters or factors known or suspected in the art to affect treatment or expected to affect treatment, and will depend, for example, on the individual's clinical history (e.g., previous treatments), the type and stage of the cancer being treated, and biomarkers of response to one or more of the therapeutic agents in the combination therapy.
[0273] For example, pembrolizumab is currently approved by the U.S. FDA for (i) combination therapy with pembrolizumab with either pemetrexed and platinum chemotherapy or carboplatin and paclitaxel or nab-paclitaxel for the treatment of non-small cell lung cancer (NSCLC), and (ii) combination therapy with pembrolizumab and platinum-containing chemotherapy for the treatment of head and neck squamous cell carcinoma (HNSCC), and atezolizumab is currently approved for combination therapy with bevacizumab (an anti-VEGF-A antibody sold under the trade name AVASTIN), paclitaxel, and carboplatin for the treatment of NSCLC.
[0274] Thus, the present invention includes embodiments of the combination therapy of the present invention further comprising a step of chemotherapy comprising platinum-containing chemotherapy, pemetrexed and platinum chemotherapy, or carboplatin and either paclitaxel or nab-paclitaxel. In certain embodiments, the combination therapy with a chemotherapy step can be used to treat at least NSCLC and HNSCC.
[0275] The combination therapy further combined with a chemotherapy step can be used to treat any proliferative disease, especially cancer. In a particular embodiment, the combination therapy of the present invention can be used to treat melanoma, non-small cell lung cancer, head and neck cancer, urothelial cancer, breast cancer, gastrointestinal cancer, multiple myeloma, hepatocellular carcinoma, non-Hodgkin's lymphoma, renal cancer, Hodgkin's lymphoma, mesothelioma, ovarian cancer, small cell lung cancer, esophageal cancer, anal cancer, biliary tract cancer, colorectal cancer, cervical cancer, thyroid cancer or salivary gland cancer.
[0276] In another embodiment, the combination therapy further combined with a chemotherapy step may be used to treat pancreatic cancer, bronchial cancer, prostate cancer, pancreatic cancer, gastric cancer, ovarian cancer, bladder cancer, brain or central nervous system cancer, peripheral nervous system cancer, uterine or endometrial cancer, oral or pharyngeal cancer, liver cancer, kidney cancer, testicular cancer, biliary tract cancer, small intestine or appendix cancer, adrenal cancer, osteosarcoma, chondrosarcoma, or cancer of the blood tissue.
[0277] In certain embodiments, the combination therapy with chemotherapy step may be used to treat at least one or more cancers selected from melanoma (metastatic or unresectable), primary mediastinal large B-cell lymphoma (PMBCL), urothelial carcinoma, MSIHC, gastric cancer, cervical cancer, hepatocellular carcinoma (HCC), Merkel cell carcinoma (MCC), renal cell carcinoma (including advanced), and cutaneous squamous cell carcinoma. EXAMPLES
[0278] The following examples are intended to provide a more detailed understanding of the invention.
[0279] Example 1 Fc function is required for induction of intestinal inflammatory irAEs Intestinal inflammatory irAEs have been observed in cancer patients during immunotherapy with anti-CTLA-4 antibodies alone or in combination with anti-PD-1 antibodies. Preclinical studies of CTLA-4-deficient mice in constitutive and conditional knockout models have shown the development of severe immune-mediated inflammatory disease in multiple organs. However, treatment of syngeneic tumor models with surrogate anti-CTLA-4 antibodies has not been reported to induce overt irAEs predictive of toxicity observed in cancer patients. Similarly, histopathological assessment of intestinal inflammation was evaluated in a CT26 syngeneic or xenograft model (mice inoculated with the CT26 colon cancer cell line). Fc-competent anti-mouse CTLA-4 mAb 9D9-mIgG 2aCT26 tumor-bearing mice treated with (α-CTLA-4 or α-CTLA4) (q4×4) caused minimal granulocytic infiltration (grade 1 / 5) observed in the intestinal tissue lamina propria. No granulocytic infiltration was observed in cohorts treated with Fc-mutated anti-mCTLA-4 mAb 9D9-mIgG1-D265A (α-CTLA-4(D265A)), Fc-free anti-mCTLA-4 ISVD F894 (CTLA-4 Nab) or isotype, whereas no associated ulceration or other tissue damage was observed.
[0280] The α-CTLA-4(D265A) Fc mutant lacks measurable affinity for Fcγ receptors (Nimmerjahn et al., Immunity, 23:41-51 (2005)) and therefore lacks Fc effector function. In mice, the antitumor efficacy of anti-mouse CTLA4 mAb monotherapy depends on the ability of the antibody to effect intratumoral regulatory T cell depletion via Fc effector function (Selby et al., supra). Thus, both CTLA-4 Nab and α-CTLA-4(D265A) were not expected to have monotherapy antitumor efficacy.
[0281] The minimal histopathological findings prompted us to evaluate gene expression profiling as a potentially more sensitive means of detecting markers of inflammatory cell activation in the intestine. We utilized a PCR gene expression panel that we had previously developed for proteomic and expression profiling of genes associated with intestinal inflammation in fecal samples and biopsies from inflammatory bowel disease (IBD) preclinical models and patients (Cayatte, C. et al., Clinical and Translational Gastroenterology, 3:e10 (2012)).
[0282] Gene expression profiles were measured in small intestine and colon tissue samples at various time points after the initiation of treatment with α-CTLA-4 compared to α-CTLA-4(D265A) to further evaluate the role of Fc function for inducing intestinal inflammation. As shown in Figure 1A, the expression of multiple intestinal inflammatory genes was upregulated in proximal small intestine samples from mice treated with α-CTLA-4, but not with α-CTLA-4(D265A). The results indicated that the expression of intestinal inflammatory pathways could be detected by gene expression in small intestine and colon tissues in the subclinical setting.
[0283] Upregulation of genes associated with intestinal inflammation, as observed in ipilimumab-treated patients after more than 6–7 weeks of treatment, allowed us to evaluate the effect of sustained treatment on progression to clinical enteritis (Samaan et al., Nat. Rev. Gastroenterol. Hepatol. 15:222-234 (2018)). To evaluate the relative effects of CTLA-4 blockade and Fc function on intestinal inflammation and progression to enteritis, BALB / c mice were administered α-CTLA-4, α-CTLA-4(D265A) twice weekly. Two groups of mice (one group bearing CT26 tumors and one group of naive BALB / c mice without tumors) were treated with Fc-competent α-CTLA-4 to evaluate the potential contribution from induction of tumor immunity and tumor growth to the induction of intestinal inflammation. To monitor progression to enteritis, body weight and body condition scores were assessed twice weekly throughout the entire duration of sustained treatment.
[0284] Body weight continued to increase until day 50 in mice administered isotype antibody and α-CTLA-4(D265A). In contrast, mice administered α-CTLA-4 showed a decrease in mean body weight after approximately 35-40 days (Figure 1B). Assessment in FITC-dextran gavage-fed mice on days 49 and 50 showed that intestinal permeability was increased in both α-CTLA-4-treated groups, but not in α-CTLA-4(D265A)-treated mice (Figure 1C). Histological evidence of inflammation in the proximal small intestine and colon, assessed by a pathologist (LA), showed progression to moderate and severe enteritis in the α-CTLA-4-treated groups (Figure 1D and Figure 1E), with extensive immune infiltration, mucosal thickening, and loss of goblet cells. In contrast, no intestinal inflammation was observed in α-CTLA-4(D265A)-treated mice, providing evidence that Fc function is required for CTLA-4 blockade-induced intestinal inflammation. Notably, tumor growth and antitumor responses were not required for α-CTLA-4-induced intestinal inflammation.
[0285] Mouse IgG with high FcγR affinity 2a It has previously been reported that a strong monotherapy antitumor response requires an anti-CTLA-4 antibody with strong FcγR function in an experiment comparing a chimeric antibody with a mutated IgG1 chimera with no detectable FcγR binding (Selby et al., Cancer Immunol. Res. 1:32-42 (2013)). Mouse IgG 2a (mIgG 2a ) in tumors in a potent monotherapy observed with anti-CTLA-4 antibodies on the backbone. reg Specific depletion of CD28 appears to play a key role (Simpson et al., J. Exp. Med. 210:1695-710 (2013)). A recent report showing the importance of CD28 for the efficacy of anti-PD-1 (see references) suggested that augmenting CD28 function by blocking the stronger interaction of CTLA-4 with its ligands CD80 and CD86 with a CTLA-4 antagonist may be able to mediate the proliferation and proliferation of T cells. regThis suggested to us that a potent combination antitumor effect could be achieved without the need for TIL depletion. The ISVD specific for mouse CTLA-4 (mCTLA-4), which can block binding to CD80 and CD86, was integrated with a single domain VSVD derived from a heavy chain-only camelid antibody. HH Developed using antibody fragments. These small 15 kDa proteins lack the Fc region and therefore do not bind to FcγR. To compare with antibodies with full Fc function, α-CTLA-4 (see references), which has already been shown to have potent monotherapy antitumor efficacy, was used. To control for the potential impact of binding to a different CTLA-4 epitope, α-CTLA-4(D265A), which lacks detectable affinity for FcγR, was used to control for the requirement of strong FcγR function for antitumor efficacy and tolerability.
[0286] CTLA-4 nAbs express anti-human albumin V as a half-life extension (HLE) subunit. HH Two anti-CTLA-4 V domains linked by a 35GS linker HH The anti-CTLA-4 V domain is composed of the α-CTLA-4 V domain (see SEQ ID NO: 61). HH demonstrated 96% inhibition of both CD80 and CD86 (Figures 2A and 2B). CTLA-4 nAbs were further compared to α-CTLA-4 and effector-silent α-CTLA-4(D265A) in in vitro MLR-based bioassays for their ability to enhance proliferation (Figure 2C), IFNγ (Figure 2D), and IL-2 responses (Figure 2E).
[0287] Fc function for CTLA-4 blockade is not required for PD-1 combination immunotherapy The relative antitumor efficacy induced by monotherapy with the three CTLA-4 antagonists and combination therapy with the anti-mouse PD-1 antibody mDX400 (α-PD-1) was assessed by measuring the change in tumor volume over time in a syngeneic CT26 colon cancer tumor model that shows only a moderate response to anti-PD-1 monotherapy (Figures 3A-3E). No antitumor activity was observed in the monotherapy cohorts treated with either CTLA-4 nAb or α-CTLA-4 (D265A) and was comparable to the isotype control (group 1 in Figure 3A). Potent antitumor monotherapy activity was observed in mice treated with α-CTLA-4, consistent with a previous report showing that Fc function in anti-CTLA-4 antibodies is required for efficacy of antitumor monotherapy in a mouse syngeneic tumor model (Simpson et al., J. Exp. Med. 210:1695-710 (2013)) (group 2 in Figure 3A). Treatment with α-PD-1 alone showed low to moderate anti-tumor growth inhibition compared to α-CTLA-4. However, combination therapy of CTLA-4 nAb or α-CTLA-4(D265A) with α-PD-1 resulted in potent anti-tumor effects comparable to those observed with α-CTLA-4 alone or in combination with α-CTLA-4 and α-PD-1 (group 2 in Figure 3A). CTLA-4 nAb and α-CTLA-4(D265A) bind separate epitopes on CTLA-4, so the effect is not epitope specific. Further evidence of a potent combination effect was evident, independent of Fc function, as similar anti-tumor responses were observed in α-PD-1 combination treatments between CTLA-4 nAb, α-CTLA-4(D265A) and α-CTLA-4. Figure 3D shows the individual results for each of the 10 mouse treatments summarized in Figure 3A. Increased CD8 T cell proliferation and CD8 / Treg ratios were observed in α-CTLA-4-treated mice and in mice treated with the combination of α-CTLA-4(D265S) and α-PD-1 compared to mice receiving α-CTLA-4(D265S) alone (Figure 3B).These results indicate that combining an anti-CTLA-4 antagonist lacking Fc function with an anti-PD-1 antagonist resulted in an anti-tumor effect superior to that achievable with anti-PD-1 antagonist monotherapy, and that the combination produced an anti-tumor effect similar to that of an anti-CTLA-4 antibody with Fc function in monotherapy.
[0288] To elucidate potential complementary mechanisms associated with the strong combinatorial activity, we investigated the regulation of immune response genes associated with effective cancer immunotherapy in tumors 9 days after treatment initiation. PCR expression profiling of tumors from α-CTLA-4 treated mice showed strong upregulation of numerous genes associated with effective immunotherapy, including IFNγ, IFN response genes, chemokines, inflammatory cytokines, and MHC (Figure 3C). Only moderate upregulation was observed in tumors from α-CTLA-4(D265A) treated mice, indicating that the strong upregulation observed in α-CTLA-4 treated tumors was at least partially dependent on Fc function. Moderate responses were also observed in tumors from CTLA-4 nAb and α-PD-1 treated mice. In contrast, strong upregulation of tumor immune response genes was observed in combination therapy cohorts treated with CTLA-4 nAb or α-CTLA-4(D265A) and α-PD-1. Figure 3D shows that in the absence of PD-1 blockade, neither CTLA-4 nAb nor α-CTLA-4(D265A) has antitumor activity. These data support the hypothesis that the complementary mechanisms of pure CTLA-4 blockade and PD-1 blockade may provide a potent combinatorial benefit in an Fc-independent manner.
[0289] Fc-function-free CTLA-4 blockade combined with anti-PD-1 provides a superior therapeutic index A hallmark of immune checkpoint blockade is the benefit of the clinically validated combination of anti-PD-1 and anti-CTLA-4 antibodies, which results in superior clinical efficacy compared to targeting either checkpoint alone. However, immune-related toxicities (irAEs) associated with CTLA-4 blockade combination therapy with anti-PD-1 have been linked to increased induction of intestinal inflammation in patients (Ribas & Wolchok, Science 359:1350-1355 (2018)). Also, both α-CTLA(D265A) and Fc-free CTLA-4 nAb required combination with α-PD-1 to induce potent antitumor immunity. To perform a control experiment on the potential impact of potent tumor immunity on induction of intestinal inflammation, we examined the intestinal inflammation expression profile in mice that received combination therapy of α-PD-1 with either α-CTLA, α-CTLA(D265A) or CTLA-4 nAb after five treatments on day 18 after the start of treatment (Figure 4D).
[0290] To evaluate the relative effects of CTLA-4 blockade and Fc function on intestinal inflammation, naïve BALB / c mice were administered α-CTLA, α-CTLA(D265A), Fc-free CTLA4 nAb, α-PD-1, or a combination of α-PD-1 and various anti-mCTLA4 antagonists twice weekly. Body weight and condition scores were assessed twice weekly for the entire duration of the study. Mice in all groups gained weight until approximately day 20 (Figure 4A). Body weight continued to increase until day 50 in mice administered isotype, α-CTLA(D265A), CTLA4 nAb, or α-PD-1, or combinations thereof. Mice administered α-CTLA showed a decrease in mean body weight after approximately day 30, decreasing to near pretreatment levels by day 50. Administration of α-CTLA in combination with α-PD-1 led to a more rapid loss in mean body weight, which declined to below pretreatment levels from day 20 to day 50. Notably, the body condition score of 2 of 8 mice declined to 2 (poor body condition) from day 28 in mice treated with α-CTLA in combination with α-PD-1 and from day 42 in mice administered α-CTLA. These cohorts exhibited shiny, shaggy fur and abdominal swelling was observed in these cohorts.
[0291] Analysis of inflammation was scheduled after 7 weeks of treatment, at which time mice treated with α-CTLA showed a loss of body weight over that period, which was exacerbated when administered in combination with α-PD-1 (Group B in FIG. 4A). In contrast, neither effector-silent CTLA-4 blockers nor α-PD-1 showed significant weight loss compared to isotype controls over that period (Group A in FIG. 4B).
[0292] All mice in the combination treatment group and four mice in the isotype control and α-PD-1 treatment groups were euthanized on day 50 for tissue collection. The remaining four mice in the isotype control and α-PD-1 treatment groups and all mice in the single agent treatment groups were euthanized on day 54 for tissue collection. At necropsy, the proximal small intestine and colon were removed for RT-qPCR to determine inflammatory gene expression and for evaluation of inflammation by histopathological examination.
[0293] Heat maps of gene expression in the proximal small intestine from each treatment group compared to isotype control are shown in (Figure 4D). Administration of α-CTLA was sufficient to induce upregulation of inflammatory genes in the jejunum (Figure 4D) and colon (Figure 4E). The combination of α-CTLA and α-PD-1 induced a more potent upregulation of inflammatory genes than α-CTLA monotherapy. In contrast, administration of CTLA-4 nAb induced little or no intestinal inflammatory gene expression and only induced a slight upregulation when combined with α-PD-1. Similarly, administration of α-CTLA(D265A) alone or in combination with α-PD-1 resulted in minimal to low induction of inflammatory genes. Intestinal permeability, assessed in serum after oral gavage of FITC-dextran, was significantly increased in α-CTLA-treated mice and mice receiving combined treatment with α-CTLA and α-PD-1.
[0294] The severity of inflammation in the proximal small intestine was scored by histological evaluation of enteritis in the proximal jejunum on day 50. By histopathological evaluation, administration of α-CTLA resulted in mild to severe inflammation in most mice. In the cohort treated with the combination of α-CTLA and α-PD-1, continuous treatment induced moderate to very severe inflammation in all mice (Figure 4B). Mice with very severe enteritis showed jejunitis, diffuse neutrophilic lesions with moderate numbers of mast cells, and degeneration of neurons in Meissner's plexus. In contrast, administration of either CTLA-4 nAb or α-CTLA(D265A) did not induce inflammation by histopathological evaluation. Administration of CTLA-4 nAb in combination with α-PD-1 caused no inflammation or minimal to mild inflammation in some mice. Administration of α-CTLA(D265A) in combination with α-PD-1 caused mild inflammation in only 1 of 8 mice. Representative photomicrographs show the relative levels of inflammation in each treatment group (Figure 4C).
[0295] As shown in Figures 5A-5C, α-CTLA-4 Fc effector function induces skin inflammation (Figure 5A) but not systemic inflammation, in which no detectable inflammation was observed in the kidney, liver, or lung (Figure 5C). The absolute numbers of IL-17-producing T cells, Foxp3+ Treg cells, and neutrophils in the ear skin were measured by flow cytometry. As shown in Figure 5B, there were high levels of IL-17-producing T cells, Foxp3+ Treg cells, and neutrophils in the ear skin of α-CTLA-4-treated mice, but not in those treated with α-CTLA-4(D265A). Taken together, these data support the important role of Fc effector function in the induction of intestinal inflammation by anti-mouse CTLA-4 antibodies with effector function. Fc effector functions contributed to anti-mouse α-CTLA-induced intestinal inflammation in a BALB / c mouse model of intestinal inflammation, whereas intestinal inflammation was mild or absent in CTLA-4 nAb- or α-CTLA(D265A)-treated mice.
[0296] In summary, two properties were relevant for induction of intestinal inflammation in the CT26 tumor model by α-CTLA-4. First, the specificity of CTLA-4 was required, since an Fc functional isotype control did not induce inflammation-related gene expression. However, blocking CTLA-4 binding to CD80 / CD86 ligands was insufficient to induce upregulation of inflammatory genes in the intestine of CTLA-4 nAb and α-CTLA-4(D265A)-treated mice. Thus, IgG in α-CTLA-4 2a The capacity for strong Fc function present in the isoforms was required for induction of intestinal inflammation.
[0297] Activation of intestinal inflammation is mediated by Tregs independently of Treg depletion eff Initiated by cell activation The mechanism of action (MOA) of anti-CTLA-4-mediated antitumor immunity is theoretically T regulatory (T reg ) cells and T effector (T eff ) cell populations (CTL, TH1 cells, etc.) within the tumor microenvironment (TIL). reg Cell depletion is a prominent MOA of anti-CTLA-4 antibodies in mouse syngeneic tumor models (Simpson et al., supra). Also, Fc-FcγR co-engagement by anti-CTLA-4 mAbs modulates T cell receptor (TCR) and CD28 signaling to promote T cell proliferation and cell death. reg This leads to enhanced T cell activation independent of T cell depletion (Waight et al., Cancer Cell, 33:1033-1047 (2018)).
[0298] T regTo characterize the differential effects of α-CTLA-4 on T effector cells and TILs from CTLA-4 nAb, flow cytometry was performed on T cell populations from tumor (TIL), colonic lamina propria, blood and spleen 20 h after subcutaneous administration. TILs from mice treated with α-CTLA-4 or α-CTLA-4(D265A) were analyzed using anti-CTLA-4 mAb clone UC10-4B9 (ThermoFisher), which allows staining of drug-bound CTLA-4 without cross-blocking. reg As previously reported in the literature (Selby et al., supra; Simpson et al., supra), the present inventors were able to measure the expression levels of CTLA-4 in the spleens (CTLA-4 lo ) and the tumor microenvironment (T reg hi ) in T reg We observed differential expression of CTLA-4 in PBMCs. reg showed bimodal levels of CTLA-4 lo-mid Interestingly, T reg Bimodal levels of CTLA-4 mid-hi CTLA-4 in the colon hi T reg expressed similar levels of Treg TIL populations. Differential expression levels of CTLA-4 on various T cell populations affect the capacity for ADCC-mediated depletion through a receptor density-dependent killing mechanism. reg The population expresses higher than normal levels of CTLA-4, but is not associated with T reg Treg TILs express much higher levels (3.3-fold higher; MFI=8,100 in isotype control) than those found in the spleen (MFI=2,400). hi lamina propria T from the colon expressing 100% β-glucose (mode MFI = 10,000) reg was analyzed for relative expression levels using flow cytometry. reg As shown in Figures 6B-6D, T regSignificant depletion of TILs was restricted to TILs from the tumor microenvironment of α-CTLA-4-treated mice, which exhibit the highest CTLA-4 expression density. Treatment with the Fc mutant α-CTLA-4(D265A), which lacks Fc function, reduced T reg did not cause depletion of
[0299] Based on the assumption that cells expressing higher CTLA-4 levels are more susceptible to depletion by α-CTLA, we reg CTLA-4 in the lamina propria, as well as in TIL populations hi T reg Surprisingly, T cells isolated from tumors of α-CTLA-4-treated mice were reg Only TILs appeared to be depleted. Lamina propria-derived TILs from the colon of α-CTLA-4-treated mice reg Lamina propria-derived T cells from the colon of α-CTLA-4-treated mice did not appear to be depleted. reg No detectable depletion of T was observed, suggesting that induction of intestinal inflammation is associated with increased T cell proliferation in the intestinal mucosa. reg This suggests that the loss of
[0300] We found that T α-CTLA-4 conferred a suppressor function that may have contributed to α-CTLA-4-induced intestinal inflammation. reg We investigated possible phenotypic changes in colonic lamina propria (LP) T cells from FoxP3 GLD reporter mice implanted with MC38 tumors. reg , T reg Genes associated with function were selected for PCR expression profiling (Figure 7A). However, α-CTLA-4(D265A)-treated mice showed no significant difference in LP T reg No significant gene expression differences were observed in the cells. hi Using a T cell transfer model, reg The potential effects of Fc function on CD45RB were investigated in more detail. hi T in the presence of T cells reg Passive transfer of cells protected mice from developing colitis (Figures 7B-7C). regMice co-administered with α-CTLA-4 cells and CD45RBhi T cells showed increased T reg This resulted in loss of protection and the development of colitis. In contrast, no loss of protection was observed in CTLA-4 nAb-treated mice (Figures 7B-7C). Flow cytometry-sorted colonic Foxp3+ T cells from mice 24 hours after treatment. reg Gene expression profiling of the cells showed a significant upregulation of gene expression in α-CTLA-4 treated mice compared to that observed in cells obtained from mice treated with CTLA-4 nAb or isotype control, which was consistent with the upregulation of CD45RB high Overall, these results suggest that Fc-mediated T reg Although depletion is not essential for induction of intestinal inflammation by α-CTLA-4, it suppresses T reg The regulatory function of can be modulated.
[0301] The restricted expression of CD80, CD86, and FcγR on antigen-presenting cells and CTLA-4 and CD28 on T cells defines the T reg Fc functional α-CTLA-4 nAb may play an important role in T cell activation independent of exhaustion (Waight et al., Cancer Cell, 33:1033-1047, 2018). Fc-enhanced activation in tumors is advantageous but may result in unintended irAEs in intestinal tissue. We investigated the possible contribution of Fc function in immune effector cell activation in intestinal tissue. Flow cytometry analysis of CD16 / 32 expression in macrophages from both tumors and colon showed significantly higher levels of FcR on antigen-presenting cells compared to splenic macrophages (Figures 8A and 8B). We also found that CD45 expression in tumor and colonic lamina propria mucosa was significantly higher in the tumor and colonic lamina propria mucosa than in the colonic lamina propria mucosa. + CD11b + F4 / 80 +The proportion of macrophages was substantially higher than that in the spleen (Figure 8C).Fc function is required for activation of IL1β, TNFα and IFNγ cytokine responses in intestinal tissue and was evident as early as 10 days after treatment initiation, well before overt evidence of intestinal inflammation was seen, suggesting an important role in irAE induction (Figure 8C).
[0302] Cytokine responses in CD4 T cells isolated from the colonic lamina propria of α-CTLA-4 treated mice after one month of treatment showed higher percentages of IL-17, TNFα and IFNγ producing cells associated with Fc-mediated intestinal inflammation (Figure 8E). An Fc-dependent increase in neutrophils was also induced in α-CTLA-4 treated mice (Figure 8E). Overall, these results indicate that CTLA-4 blockade associated intestinal inflammation was triggered by Fc-mediated activation of effector cells, which is enhanced by FcγR antibody enhancement of cellular cross-linking of APCs with T cells resulting in stimulation of inflammatory cytokine responses, as shown in Figure 11. Fc-mediated induction of intestinal inflammation is mediated by T reg It can be induced by effector T cells regardless of exhaustion.
[0303] Consideration Several recent reports support the important role of Fc function for CTLA-4 blockade monotherapy in syngeneic mouse cancer immunotherapy tumor models (International Patent Application WO 2014 / 089113; Selby et al., Cancer Immunol. Res. 32-42 (2013); Vargas et al., Cancer Cell, 33:649-663 (2018)). Ingram et al. reported in Proc. Natl. Acad. Sci. USA 115:3912-3917, (2018) that an Fc domain must be fused to an anti-CTLA-4 ISVD to confer antitumor efficacy to the ISVD. Indeed, we treated tumors with CTLA-4 nAb or α-CTLA-4(D265A) as monotherapy and observed a lack of efficacy. Tumor-infiltrating T cells expressing higher cell surface CTLA-4 levels regSpecific depletion of has been shown to contribute to tumor efficacy in tumor models (Simpson et al., J. Exp. Med., 210:1695-1710 (2013); Selby et al., Cancer Immunol. Res 1:32-42 (2013)).
[0304] Induction of colitis by α-CTLA-4 is mediated by T cells present in the lamina propria. reg The results were not associated with detectable depletion of T cells. Our study expands the potential of CTLA-4 blockade in anti-cancer therapy by showing strong anti-tumor activity without inducing strong intestinal inflammation when combined with anti-PD-1 antibodies. Fc function was not required to obtain the benefit of combining CTLA-4 blockade with PD-1 blockade. Combination treatments including CTLA-4 nAb or α-CTLA-4(D265A) with α-PD-1 induced activation of IFNγ-related immune response genes in tumors similar to that induced by α-CTLA-4 with strong Fc function. In contrast, strong intestinal inflammation progressing to intestinal inflammation was observed primarily in α-CTLA-4 treated mice and was enhanced when combined with anti-PD-1 antibody mDX400. These results indicate that simple blockade of CTLA-4, which promotes activation of CD28, is sufficient to enhance the anti-tumor response of exhausted T cells when combined with PD-1 blockade.
[0305] A previous report in Kamphorst et al., Science 355:1423-1427 (2017) showed that PD-1 blockade rescue of exhausted CD8 T cells requires CD28 costimulation of TCR activation. Furthermore, a companion report in Hui et al., Science 355:1428-1433 (2017) showed that the coreceptor CD28 is a much more preferred target for dephosphorylation by the PD-1-recruiting Shp2 phosphatase than TCR, and that CD28 is preferentially dephosphorylated. Our results indicate that the complementary activation of the TCR coreceptor CD28 provided by simple blockade of CTLA-4 with anti-CTLA-4 antibodies lacking Fc function and blocking PD-1-mediated dephosphorylation of CD28 may be sufficient to obtain combinatorial benefits for cancer immunotherapy. The advantage of simple combination blockade without Fc-mediated enhanced activation by Fc-FcγR cross-linking may be that it allows for a larger therapeutic index, allowing for a higher dose range and longer treatment times, which may also facilitate further combination with chemotherapy standard of care due to the lower intestinal inflammatory irAE risk profile.
[0306] Experimental procedure mouse Wild-type C57BL / 6J mice were obtained from Jackson laboratories. Wild-type Balb / c and CB17-SCID mice were obtained from Taconic. B6.Foxp3GDL(GFP-DTR-luciferase) mice were born and maintained under specific pathogen-free conditions and housed in microisolators in the presence of filtered air at the Merck Research Laboratories (MRL) animal facility (Palo Alto, California). All animal handling followed the guidelines of the Association for Assessment and Accreditation of Laboratory Animal Care and was approved by the Institutional Animal Care and Use Committee at MRL.
[0307] Tumor challenge and treatment For syngeneic tumor experiments, CT26, MC38 and MB49 tumor models were used. Balb / C or C57BL / 6J mice aged 8–12 weeks were inoculated with 3 × 10 5 CT26 cells were injected subcutaneously (sc). The tumor diameter was measured with an electronic caliper, and the tumor volume was calculated by length x width x width x 1 / 2. 3 Treatment was initiated when the α-CTLA-4, α-CTLA-4(D265A), mouse anti-IgG1-D265A antibody isotype control, mouse anti-IgG 2a Mice were treated subcutaneously (sc) with antibody isotype control, α-PD-1 antibody at 10 mg / kg twice weekly. Mice were treated subcutaneously with CTLA-4 nAb or ISVD control at 30 mg / kg twice weekly.
[0308] α-CTLA-4 comprises an HC having the amino acid sequence set forth in SEQ ID NO:58 and an LC having the amino acid sequence of SEQ ID NO:59.
[0309] α-CTLA-4(D265A) comprises an HC having the amino acid sequence set forth in SEQ ID NO:60 and an LC having the amino acid sequence of SEQ ID NO:60.
[0310] α-PD-1 comprises an HC having the amino acid sequence set forth in SEQ ID NO:63 and an LC having the amino acid sequence of SEQ ID NO:64.
[0311] The CTLA-4 nAb comprises the amino acid sequence set forth in SEQ ID NO:61.
[0312] Anti-PD-1 ISVD F037 (PD-1 nAb) comprises the amino acid sequence set forth in SEQ ID NO:62.
[0313] Induction of colitis and skin inflammation Naïve Balb / c mice aged 8–12 weeks were cultured with α-CTLA-4(D265A), mouse anti-IgG1-D265A isotype control, mouse anti-IgG2a Mice were treated subcutaneously with 20 mg / kg of isotype control antibody twice weekly for 8 weeks. Mice were treated subcutaneously with 30 mg / kg of CTLA-4 nAb or ISVD control twice weekly. Plasma was collected for ELISA and Luminex assays on day 55. Organs were harvested and processed as follows: 1) fixed in 10% neutral buffered formalin and paraffin-embedded tissue sections stained with H&E for histopathology evaluation; 2) snap frozen in liquid nitrogen for further RNA extraction; or 3) placed in HBSS for cell isolation.
[0314] T cell-induced colitis Spleen cells from Balb / c mice were processed and purified for CD4 using magnetic bead separation (STEM CELL Technologies). TCRb+ CD4+ CD25- CD45RB high T cells (CD45RB high T cells) and TCRb+ CD4+ CD25+ CD45RBlow (T reg Cells) were sorted using FACS Aria (BD). 3 × 10 5 CD45RB high T cells and 1 × 10 5 T's reg Cells were injected intravenously. Mice were administered 350 μg of α-CTLA-4 or isotype control or 600 μg of CTLA-4 nAb or ISVD control (ip) twice weekly. Mice were monitored and weighed for 7 weeks after injection.
[0315] intestinal permeability Mice were gavaged with FITC-dextran (4 kDa, Sigma-Aldrich) 4 h before measuring FITC fluorescence in serum.
[0316] Colonic lamina propria, skin and tumor cell isolation Colonic lamina propria cells were isolated by first incubating 0.5 cm intestinal tissue pieces in Hank's buffered saline containing 5 mM EDTA and 10 mM HEPES at 37°C for 20 min to remove epithelial cells, and then repeating this incubation once more. The remaining tissue was cut into small pieces and then digested under the same conditions with HBSS 1x medium containing 0.250 mg / mL LIBERASE (Roche), 30 U / mL DNase I (Sigma-Aldrich) and DISPASE (Corning). The resulting cell suspension was layered on a 40% / 80% PERCOLL gradient and centrifuged at 600 g for 10 min. LP cells were collected at the interface.
[0317] The ear skin was minced and digested with HBSS 1x medium containing 0.250mg / ml LIBERASE (Roche), 30U / mL DNase I (Sigma-Aldrich) and DISPASE (Corning) for 90 minutes at 37°C. The cell suspension was filtered and washed twice with HBSS 1x buffer. The tumor was minced and digested with HBSS 1x medium containing 0.250mg / ml LIBERASE (Roche), 30U / mL DNase I (Sigma-Aldrich) and DISPASE (Corning) for 30 minutes at 37°C. The cell suspension was filtered and washed twice with HBSS 1x buffer.
[0318] Histological samples from colon, ear skin, liver, lung, and kidney pieces were fixed overnight in 10% neutral buffered formalin, transferred to 70% ethanol, routinely processed, embedded in paraffin, sectioned at 4-5 μm, and then stained with hematoxylin and eosin (H&E). Colons were scored in a blinded fashion by a pathologist for severity of disease according to three criteria: Inflammation: When present, was characterized by infiltration of numerous (60-70%) mononuclear cells (macrophages and lymphocytes) and 30-40% neutrophils and zona cells. Scoring of inflammation included the severity of infiltration, the presence of gland loss, erosions, dilation of glandular lumens, crypt abscesses, and degeneration of epithelial cells. Inflammation was scored on a scale of 0-4: 0=negative; 1=minimal; 2=mild; 3=moderate; 4=severe. Apoptosis: Presence of apoptotic bodies was scored on a scale of 0 to 3: 0 = negative; 1 = low; 2 = moderate; 3 = high. Regeneration: Regenerative changes assessed included scoring of the presence of mitotic figures in the upper third of the mucosa, nuclear density within individual glandular structures, and regularity of the surface epithelium. Apoptosis was scored on a scale of 0 to 3: 0 = negative; 1 = low; 2 = moderate; 3 = high.
[0319] Flow cytometry and antibodies Cells were resuspended in PBS and stained with fixable viability stain (BD Bioscience) for 30 min on ice in the dark. Cells were then resuspended in staining buffer (FBS, BD Bioscience) and stained with various combinations of directly fluorochrome-conjugated dyes for 30 min on ice. For intracellular antigens, surface-stained cells were permeabilized and fixed with Foxp3 staining buffer set (eBiosciences) for 30 min on ice and then stained with specific antibodies. Mouse antibodies: CD45 (30-F11), CD8a (53-6.7), CTLA-4 (UC10-4B9), CD11c (HL3), CD11b (M1 / 70), TCRβ (H57-597), TCRγδ (GL3), CD4 (RM4-5 or GK1.5), CD25 (PC61), CD45RB (16A), Ly6G (1A8), F4 / 80 (T45-2342), CD16 / 32 (2.4G2), IFNγ (XMG1.2), IL-17A (TC11-18H10), TNFα (MP6-XT22), Foxp3 (FJK-16s). All antibodies were purchased from BD biosciences, Biolegend or eBioscience. Data acquisition for all samples was performed on an LSR II flow cytometer (BD) and data were analyzed using FLOWJO software (Tree Star).
[0320] For measuring cytokine production by flow cytometry, cells were stimulated with 500 ng / mL ionomycin, 50 ng / mL PMA (Sigma-Aldrich) for 1 h, and Brefeldin A (BD Bioscience) was added for an additional 2 h before staining.
[0321] Murine allogeneic mixed lymphocyte reaction (MLR) assay 2.105 mouse C57B6 / J (8–12 weeks old, female) splenic T cells were isolated using the EASYSEP Mouse T Cell Isolation Kit (STEMCELL) and incubated at 1 × 10 in the presence of the indicated concentrations of α-CTLA-4, α-CTLA-4(D265A), CTLA-4 nAb or isotype control. 5 The cells were co-cultured with irradiated (2000 rad) Balb / c mouse splenocytes. Supernatants were harvested on day 3 and IL-2 and IFN-γ production was measured by ELISA according to the manufacturer's protocol (Meso Scale Discovery). The cells were then 3 Cells were pulsed with [H]-thymidine (1 μCi / well) for 6 h or 16–18 h. Cells were harvested onto glass fiber filters using a cell harvester. Filters were counted using a MicroBeta plate counter (PerkinElmer Microbeta 2450) according to the manufacturer's instructions.
[0322] Isolation of total RNA from tissues and cells followed by gene expression analysis using the Fluidigm BIOMARK platform For real-time PCR analysis, total RNA was isolated by one of two methods. Organs were homogenized with a Polytron homogenizer in an RNA STAT-60 (Tel-Test Inc., Friendswood, TX), and RNA extraction was then performed using the MagMAX-96 for Microarrays Kit (ThermoFisher Scientific, Waltham, MA) according to the manufacturer's instructions. For cell samples, RNA was isolated using the ARCTURUS PICOPURE RNA isolation kit according to the manufacturer's instructions.
[0323] DNase-treated total RNA was reverse transcribed using QUANTITECT reverse transcription (Qiagen, Valencia, CA) according to the manufacturer's instructions. Primers were commercially obtained from ThermoFisher Scientific (Foster City, CA). Gene-specific preamplification was performed on at least 2 ng of cDNA according to the Fluidigm BIOMARK manufacturer's instructions (Fluidigm, Foster City). Real-time quantitative PCR was then performed on a Fluidigm BIOMARK using 900 nM each of two unlabeled primers and 250 nM of FAM-labeled probe (ThermoFisher Scientific, Foster City, CA) with TAQMAN Universal PCR Master Mix containing UNG. Samples and primers were run according to the manufacturer's instructions (Fluidigm, Foster City) on 48 x 48 or 96 x 96 arrays. Ubiquitin levels were measured in separate reactions and used to normalize the data by the ΔCt method [using the average cycle threshold values for the gene of interest and ubiquitin for each sample, calculated using the formula 1.8 ≈ (Ct ubiquitin - Ct gene of interest) x 10 4 Normalized values were obtained using the following method. Primer reference sequences are available upon request.
[0324] statistics Two-tailed paired t-tests and independent t-tests were used to calculate statistical significance in the remainder of the study. * P < 0.05, ** P < 0.01, *** P<0.001. Statistics were performed using GraphPad PRISM7 software.
[0325] Example 2 The antitumor efficacy of CTLA-4 nAb was evaluated in a mouse syngeneic MB49 tumor model. MB49 cells are a urothelial carcinoma line that were derived from adult C57BL / 6 mice by exposure of primary bladder epithelial cell explants to 7,12-dimethylbenz[a]anthracene (DMBA) for 24 hours followed by long-term culture. Syngeneic mouse models of bladder cancer have been used extensively for over 35 years.
[0326] MB49 murine bladder cancer cells were implanted subcutaneously (sc) into 80 mice and the animals were assigned to five treatment groups of 10 mice each. Median initial tumor volume was 103 mm 3 Once tumor size reached 100%, mice were injected subcutaneously once every 4 days for a total of 4 doses. An irrelevant control ISVD (30 mg / kg, lot no. 01AQL) and 5 mg / kg mIgG1 isotype control mAb (lot no. 64AIS) were administered as treatment controls. Treatments included 30 mg / kg CTLA-4 nAb, 10 mg / kg Fc-competent α-CTLA-4 (D265A), 5 mg / kg α-PD-1, or a combination of CTLA4 targeting agent and α-PD-1. Tumor growth was monitored for 21 days after treatment initiation.
[0327] Figure 9A shows the tumor volumes of individual animals in each treatment group. Complete responses (CR) by day 21 are shown for responding treatment groups. Figure 9B shows the mean tumor volumes and standard error of the mean for each treatment group (initial count n=10 / group). Tumor volumes of animals removed from the study due to large tumor volumes were carried forward in the average until the last measurement for that treatment group. Figures 9A-9B show that, as in the CT26 colon tumor model (see Figure 3A), MB49 bladder tumor model, and MC38 colon tumor model, combination therapy with Fc-free CTLA-4 nAb and α-PD-1 produced potent antitumor effects, independent of Fc function.
[0328] Example 3 The antitumor efficacy of CTLA-4 nAbs was evaluated in a mouse syngeneic MC38 tumor model. MC38 murine colon carcinoma cells were implanted subcutaneously in 80 mice and the animals were assigned to five treatment groups of 10 mice each. The median initial tumor volume was 246 mm 3 Once tumor size reached 100%, mice were injected subcutaneously once every 4 days for a total of 4 doses. An irrelevant control ISVD (30 mg / kg) and 5 mg / kg mIgG1 isotype control mAb were administered as treatment controls. Treatments included 30 mg / kg CTLA-4 nAb, 10 mg / kg Fc-competent α-CTLA-4(D265A), 5 mg / kg α-PD-1, or a combination of CTLA4 targeting agents and α-PD-1. Tumor growth was monitored for 23 days after treatment initiation.
[0329] Figure 10A shows the tumor volumes of individual animals in each treatment group. Complete responses (CR) by day 23 are shown for the responding treatment groups. Figure 10B shows the mean tumor volumes and standard error of the mean for each treatment group (initial number n=10 / group). Tumor volumes of animals removed from the study due to large tumor volumes were carried forward in the average until the last measurement for that treatment group. Figures 10A-10B show that, as in the CT26 colon tumor model (see Figure 3A), MB49 bladder tumor model, and MC38 colon tumor model, combination therapy with Fc-free CTLA-4 nAb and α-PD-1 produced potent antitumor effects independent of Fc function.
[0330] array [Table 6]
[0331] TIFF0007581225000038.tif234158
[0332] TIFF0007581225000039.tif234157
[0333] TIFF0007581225000040.tif234158
[0334] TIFF0007581225000041.tif234157
[0335] TIFF0007581225000042.tif234157
[0336] TIFF0007581225000043.tif234157
[0337] TIFF0007581225000044.tif234157
[0338] TIFF0007581225000045.tif236157
[0339] TIFF0007581225000046.tif235157
[0340] TIFF0007581225000047.tif235157
[0341] TIFF0007581225000048.tif235158
[0342] TIFF0007581225000049.tif235157
[0343] TIFF0007581225000050.tif57157
[0344] References Azuma et al., B70 antigen is a second ligand for CTLA-4 and CD28. Nature. 1993 Nov 4;366(6450):76-9. Collins et al., The interaction properties of costimulatory molecules revisited. Immunity. 2002 Aug;17(2):201-10. Huiら,T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition.Science.2017 Mar 31;355(6332):1428-1433. Ingramら,Anti-CTLA-4 therapy requires an Fc domain for efficacy.Proc Natl Acad Sci US A.2018 Apr 10;115(15):3912-3917. Kamphorstら,Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent. Science.2017 Mar 31;355(6332):1423-1427. Konitzerら,Reformatting Rituximab into Human IgG2 and IgG4 Isotypes Dramatically Improves Apoptosis Induction In Vitro.PLoS One.2015 Dec 29;10(12):e0145633. Lanierら,CD80(B7)and CD86(B70)provide similar costimulatory signals for T cell proliferation,cytokine production,and generation of CTL.J Immunol.1995 Jan 1;154(1):97-105. Leachら,Enhancement of antitumor immunity by CTLA-4 blockade.Science.1996 Mar 22;271(5256):1734-6. Paiら, Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-relatedtoxicity.J Clin Invest.2019 Jan 2;129(1):349-363. Ribas & Wolchok,Cancer immunotherapy using checkpoint blockade.Science.2018 Mar 23;359(6382):1350-1355. Schneider-Merckら,Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but,in contrast to IgG1,only by cells of myeloid lineage.J Immunol.2010 Jan 1;184(1):512-20. Selbyら,Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells.Cancer Immunol Res.2013 Jul;1(1):32-42. Sharmaら,Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells(Tregs)in Human Cancers.Clin Cancer Res.2018 Jul 27. Simpson et al., Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.J Exp Med.2013 Aug 26;210(9):1695-710. Ullman-Cullere & Foltz,Body condition scoring: a rapid and accurate method for assessing health status in mice.Lab Anim Sci.1999 Jun;49(3):319-23. Vargas et al., Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies.Cancer Cell.2018 Apr 9;33(4):649-663.e4. Waight et al., Selective FcγR Co-engagement on APCs Modulates the Activity of Therapeutic Antibodies Targeting T Cell Antigens.Cancer Cell.2018 Jun 11;33(6):1033-1047.e5.
[0345] While the present invention has been described herein with reference to exemplary embodiments, it should be understood that the invention is not limited thereto. Those skilled in the art and readers of the teachings herein will recognize additional modifications and embodiments within the scope. Accordingly, the present invention is limited only by the scope of the claims.
Claims
1. A composition comprising an effector-silent anti-CTLA-4 antibody for use in combination with an anti-PD-1 antibody or an anti-PD-L1 antibody having effector function, and for treating cancer in an individual without causing moderate to severe skin or gut inflammatory immune-related toxicity, comprising: wherein the effector-silent anti-CTLA-4 antibody is (i) an effector-silent anti-CTLA-4 antibody that exhibits no measurable binding to one or more Fc receptors (FcRs) or that exhibits reduced binding to one or more FcRs as compared to a wild-type IgG of the same isotype as the antibody, as measured by a Biacore assay; or (ii) an effector-silent anti-CTLA-4 antibody fragment that lacks an Fc domain or lacks a region of the Fc domain that binds to one or more Fc receptors; composition.
2. Effector-silent anti-CTLA-4 antibodies an IgG1, IgG2 or IgG4 Fc domain comprising a mutation in the N-glycosylation site Asn-Xaa-Ser / Thr starting at amino acid position 297, which prevents N-glycosylation at said N-glycosylation site, or said mutated Fc domain further comprising 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional amino acid substitutions, insertions and / or deletions; an IgG1 Fc domain comprising an N297A, L234A / L235A / D265A, L234A / L235A / P329G, L235E, D265A, E233A / L235A, N297A / D356E / L358M, L234F / L235E / P331S / D365E / L358M, or D265A / N297G amino acid substitution, or said mutant Fc domain further comprising 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional amino acid substitutions, insertions and / or deletions; an IgG2 Fc domain comprising N297A / D265S, D265A, P329G / D265A / N297G, or V234A / G237A / P238S / H268A / V309L / A330S / P331S amino acid substitutions, or said mutant Fc domain further comprising 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional amino acid substitutions, insertions and / or deletions; or an IgG4 Fc domain comprising an S228P amino acid substitution and an N267A, P329G, D265A / N297A amino acid substitution, or said mutant Fc domain further comprising 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional amino acid substitutions, insertions and / or deletions; Including, The composition of claim 1 , wherein the amino acid positions are identified according to Eu numbering.
3. (a) the anti-PD1 antibody comprises (i) the three heavy chain (HC) complementarity determining regions (CDRs) and three light chain (LC) CDRs of pembrolizumab, (ii) the three HC CDRs and three LC CDRs of nivolumab, or (iii) the three HC CDRs and three LC CDRs of cemiplimab-rwlc; and 2. The composition of claim 1, wherein (b) the anti-PD-L1 antibody comprises: (i) the three HC CDRs and three LC CDRs of durvalumab, (ii) the three HC CDRAs and three LC CDRs of avelumab, or (iii) the three HC CDRAs and three LC CDRs of atezolizumab.
4. The anti-CTLA-4 antibody or anti-CTLA-4 antibody fragment comprises: (i) three heavy chain (HC) complementarity determining regions (CDRs) and three light chain (LC) CDRs of ipilimumab; (ii) three HC CDRs and three LC CDRs of tremelimumab; (iii) three HC CDRs and three LC CDRs of REGN4659; (iv) three HC CDRs and three LC CDRs of AGEN1884w; (v) three HC CDRs and three LC CDRs of 8D2 / 8D2(RE); (vi) three HC CDRs and three LC CDRs of 8D2 / 8D2(RE)-mutant 1; (vii) three HC CDRs and three LC CDRs of 8D2H1L1; (viii) the three HC CDRs and three LC CDRs of 8D2H1L1-variant1, (ix) the three HC CDRs and three LC CDRs of 8D2H2L2, (x) the three HC CDRs and three LC CDRs of 8D2H2L2-variant1, (xi) the three HC CDRs and three LC CDRs of 8D3H3L3, (xii) the three HC CDRs and three LC CDRs of 8D2H2L15, (xiii) the three HC CDRs and three LC CDRs of 8D2H2L15-variant1, (xiv) the three HC CDRs and three LC CDRs of 8D2H2L17, or (xv) the three HC CDRs and three LC CDRs of 8D2H2L17-variant1. The composition of claim 1, comprising a CDR.
5. 2. The composition of claim 1, wherein the cancer is melanoma, non-small cell lung cancer, head and neck cancer, urothelial carcinoma, breast cancer, gastrointestinal cancer, multiple myeloma, hepatocellular carcinoma, non-Hodgkin's lymphoma, renal cancer, Hodgkin's lymphoma, mesothelioma, ovarian cancer, small cell lung cancer, esophageal cancer, anal cancer, biliary tract cancer, colorectal cancer, cervical cancer, thyroid cancer or salivary gland cancer.
6. 2. The composition of claim 1, wherein the cancer is pancreatic cancer, bronchial cancer, prostate cancer, pancreatic cancer, gastric cancer, ovarian cancer, bladder cancer, brain or central nervous system cancer, peripheral nervous system cancer, uterine or endometrial cancer, oral or pharyngeal cancer, liver cancer, kidney cancer, testicular cancer, biliary tract cancer, small intestine or appendix cancer, adrenal cancer, osteosarcoma, chondrosarcoma, or blood tissue cancer.
Citation Information
Patent Citations
Optimized fc mutants and methods for their generation
JP2006512407A
Treatment of lung cancer using a combination of anti-PD-1 antibodies and other anticancer drugs
JP2017515859A
